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ABSTRACT 
The Expression and Analysis of Tetraspanin Large Extracellular 
Domains 
There are 33 tetraspanin proteins in mammals and these are Widely expressed on the 
majority of cells and tissues. Tetraspanin proteins are differentiated from other tetraspan 
proteins by a number of conserved motifs, in particular an absolutely conserved Cys- 
Cys-Gly motif in the large extracellular loop (EC2). This EC2 domain is the most 
variable region between tetraspanin proteins in length and amino acid sequence, and 
consequently is the most intriguing domain. Soluble recombinant EC2 domains have 
been used to study tetraspanin function, and so one of the main aims of this work was to 
optimise the production of GST-EC2 proteins from CD9, CD81, CD63, CD151. 
Methods were developed to produce these domains in large quantifies, and they were 
shown to have biological activity in the inhibition of giant cell formation in human 
monocytes. The soluble EC2 domains from CD63, CD9, CD81 and CD151 were all 
shown to potently inhibit HIV-1 infection of macrophages. Infection of the two major 
HIV-1 strains R5 and X4 was prevented by all the tetraspanins tested, suggesting an 
involvement of a tetraspanin enriched microdomain. The inhibition was macrophage 
specific since infection of PBMC was not prevented. 
' 
Another aim was to clone and 
express EC2 domains from CD82 and CD231. CD82 and CD231 EC2 domains are 
larger and consequently proved more difficult to express. Both were cloned successfully 
into the pGEX-2T expression vector and CD82 was expressed in Origami cells 
(Novagen). CD82 EC2 was considered to be a valuable tool to make because of the 
involvement of CD82 in tumor cell metastasis. The original aim of the work was to 
characterise the binding between tetraspanin EC2 domains and primary ligands. 
However, no appropriate ligands were found. We did show by ELISA that mouse, but 
not human, CD9 bound to murine PGS17 but we could not detect the reported binding 
between CD9 and fibronectin. Additionally, efforts were made to clone and express two 
immunoglobulin-like proteins that had recently been identified as CD9 and CD81 
primary binding partners. The cloning of full length EWI DNA as well and double Ig 
domains was carried out successfully into four different expression vectors, however, no 
protein expression was'detected in eukaryotic and a range of prokaryotic expression 
systems. Structural studies were performed using CD63 EC2. Strategies to cleave GST 
and to purify the EC2 domain were successfully developed. Instability problems of 
CD63 EC2 in the absence of GST did not allow for concentration of the cleaved product 
to levels required for crystal trials. CD63 EC2-His6 recombinant protein was used in X- 
ray crystallography studies, and over 1000 crystallisation conditions were tested in 
preliminary structural studies. 
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CHAPTER1 
INTRODUCTION 
1.1 THE TETRASPANIN SUPERFAMILY 
Over the past decade there has been increasing interest in a recently identified family 
of membrane proteins, the tetraspanins (transmembrane 4 (TM4) superfamily, 
TM4SF, 4TM or tetraspan family). This large and abundantly expressed family of 
proteins that span the membrane four times is highly intriguing. At least one member 
of the family appears to be expressed on all mammalian cells and their unique 
structure gives no obvious clues as to their function. The first tetraspanin to be 
discovered was the melanoma-associated protein, ME491, now more commonly 
known as CD63 (Hotta 1988). CD9 was originally described as a surface antigen on 
T-cells and developing B lymphocytes and was also known to be highly expressed on 
platelets. In 1991, the CD9 antigen was cloned and shown to be similar to CD63 
(Boucheix et al. 1991): the novel family of proteins was named the tetraspanin family 
(Horejsi et al. 1991). Murine CD81 was identified due to its role as the target of 
antiproliferative antibody-1 (TAPA-1), and this mouse antigen was later found to be 
similar to human CD81 and CD9 (Andria et al. 1991; Levy et al. 1991; Andria et al. 
1992). The advances in gene cloning and sequence database technologies have 
allowed the rapid identification of more tetraspanin family members, and in 1998 
alone, six new members were discovered (Todd et al. 1998). Now there are 32 or 33 
members of the tetraspanin family in humans (Table 1.1), 37 in Drosophila, and 20 in 
Caenorhabdifis elegans. The conserved nature of tetraspanins over such diverse 
species suggests an ancient evolutionary origin of these membrane spanning proteins, 
and it is likely that homologous members of this family will be discovered in other 
species as more genomes are researched. 
Indeed, in the invertebrates Schistosoma mansoni and Schistosoma japonicum cell 
surface proteins have been identified and assigned to the tetraspanin family. PLSI, a 
tetraspanin encoding gene, has been identified in a plant pathogenic fungus, 
Magriaporthe grisea as well as other fungi including B. cinerea, N. crassa and C 
lindemuthianum (Gourgues et al. 2002). 
Tetraspanins are expressed on cell surface membranes and are also found in 
intracellular compartments, such as the endosome and lysosome. Some tetraspanins, 
such as CD9, are ubiquitously expressed whereas others are restricted to particular 
cell lineages (Table 1.2). Recent studies have shown that tetraspanins are implicated 
in a wide range of diverse biological functions. Here, the properties of mammalian 
tetraspanin proteins will be discussed and an overview of the main tetraspanin 
functions relevant to this work will be given. 
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Tetraspanin Alternative names New 
Name#1 
Protein Chr 
MGC50844 Penumbra TM4SF24? NP 848657 7q32.3 
NETI TM4-C TM4SF17 NP 005718 Ip34.1 
Tspan2 FLJ12082 TM4SF14 NP005716 
Tspan3 TM4-A, TM4SF8.1,2 TM4SF8 NP 005715, 
NP 944492 
15q24.3 
NAG2 TM4SF7 TM4SF7 NP 003262 Hp15.5 
NET4 TM4SF9 NP 005714 4q23 
TM4SF6 T245 TM4SF6 NP 003261 Xq22 
CD231 A15, MXSI, CCG- 
B7, TALLA-1, 
TM4SF2b, DXS I 692E 
TM4SF2 NP 004606 Xp 11.4 
CO-029 TM4SF3 NP 004607 12ql4. lq2l. 
I 
NET5 TM4SF19 NP 006666 12pl3.33-32 
Oculospanin __ TM4SF21 NP 114151 17q25.3 
TSPANII DN930492 ENST0000026117 12p 11.21 
7 
NET2 TMFSF12 NP 036470 
NET6 TM4SF 13, FLJ22934 TM4SF13 NP055214 7 1.1 
DC-TM4F2 DC-TM4F2 TM4SF14 NP 112189 1 Oq22.3 
NET7 2700063A19Rik TM4SF15 NP 036471 1 Oq22.1 
TM4B TM4SF16 NP 036598 19PI3.2 
CAD35489 F-Box23, SB134 TM4SF I 7b NP 569732 5q3l 
BAB55318 TM4SF16 NP 570139 1 IpI 1.2 
XP 084868 TM4SF20? Xp 084868 12q2l. 31 
Uroplakin Ib UPIB, UPKI TM4SF30 NP 008883 3q I 3.3-q2l 
Uroplakin la UPIA, UPIA, UPKA, 
MGC14388 
TM4SF31 NP 008931 19q 13.13 
Peripherin RP7, AVMD, PRPH, 
AOFMD, PRPH2 
TM4SF29 NP 000313 6p2l. 2- 
Rom] ROSP I TM4SF28 NP 000318 lIqI3 
CD151 (2 
variants, UTR) 
PETA3, SFA I, gp27 TM4SF32 NP 004348, 
NP 6205999 
11 pI 5.5 
CD53 MOX44 TM4SF5 NP 000551 IpI3 
CD37 GP52-40 TM4SF4 NP 001765 19p] 3-q 13.4 
CD82 Kangai 1, R2, 
4F9, C33, IA4, ST6GRI 
5, KAI I, SAR2 
TM4SF II NP 002222 1 IpI 1.2 
CD81 TAPA-1, S5.7 TM4SFIO NP 004347 1 1p] 5.5 
CD9 BA2, P24, GIG2, 
MIC3, MRP-1, 
BTCC-1, DRAP-27 
TM4SF2 NP 001760 12p 13.3 
CD63 MELI, MLAI, ME491, 
granulophysin, 
LAMP3, OMA81 H, 
TM4SFI NP 001771 12ql2-ql3 
SAS TM4SF26 Nil 005972 12q 13.3 
TSSC6 (3 
variants; UTR) 
PHENIX, MGC22455 TM4SF15 NP 620593, 
NP 620591, 
NP 005696 
1 IpI5.5 
Table I. I. The human tetraspanin proteins. The table lists the 33 human tetraspanin proteins. 
Alternative names, TM4SF names and the suggested new nomenclature are also shown. *isoform 2 is 
30 residues shorter than i I. 
Tetraspanin Tissue distribution Refs 
CD9 Platelets, early B cells, activated (Boucheix 2001); 
and differentiating B cells, (Wright 1994); 
activated T cells, eosinophils, (Sincock 1997) basophils, endothelial cells, 
megakaryocytes, epithelium, 
dendritic cells, brain and 
peripheral nerves, fibroblasts, 
lung, kidney, liver, 
vascular smooth muscle, skeletal 
muscle, keratinocytes 
CD63 Wide lymphoid and non-lymphoid (Boucheix2001); 
distribution including platelets, (Wright 1994); 
neutrophils, monocytes, (Sincock 1997) 
macrophages, dendritic 
cells, endothelium, 
megakaryocytes, epithelium, 
fibroblasts, lung, kidney, liver, 
smooth muscle, skeletal muscle, 
peripheral nerves, pancreas, 
cardiac muscle 
CD81 Broad expression on non- (Levy 1998); 
lymphoid tissues and on (Jones 1997); 
lymphocytes, thymocytes, (Silvie 2003) follicular dendritic cells, 
eosinophils and epithelium 
CD82 B and T cells, NK cells, (Boucheix 2001); 
monocytes, granulocytes, (Lagaudriere- 
platelets. Various non- Gesbert 1997) haemopoietic cells. 
CD151 Endothelial cells, platelets, 
dcndritic cells, megakaryocytes, 
epithelium, lung, kidney, liver, (Ashman 1997; 
smooth and skeletal muscle and Sincock 1997) 
peripheral nerves, keratinocytes, 
pancreas, cardiac muscle 
CD231 Heart, brain, lung, liver, skeletal (Zemni R 2000); 
muscle, kidney, pancreas, (Wright 1994) 
immature T-cells 
ROMI Photoreceptor cells (Goldberg 1996) 
Peripherin Photoreceptor cells (Goldberg 1996) 
Table 1.2. Tissue distribution of a selection of the better characterised tetraspanin proteins. 
1.2 TETRASPANIN STRUCTURE AND DOMAIN PROPERTIES 
Tetraspanins are type III membrane glycoproteins which traverse the membrane four 
times producing short intracellular N- and C-termini and two extracellular loops (the 
small extracellular loop (SEL or EC I) and the large extracellular loop (LEL or EC2)), 
as well as a small intracellular loop located between TM2 and TM3 (Figure 1.1). 
Members of the tetraspanin family are differentiated from other tetraspan. proteins by 
a number of structural and sequence motifs that are discussed in this chapter. 
Small extracellular loop 
(EC 1) 
Extracellular 
I 
0* ***oO " ##too* * ý1' 
Short intracelluLar'' 4, o'I 
Large extracellular loop 
(EC2) 
ý11 4 
Short intracellular 
C-tenninal 
Intracellular Small intracellular loop 
Figure I. I. Simplified schematic sketch of a tetraspanin. This simplified diagram shows the basic 
outline of a tetraspanin protein. The small, intracellular ten-nini and the intracellular loop between 
transmembrane regions 2 and 3 are noted, as are the extracellular loops; ECI between TMI and TM2 
and the larger EC2 between TM3 and TM4. 
5 
Intracellular domains 
The intracellular N- and C- termini and the short intracellular loop between TM2 and 
TM3 are 72 - 78 % identical between mammal and zebra fish homologues, but share 
only 21 - 38 % identity among different family members (Stipp 2003), suggesting 
important conserved functions that differ between each tetraspanin. The C- terminal 
tail is the most divergent of the intracellular domains and so may have functional 
significance. For instance, this region of CD63 possesses the lysosomal targeting 
motif YXXO, where X is any amino acid and 0 is a bulky hydrophobic amino acid 
(Bonifacino et al. 1999). CD63 possess the motif GYEVM which interacts, in a 
tyrosine dependent manner, with adapter proteins- (AP-) 1,2 and 3 and subsequently 
allows sorting into clathrin coated vesicles and subsequent accumulation in 
lysosomes. Mutations of residues in the GYEVM motif block internalisation of 
CD63 causing it to reside on the cell surface (Rous et al. 2002). 
The intracellular (cytoplasmic) domains have been linked to the binding of signalling 
molecules. For example, immunoprecipitation experiments revealed direct 
associations between CD9, CD53, CD81, CD82 and CD151 with protein kinase C 
(PKQ (Zhang et al. 2001) and mutagenesis studies demonstrated that TM I, TM2 and 
the intracellular domain are likely to be involved in these interactions. In addition, 
phosphatidylinositol 4-kinase has been found in complexes with CD151, CD63 and 
CD81 (Berditchevski et al. 1997; Berditchevski et al. 2002). 
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1.2.2 Transmembrane regions 
The hydrophobic transmembrane domains are the regions of greatest homology 
between humans and zebra fish (86 %) underlying the crucial function of these 
regions (Stipp et al. 2003). Transmembrane regions are thought to form the interface 
of both homo- and hetero, tetraspanin interactions in tetraspanin rich microdomains 
(TEMs) (see 1.3. ). Highly conserved polar residues in the TM regions are postulated 
to promote tight packing and stabilisation of the membrane spanning regions. 
Juxtamembrane cysteine residues in all 4 TM regions have been identified by site- 
directed mutagenesis to be palmitoylation sites in CD9 and CD151 (discussed in 1.3). 
The importance of the TM regions was emphasised by the use of truncated forms of 
CD82 lacking one or more transmembrane regions (Cannon et al. 2001); these 
truncated forms accumulate in the ER, have no Golgi processing and are not 
transported to the cell surface. Absence of TM3 prevents the folding of the EC2 
suggesting that the TM3 and TM4 play crucial roles in bringing together membrane 
proximal regions of the EC2 to allow proper folding to occur (Cannon et al. 2001). 
Recent structural studies using molecular modelling computer programs and the 
crystal structure of CD81 EC2 predict that the transmembrane helices in the majority 
of tetraspanins are positioned in a square pattern in the membrane and are left-handed 
coiled-coils (Seigneuret 2006) (Figure 1.2 ). 
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EC1 
Figure 1.2. Arrangement of helices in the TM bundle. The 
helices are arranged in a square in the membrane. The ECI, 
C2 EC2 and intracellular loop (IC) are shown. 
1.2.3 The small extracellular domain (EC1) 
The small extracellular region, ECI (small extracellular loop SEL), is located 
between TMI and TM2 and is composed of 13 - 30 amino acids. It has been 
reported that the ECI is required for optimal surface expression of the larger 
extracellular loop (Masciopinto et al. 2001), where is was noted that in the absence of 
the ECI, EC2 is expressed at lower levels because it is retained intracellularly. 
Molecular modelling of ECI domains has predicted small P-strands enriched in 
hydrophobic residues in the ECI of most tetraspanins (Seigneuret 2006). 
1.2.4 The large extracellular loop (EC2) 
The EC2 domains show more variation than the other tetraspanin domains both in 
length and amino acid sequence (Figure 1.2). These large extracellular domains are 
typically composed of between 70 and 140 amino acids and are topologically located 
between TM3 and TM4. In 2001, the crystal structure of EC2 from CD81 was 
determined at 1.6 A resolution (Kitadokoro et al. 2001). As previously predicted by 
modelling, it was confirmed that the CD81 EC2 is composed of 5 helical regions (A- 
E) spanning residues: - Asn 115-Asp 137, Ala 140-Asp 155, Leu. 165-Asn 172, Asn 
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180-Phe 186 and Asp 189-Gly 200. Helices A, B and E are collectively known as 
the constant region and form a hydrophobic surface, that was initially thought to be 
involved in CD81 homodimerization as the crystal studies revealed that this region 
was the point of contact between adjacent CD81 EC2 proteins (Kitadokoro et al. 
2001). However, molecular modelling of full tetraspanin proteins predicts that this 
hydrophobic patch or "groove" interacts with the hydrophobic P-strand from the ECI 
domain (Seigneuret 2006). This modelling proposes that the EC1 and EC2 are 
packed together to form a structurally conserved extracellular domain. A so-called, 
66stalk" region is formed by EC I and EC2 helices A and E and is held together by two 
salt bridges in the EC2 (Lys 124-Asp 195 and Asp 128-His 191) as well as a number 
of hydrophobic contacts. This stalk region forms the base for the "mushroom-like" 
head which is composed of the remaining helices. The C and D helix region forms a 
low polarity patch that is predicted to be the site of specific protein-protein 
interactions and, consistent with this theory, this is the region of most variability 
among family members and species homologues (Kitadokoro, et al. 2001; Seigneuret 
et al. 2001). Several studies support the evidence that this low polarity patch is 
crucial for specific protein - protein interactions. This subloop, or tetraspanin fold, is 
formed by disulphide bonding between four absolutely conserved cysteines that are 
present in three variously contained motifs (Cys-Cys-Gly, Pro-X-Ser-Cys [X = any 
amino acid], and Glu-Gly-Cys). In addition to the disulphide bridges, the head 
subdomain is also stabilised by GlyI58 and Prol76 residues whose unique backbone 
conformations allow the structural constraints imparted by the disulphides to be 
accommodated (Kitadokoro et al. 2001). A number of salt bridges in the head domain 
further act to stabilise the structure (Kitadokoro et al. 2001). The EC2 fold is 
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unique: it does not have significant homology to any other tertiary structure (Figure 
1.3. ). 
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Figure 1.4. Multiple sequence alignment of tetraspanin EC2 domains. The absolutely conserved 
motif CCG is aligned and highlighted in red. Residues that are > 50 % conserved are shown in blue. 
Due to the varying nature of the EC2 domains of tetraspanins, it is commonly 
predicted that this large extracellular domain is responsible for the unique properties 
of individual members of the tetraspanin family. The EC2 domains have been 
suggested to mediate the primary interactions of tetraspanin proteins (Stipp 2003), 
and in the few cases where primary binding partners have been identified, this 
hypothesis has proved to be correct. For example: The interaction between CD9 and 
CD81 and two members of the EWI Immunoglobulin sub-family(IgSF) utilises the 
EC2 domain, (Charrin et al. 2001; Stipp et al. 2001) (see 1.3.1.1.1), murine PSG17 
interacts with murine CD9 via the EC2 region (Waterhouse et al. 2002) (see 
1.3.1.1.2), and the high affinity interaction between CD151 and integrin alpha-3 beta- 
I maps within the EC2 region of CD151, (Berditchevski et al. 2001). As with all 
transmembrane proteins, the study of this family of membrane proteins is limited 
because the full length proteins cannot be solubly expressed and used to study 
tetraspanin functions in vitro. The fact that the EC2 domains are likely to be 
essential for function coupled with the need for new tools to investigate tetraspanin 
function gave rise to the production of recombinant tetraspanin EC2 proteins. The 
first recombinant EC2 fusion proteins were produced to study the epitope mapping of 
various anti-CD53 mAbs (Tomlinson et al. 1993; Tomlinson et al. 1995). 
Recombinant tetraspanin EC2 domains, made here in Sheffield and elsewhere, have 
since been used to study tetraspanin functions (Higginbottom et al. 2000; Zhu, G. Z. 
et al. 2002; Higginbottom et al. 2003). Critical residues involved in the interaction of 
HCV glycoprotein E2 with CD81 were determined by constructing mutant CD81- 
EC2 domains. Human CD81 EC2 binds to the HCV glycoprotein E2 but the EC2 
from African Green Monkey CD81 does not, although the EC2 regions from these 
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two species differ by only 4 amino acids (highlighted in Figure 1.3). Each of the 4 
residues was sequentiaily mutated in human CD81 to match that of AGM and the 
mutants were expressed as GST-EC2 fusion proteins. Binding studies revealed that 
Phe 186 in human EC2 was the critical residue for binding to HCV E2, since when 
this residue alone was mutated to match the AGM homologue, binding was abolished 
(Higginbottom et al. 2000) (see 1.4 for more detail). In another example, the 
recombinant fusion proteins were used in sperm-egg binding and fusion assays. 
Previously, antibodies against CD9 were shown to inhibit oocyte fusion and 
recombinant-CD9 EC2 was demonstrated to have the same effect. In our laboratory, 
the critical cysteine residues that are predicted to form the disulphides were mutated 
to alanines (Figure 1.5) and it was shown that these constructs were not recognised 
by the con formation -dependent anti-CD9 antibody, ALMA-1. The mutant EC2 
domains, lacking at least part of their native structure, no longer possessed the 
inhibitory property in the sperm-egg fusion assays, thus suggesting a structural 
requirement for CD9 in this role (Higginbottom et al. 2003). 
CD9 C152A C 166A 
GST C153A CI 81 A 
F 
am 
12 
lip 
Figure 1.5. Coomassic stained gel (top) and Western blot showing WT GST-CD9 EC2 and the 
four Cys-Ala mutants (1-ligginbottom et al. 2003). the Western blot shows that CD9 EC2 (lane I 
is recognised by the structurally sensitive antibody. ALMA-I but the CD9 cysteine mutants are not. 
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1.3 TETRASPANIN ENRICHED MICRODOMAINS 
It is predicted that the predominant function of tetraspanin proteins is to act as 
facilitators and organisers of large, multimolecular complexes on the cell surface, 
know as tetraspanin enriched microdomains (TEMs) or tetraspanin webs (Boucheix 
et al. 2001; Chaffin et al. 2001; Chaffin et al. 2003; Stipp et al. 2003). To participate 
in these microenvirorunents on the cell surface, tetraspanins exploit their ability to 
form homo and heterodimers and multimers, which, coupled with their ability to bind 
a diverse range of other molecules, helps to form the complex networks of organised 
proteins on the cell surface that are involved in complex cellular events such as cell 
fusion (Figure 1.6). Analogies have been drawn between TEMs and lipid rafts. In the 
latter, protein-protein interactions are facilitated by association with membrane 
regions enriched for cholesterol and glycosphingolipids (Simons et al. 1997). In 
either lipid rafts or TEMs the associated proteins are believed to form large integrated 
signalling platfonns. Although TEMs and lipid rafts exist as separate entities, they 
have been shown to interact physically and functionally (Cherukuri et al. 2004; 
Delaguillaumie et al. 2004). 
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Figure 1.6. Predicted mechanism for the formation of tetraspanin enriched microdomains. 
Tetraspanin molecules (hexagons) bind to their individual primary ligands (rectangles). Tetraspanin 
homo- and hetero-dimerisation and binding of shared, secondary ligands causes clustering of' 
complexes. Tertiary interactions form (stars) by the ligation of neighbouring complexes to create a 
multimolecular complex, a tetraspanin enriched microdomain. 
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1.3.1 Hierarchy within tetraspanin enriched microdomains 
Recent studies assessing the strength/proximity of tetraspanin interactions have 
indicated that TEMs are constructed from a hierarchy of interactions (Figure 1.6) 
(Charrin et al. 2003) 
1.3.1.1 Primary interactions 
Primary (or high order) tetraspanin interactions generally appear to be mediated by 
the EC2 region, particularly the subloop and proximal regions (Berditchevski et al. 
2001). These are the most robust of TEM interactions, being stable in relatively 
hydrophobic detergents such as Triton X-100. The fact that they can be stabilised by 
short covalent chemical cross linkers indicates that they involve direct extracellular 
interactions. Examples of some primary tetraspanin ligands are discussed here. 
1.3.1.1.1 EWI proteins 
In 2001, three independent groups identified two novel primary binding partners for 
CD9 and CD81 (Charrin et al. 2001; Clark et al. 2001; Stipp et al. 2001). The first 
major molecular partner for CD9 was identified by using digitonin solubilisation to 
reveal high affinity complexes in tetraspanin webs in carcinoma cells (Serru et al. 
1999). This 135 kDal protein, initially named CD9P-1 and now more commonly 
called EWI-F, is a member of the IgSF and is the human homologue of the rat 
prostaglandin Fa2 regulatory protein (FPRP). EWI-F was isolated by affinity 
purification using anti-CD9 antibodies and, using CD9/CD82 chimeric molecules, the 
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binding region on CD9 was defined as the EC2 and fourth TM domain. The same 
study also revealed that CD81 could form similar complexes with CD9P-1 and other 
tetraspanins were identified in complexes with CD9P-1 under milder conditions, 
highlighting this protein's importance in TEMs (Charrin et al. 2001). A second 
protein, prostaglandin regulatory-like protein (PGRL) was identified around the same 
time as being a major molecular partner for CD81 in T-cells. Again, this 75 kDal 
protein was identified as a member of the IgSF with most similarity to FPRP, 
suggesting the existence of a new protein sub-family (Clark et al. 2001). A third 
study, again searching for CD9 and CD81 molecular partners, also identified a 70 
kDal protein that was later realised to be PGRL. In this study the protein was named 
EWI-2 and was shown to be widely expressed and 91% identical to the murine 
homologue (Stipp et al. 2001). As in the case of EWI-F, the other groups also 
pinpointed the tetraspanin EC2 domains as the region that associates with the primary 
ligand. Further database searches identified two additional members of this novel 
sub-family of the IgSF, CD101 and IgSF3. Since all four members of this subfamily 
contain a Glu-Trp-Ile (EWI) motif in their second Ig-like domain, the nomenclature 
EWI-2 and EWI-F was given to PGRL and CD9P-1/hFPRP respectively, CDlO1 was 
renamed EWI 10 1 and IgSF3 became EWI-3 (Stipp et al. 200 1). EWI-2 (or IgSF8) is 
the smallest protein in the family, being composed of four Ig-like domains. EWI-F 
has six (Fig. 1.7), EWIIO1 and EWI-3 are much larger with 14 and 16 Ig-like 
domains, respectively. Neither EWI 10 1 nor EWI-3 bind to CD9 and CD81 (Stipp et 
al. 2001). 
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Figure 1.7. EWI-2 and EWI-F. A schematic diagram showing EWI-2 and EWI-F surrounding their 
primary ligand, CD9 (or CD81). The blue hexagonal shapes represent Ig-like domains, of which there 
are 4 and 6 in EWI-2 and EWI-F, respectively (not to scale). 
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There is no described function for human EWI-2, EWI-F or EWI-3. EWI-101 (V7, 
CD 10 1) was identified in 1995 as a novel leukocyte surface protein involved in T cell 
activation. EWI-101 is also expressed on most mast cells and granulocytes as well as 
30 % of peripheral blood T-cells (Rivas et al. 1995; Ruegg et al. 1995). Ligation of 
EWI-101 on T-cells by an anti-EWI-3 mAb downregulates TCR/CD3 -dependent 
cellular proliferation by inhibiting the production of IL-2 (Rivas et al. 1995). 
However, this protein has not been shown to associate with either CD9 nor CD81 
(Stipp et al. 2001). EWI-2 has been implicated in the development of the nervous 
system and organ epithelia due to its expression patterns during mouse embryonic 
and foetal development (Murdoch et al. 2003). EWI-2 is not detectable at embryonic 
day (E) 8.5 but is observed in some tissues of the nervous system and organ epithelia 
E9.5 and 1310.5. EWI-2 expression levels in these tissues change continuously 
throughout embryonic development (Murdoch et al. 2003). Consistent with the 
described association between EWI-2 and CD9 and CD81, CD9 is present in the 
developing nervous system (Tole et al. 1993) and CD81 is expressed in pre- 
implantation mouse embryos (Andria et al. 1992) and in neural progenitor cells from 
human foetuses (Klassen et al. 2001). In the absence of signalling factor Shh, EWI-2 
is not detected in the neural tube, suggesting that EWI-2 expression in the nervous 
system is regulated by Shh (Murdoch et al. 2003). 
Lymphoid cells were screened for expression of EWI-2 and EWI-F (Charrin et al. 
2003). EWI-F was not detected on peripheral blood cells, however, EWI-2 was 
expressed on these cells in a pattern that is identical to that of CD81 i. e. present on B- 
cells, T-cells and natural killer cells but not detected on monocytes, polynuclear cells 
or platelets (Charrin et al. 2003). Interestingly, this CD81 ligand is also expressed in 
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the other main type of cells susceptible to HCV, hepatocytes, and is co-expressed 
with CD81 in these cells. It is therefore possible that EWI-2 has some pathological 
significance in HCV infection. 
This same study used chimeric CD9/CD82 molecules to define the region of CD9 
involved in the binding to EWI-2 (Charrin et al. 2003). As expected, a 40 amino acid 
region within CD9 EC2 was involved in the binding but a second region was also 
required for optimum binding. This second region included a small part of TM2, the 
cytoplasmic loop, TM3 and a small part of EC I (Charrin et al. 2003). This is the first 
example of a tetraspanin ligand interacting with 2 separate regions of a tetraspanin 
protein. Over-expression of EWI-2 in A431 cells impaired 001 integrin-dependent 
cell adhesion on laminin-5. Cell re-aggregation and motility functions were also 
impaired but not cell adhesion or spreading. Interestingly, EWI-2 over-expression 
did not have any effect on cells plated on collagen 1, an oc2P3 integrin ligand (Stipp 
et al. 2003). The increased expression of EWI-2 caused CD81 to localise into 
filipodia at the periphery of the cell, an ideal localisation to affect cell motility. Also, 
the presence of EWI-2 caused an increase in association between CD81 and a3pl. 
It is proposed that one prerequisite for cell motility is that CD81 and/or CD9 link 
EWI-2 to o3p I integrin in a TEM (Stipp et al. 2003). 
EWI-2 has been implicated in cell motility on laminin-5 in a second report that also 
describes an association between EWI-2 and CD82 although it is still somewhat 
unclear as to whether this interaction takes place independently of CD81 or whether 
CD81 mediates the interaction between CD82 and EWI-2. (Zhang et al. 2003). This 
cell surface protein, initially named KASP (KAII/CD82 associated protein), was 
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identified in Jurkat cells because of its ability to bind to CD82 and was shown by 
mass spectrometry to be to EWI-2. 
1.3.1.1.2 Pregnancy Specific Glycoprotein 17: A CD9 primary binding 
partner? 
Pregnancy-specific glycoproteins (PSGs) are a sub-group of the carcinoembryonic 
antigen (CEA) gene family that belongs to the Immunoglobulin gene superfamily 
(IgSF). PSGs are secreted proteins whereas the majority of other proteins in the CEA 
subgroup are cell surface bound. There are eleven human PSGs and they are 
composed of an Ig variable-like (IgV) domain at the N-terminus and a varying 
number of constant like domains. PSGs are produced by the placenta and the 
concentrations of PSGs in the blood of pregnant women increase during the course of 
pregnancy but are not detected in males or non-pregnant females (Lin et al. 1974). 
Low concentrations of PSGs can result in complications in pregnancy. It is predicted 
that the PSGs play a vital role in controlling the maternal immune system to prevent 
rejection of the foetus. Foetal rejection has been associated with increased 
production of inflammatory cytokines, such as interferon y (IFN-y) and tumor 
necrosis factor-cc (TNF-a). However, secretion of the anti-inflammatory cytokines 
interleukin (IL) - 10 and transforming growth factor -0 (TGF-P) have been 
associated with successful pregnancies. In 2001, Dveksler's group reported that 
human PSGs, PSGI, PSG6 and PSGII, induced the secretion of IL-10, IL-6 and 
TGF-0 by human monocytes in vitro (Snyder et al. 2001). The N-terminal domain 
from PSG6 was enough to allow the induction, suggesting that it is this domain that 
binds to PSG receptors. 
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The first report describing the involvement of CD9 and PSGs came about when a 
cDNA expression library from a murine macrophage cell line, RAW 264.7, was 
screened by panning against a mouse PSG, PSG17, in an attempt to identify a 
cellular receptor for this glycoprotein (Waterhouse et al. 2002). Sequencing of 
positive clones revealed a perfect match to murine CD9. To confirm binding, HEK 
293 cells transfected with CD9 were shown, by ELISA, to bind to PSG 17-Myc-His6 
in a dose dependent manner (Waterhouse et al. 2002). Flow cytometry studies 
demonstrated the binding of PSG17 to CD9 transfected HEK 293 cells where 66- 
87% of CD9 transfected cells showed PSG17 binding with less than 1% binding to 
cells transfected with the empty vector (Waterhouse et al. 2002). Furthermore, it was 
shown that murine PSG17 could not bind to other murine tetraspanins tested 
including CD53, CD63, CD81, CD82 and CD151. Pre-incubation of RAW 264.7 
cells with anti-CD9 antibody resulted in a reduction of binding to PSG17, and in 
addition, binding of PSG17 to macrophages extracted from CD9 deficient mice was 
reduced to almost background levels (Waterhouse et al. 2002). This was the first 
report of a cellular receptor for a PSG and it was predicted that the variable EC2 
region of CD9 would be responsible for the interaction. 
1.3.1.1.3 Fibronectin: A CD9 ligand? 
There have been some reports describing the binding of CD9 to fibronectin, a 
component of the ECM, suggesting that rather than acting through integrins, 
tetraspanins might have a direct role in binding to the ECM and controlling cell 
motility (Cook et al. 1999); (Longhurst et al. 2002); (Cook et al. 2002). It is well 
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established that tetraspanins, including CD9, associate with PI, P2, P3 and P7 
integrins in TEMs (Hadjiargyrou et al. 1996; Rubinstein et al. 1996; Berditchevski et 
al. 1999). Fibronectin is a widely expressed molecule that mediates a range of 
cellular interactions with the ECM such as cell adhesion, cell growth and motility 
(reviewed in (Pankov et al. 2004). The 250 kDal protein often exists as a dimer and 
contains multiple protein binding sites including the integrin binding site Arg-Gly- 
Asp (RGD). Fibronectin is a well established ligand for up to a dozen members of 
the integrin subfamily (Dedhar et al. 1990; Watt et al. 1994; Yokosaki et al. 1994; 
Chi-Rosso et al. 1997). The consensus is that fibronectin associates with integrin 
receptors on the plasma membrane during cellular processes such as adhesion and 
motility. However, recent reports by Jennings and co-workers describe the direct 
association between CD9 and fibronectin (Cook et al. 1999; Cook et al. 2002; 
Longhurst et al. 2002). Immobilised platelet CD9 and full length recombinant CD9 
were shown to bind fibronectin and CHO cells transfected with CD9 showed 
decreased adhesion to fibronectin coated plates and an altered spreading morphology 
when compared to mock transfected CHO cells (Cook et al. 1999). When CHO cells 
were transfected with truncated CD9 mutants that lack the EC2 domain, cell 
behaviour was reversed back to that of mock-transfected cells (Cook et al. 1999). 
Short peptides derived from CD9 EC2 (especially "peptide 6", amino acids 168-192) 
were reported to bind to fibronectin in ELISA and to disrupt the binding of 
fibronectin to immobilised CD9 in competition ELISAs (Longhurst et al. 2002). 
These data suggested that fibronectin is a potential ligand for CD9 EC2. 
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1.3.1.2 Secondary interactions 
Secondary interactions involve the transmembrane and/or intracellular regions 
(Berditchevski et al. 2001; Charrin et al. 2003). These interactions are less stable in 
high stringency detergents but are maintained in milder conditions (Brij-96, Brij-97) 
and involve tetraspanin-tetraspanin associations that show some dependency on 
palmitoylation (Charrin et al. 2002). The interactions are thought to indirectly link 
primary complexes and thereby facilitate their cross-talk. 
Tertiary interactions 
Tertiary interactions are stable only in low stringency detergents (CHAPS, Brij-99). 
While primary and secondary interactions are isolated as discrete entities, tertiary 
interactions are large complexes containing multiple tetraspanins and associated 
molecules. Thus, tertiary interactions are hypothesised to result from the large scale 
ligation of higher order complexes. The study of tertiary interactions is complicated 
by their poor stability, meaning that the composition of the complexes is less well 
defined than for higher order associations. The use of low stringency detergents to 
isolate these complexes suggests the possibility of non-specific capture of molecules 
in insoluble micelles. However, several tertiary interactions appear to be functionally 
relevant (Wright et al. 2004). Importantly, Claas et al., (Claas et al. 2001) have 
demonstrated that tertiary interactions can exist independently of lipid rafts/large 
detergent insoluble fractions. The localisation of tetraspanin complexes, 
intracellularly and in the plane of the membrane, is known to change in response to 
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certain stimuli, as does the molecular composition of isolated complexes, suggesting 
that TEMs are not static moieties (Penas et al. 2000; Israels et al. 2001). 
1.3.2 Palmitoylation of tetraspanin proteins 
There are a number of post-translational modifications that proteins undergo in order 
to enhance their stability, binding properties, enzymatic activity and localisation. 
Acylation is a common covalent modification of plasma membrane proteins and 
involves the covalent attachment of fatty acids to eukaryotic proteins. Protein 
acylation includes prenylation, myristoylation and palmitoylation, the latter of which 
is a shared feature amongst the tetraspanin proteins that have been researched in 
detail, namely CD9, CD63 CD81, CD82, and CDISI (Berditchevski et al. 2002; 
Charrin et al. 2002; Yang et al. 2002; Charrin et al. 2003; Linder et al. 2003; Stipp et 
al. 2003; Clark et al. 2004; Kovalenko et al. 2004). Diverse proteins can undergo 
palmitoylation and the purpose of this modification depends on the requirement of 
the protein. As palmitoylation increases the hydrophobicity of proteins, it contributes 
to their membrane association and since palmitoylation is a reversible process, this 
suggests a regulated modification to allow control of protein function, much like 
protein phosphorylation (Linder et al. 2003). 
Palmitoylation of CD9, CD151 and CD81 has been extensively studied. One 
example of the functional role of palmitoylation is CD81 and B cell signalling. Upon 
B cell activation, the B cell receptor (BCR) associates with the BCR complex 
(CD19/CD21/CD81) to enhance the signalling through the BCR and lower the 
threshold for B cell activation. It is thought that the BCR complex participates in this 
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process by prolonging the residency of the BCR in lipid rafts (Cherukuri et al. 2004). 
Cherukuri et al., also showed that CD81 was palmitoylated upon colligation of the 
BCR and the CD19/CD21/CD81 complex. The palmitoylation was rapid and 
reversible and necessary for the prolonged residency of the BCR complex in lipid 
rafts (Cherukuri et al. 2004). 
Juxtamembrane cysteine residues are prime candidates for palmitoylation. CD151 
has 8 such cysteines, which, when mutated to alanines, reduce the association of 
CD151 with its primary partner, 0 integrin (Berditchevski et al. 2002). This mutant 
form of CD151 also loses the ability to associate with endogenously expressed CD63 
and CD81. In addition, CD151 plays a crucial role in linking 001 integrin to other 
tetraspanins but the palmitoylation negative mutant fails to permit CD63 and CD81 
association with the integrin (Berditchevski et al. 2002). Although there is 
significant difference in the binding properties of palmitoylated CD9, CD82 and 
CD151, the partitioning of tetraspanins into TEM appears not to depend on the 
presence of palmitate (Berditchevski et al. 2002; Zhou et al. 2004); (Charrin et al. 
2002). 
1.4 TETRASPANINS AND MALIGNANCY 
Tetraspanins have frequently been identified in searches for differentially expressed 
genes in cancerous cells. Some tetraspanins are thought to work as metastasis 
suppressors whereas, in contrast, other tetraspanin proteins are over-expressed in 
certain cancers. For instance, high levels of CD9 in melanoma cells reduce their 
metastatic potential (Ikeyama et al. 1993) and CD82 is a metastasis suppressor of 
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numerous cancers including: lung cancer (Adachi et al. 1996), breast cancer (Huang 
et al. 1998) and prostate cancer (Bienstock et al. 2001). However, overexpression of 
tetraspanin CO-029 is seen in hepatocellular carcinoma (Kanetaka et al. 2001). Here, 
some of the possible mechanisms of action of tetraspanins in malignant cells are 
discussed. 
1.4.1 Effects on motility 
Tetraspanins are often found on the cell surface to be associated with integrins 
(Berditchevski et al. 1996; Hadjiargyrou et al. 1996; Hemlcr et al. 1996; 
Berditchevski et al. 1997; Berditchevski 2001; Zhang et al. 2001; Sterk et al. 2002). 
Integrins are cell surface receptors for extracellular matrix proteins (ECM) and 
transmit information both into and out of the cell. They are heterodimeric molecules 
consisting of one alpha and one beta subunit; there are many different types of alpha 
and beta subunit and the composition of the integrin determines its specificity. 
During integrin-dependent T cell migration, integrins adhere to fibronectin and 
laminin-5 (two components of the ECM), the cell develops filipodia and lamilipodia 
and the cell is "pulled" along the ECM tracks by integrins. Tetraspanins, by some 
unknown mechanism, can increase or decrease the amount of cell motility. This has 
been demonstrated by using anti-tetraspanin antibodies to inhibit T-cell motility or 
over-expression of tetraspanins to increase motility (Berditchevski 2001). 
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1.4.2 Tetraspanins and adhesion 
KA1-l/CD82 and MRP-I/CD9 have been implicated in the impairment of adhesion 
and therefore the invasive and metastatic properties of tumor cells in ovarian cancer 
(Houle et al. 2002). This work also describes the altered tissue expression of these 
tetraspanins throughout the progression of the disease. In normal surface epithelium, 
CD82 and CD9 are expressed at very low levels or are absent altogether. In low 
grade tumours, or when the surface epithelium is modified, there is much higher 
expression that is completely lost in malignant tumours. This suggests that a loss of 
tetraspanins is consistent with a loss of adhesive properties during malignant 
transformation. However, in prostate cancer there are conflicting reports that the 
expression of CD82 is increased, not decreased, during the progression of the disease 
(Lijovic et al. 2002) and CO-029 is overexpressed in hepatocellular carcinoma 
(Kanetaka et al. 2001). One theory for the discrepancies in expression of tetraspanins 
is that it is their direct or indirect effect on integrin function that modifies motility 
and therefore metastatic potential. (Rubinstein et al. 1996). It may be that they 
interfere with integrins to prevent integrin function when over-exPressed in a 
malignant tumor (tumor suppressor) or, when they are under-expressed in a 
malignant tumor, there are insufficient amounts to hold the integrins in place 
correctly and so adhesion is inadequate and metastasis takes place. This would fit in 
with the view that cancer cells have lost their tetraspanin regulatory function. 
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1.4.3 GM3 ganglioside 
There has been evidence to suggest that CD9 and its involvement in the formation of 
protruding lamellipodia and filopodia during haptotactic cell motility is controlled or 
modulated by GM3 ganglioside (Ono et al. 2001). Three lines of evidence were 
tested to support this theory: When GM3 was added to colonic carcinoma cell lines 
expressing high amounts of CD9, motility was inhibited. Cell lines that express low 
levels of CD9 needed large amounts of CD9 gene transfection before becoming 
susceptible to GM3-dependent motility inhibition. Finally, GM-3 does not have any 
affect on motility except when it co-exists with CD9. Although dose-dependent 
inhibition by GM3 could not be demonstrated, they did show that GM3 preferentially 
binds CD9 and not integrins. Further work in this area showed that it was 0- 
dependent mobility on laminin 5 that was being inhibited. It is thought that the 
interaction between a3 and CD9 is activated by GM3. The stable complex thus 
formed blocks signalling to laminin-5 rendering the cells immobile (Kawakami et al. 
2002). 
1.5 TETRASPANIN INVOLVEMENT IN SPERM EGG FUSION 
Gamete fusion is the first event that takes place in the making of a new life but 
surprisingly this process remains poorly understood. It is a strong possibility that one 
particular member of the tetraspanin superfamily, CD9, plays a vital role in the 
fusion of gamete membranes and so revealing its function could help our 
understanding of such a remarkable process. 
29 
1.5.1 Tetraspanin - Integrin Association in Oocytes 
As discussed previously, it is a known fact that tetraspanins associate with integrins, 
especially the 01 integrin sub-family heterodimers such as a3pl, a4pl, (x6PI 
(Banerjee et al. 1997; Domanico et al. 1997; Berditchevski et al. 2001). This 
information has prompted individuals to look into the role that tetraspanins play in 
the specific binding of integrins and their known molecular partners. Integrins are 
known to be involved in sperm-egg binding, cell fusion and the passage of the 
fertilised egg from the oviduct to the uterus (Bowen et al. 2000). cc6pl intcgrin 
expressed on the surface of murine eggs was believed to bind a sperm surface 
glycoprotein, Fertilin P also known as ADAM 2 (A disintegrin and a metalloprotease 
domain), Fertilin cc (ADAM 1) and Cyritestin or ADAM 3. Membcrs of this family 
associate with integrins via their disintegrin domains. It is believed that these 
proteins play an important role in mammalian fertilization. However, the role of 
integrin. ct6ol came into question when approximately 75% of eggs collected from 
cc6 null mice fertilised normally, indicating that the role of ct6ol integrins in 
fertilisation is not as important as initially thought (Miller et al. 2000). In addition, 
a range of anti-integrin antibodies, pre-incubated with murine eggs before addition of 
sperm, were shown to only partially inhibit the binding of sperm (< 55 % inhibition) 
and had no effect on the fusion process (Sengoku et al. 2004). 
An involvement of CD9 in sperm-egg fusion came about when an anti-CD9 mAb, 
JF9, was used to inhibit sperm - egg binding and fusion in a dose dependent manner. 
JF9 inhibited 99% of binding and 100 % of fusion (Chen et al. 1999). Anti-CD81 
mAbs had very little affect on these processes (Takahashi et al. 2001). 
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At this early stage, it was generally believed that the anti-CD9 mAb either sterically 
hindered the binding of fertilin 0 to a6pI integrin or somehow signalled for a6pl to 
suppress binding. Similar results were obtained when another anti-CD9 mAb (KMC 
8.8) was used to inhibit the binding of fertilin cc to its binding partner on the egg 
surface (Wong et al. 2001). This same monoclonal antibody was used by Zhu and 
Evans who found inhibition of fertilin P binding to eggs only occurred when fertilin P 
was immobilised on small beads and not when it is in a recombinant soluble form 
(Zhu, X. et al. 2002). This could be due to other multi-valent interactions taking 
place with CD9 when fertilin is in the beaded form where there are multiple 
molecules on the beads. This data supports the evidence of a multimolecular 
tetraspanin web that organises the surface distribution and expression of membrane 
proteins (Zhu, G. Z. et al. 2002). 
1.5.2 Gene Knock-Out Studies Reveal CD9 Is Critical For Sperm-Egg binding 
Three independent groups performed CD9 gene knockout studies in mice that 
reinforced these findings (Kaji et al. 2000); (Miyado et al. 2000); (Le Naour et al. 
2000). Heterozygotes for CD9 were apparently normal whereas female homozygotes 
could ovulate normally and sperm-egg binding took place but the eggs were unable to 
be fertilised because there was no spenn-egg fusion. In fact, fertilisation in these 
mice was less than 2% of WT fertilisation levels but micro-injection of sperm into 
these eggs allowed normal development to resume, thus limiting the role of CD9 to 
the fiision event (Miyado et al. 2000). In WT eggs undergoing fertilisation, CD9 was 
shown to accumulate around the acrosomal region of the sperm head but in the 
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absence of fertilisation, CD9 was seen in patches all over the surface of the egg. 
Closer inspection revealed that, in fact, the CD9 was isolated at the tips of the 
microvilli that cover the egg. A possible theory is that CD9 is involved in the initial 
fusion of the two membranes, yet the actual ligand for CD9 on the sperm membrane 
remains unidentified (Kaji et al. 2000). The mice lacking CD9 were apparently 
normal in every other way apart from being severely infertile, suggesting that in 
tissues that also express high amounts of CD9, other tetraspanins are able to take 
over. This idea of redundancy in tetraspanins was highlighted in the work done in 
Drosophila (Fradkin et al. 2002). When 25% of the Drosophila tetraspanins were 
knocked out there were delays in embryonic synapse formation, but the organism still 
managed to have an apparently normal adult lifecycle (Fradkin et al. 2002). 
The infertility seen in CD9 4mice was reversed by CD9 poly (A)-RNA injection into 
the egg cytoplasm. It was also found that CD9 +" mice have decreased expression of 
CD9 on the egg surface and hence a lower fertilisation rate compared to CD9 "' mice 
and that injection of CD9 mRNA increased fertilisation rates (KaJi et al. 2002). 
Human (h) CD9 and murine (m) CD81 poly(A) mRNA was also injected into the 
cytoplasm of oocytes from CD9 deficient mice, restoring fertilisation rates to 78 and 
75% respectively. This suggests that both hCD9 and mCD81 can compensate for lack 
of mCD9 in mouse egg fertilisation, (Kaji et al. 2002). Later studies confirmed an 
involvement of CD81 in mouse fertilisation when it was shown that CD81 "" had 
reduced fertility and CD9 and CD81 double knock-out mice were completely infertile 
(Rubinstein et al. 2005). These data suggest complementary roles for CD9 and 
CD81, probably in a TEM. 
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1.5.3 The Mechanism of Action of CD9 in sperm/egg fusion 
To investigate the binding mechanism of CD9, two question were asked: Does CD9 
bind directly to a molecule on the sperm membrane, or does CD9 have more of a 
regulatory role, interacting with other molecules on the membrane of the egg thereby 
enabling these molecules to be the direct binding partners of the ADAM proteins? 
(Zhu, G. Z. et al. 2002). GST-EC2 CD9 fusion proteins were recognised by antibody 
KMC8 (see previously) suggesting that CD9 EC2 is responsible for the events 
leading up to sperm-egg fusion. Fertilisation was inhibited when GST-EC2 CD9 was 
incubated with eggs prior to insemination but when incubated with sperm, no 
significant inhibition was observed. This suggests that sperm do not have a receptor 
for CD9 and that CD9 probably interacts with another protein on the egg membrane. 
Mutant CD9 EC2 constructs were injected into null CD9 mice eggs to determine the 
specific residues required for fertilization to occur. Ser-Phe-Gln (173 - 175) 
sequence in the EC2 was pinpointed as the functional site (Zhu, G. Z. et al. 2002). 
Human GST-CD9 EC2 and GST-CD81 EC2 can also inhibit fertilisation of CD9 
positive mouse oocytes but not the EC2 from CD63 (Higginbottom et al. 2003). In 
this work, the binding of sperm to the oocyte was not significantly inhibited but the 
fusion of the sperm with the oocyte was significantly inhibited, emphasizing the fact 
that CD9 is affecting the fusion event. Furthermore, a structural requirement of CD9 
EC2 for the observed inhibition of sperin-egg binding and fusion was identified 
(Higginbottom et al. 2003). CD9-EC2 mutants lacking one or more cysteine residues 
that are predicted to form the disulphide bridges in the EC2 required for proper 
folding, failed to inhibit sperm-egg binding and fusion events in vitro when pre- 
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incubated with CD9 positive oocytes before addition of sperm (Higginbottom et al. 
2003). 
1.6 THE INVOLVEMENT OF TETRASPANINS IN VIRAL INFECTIONS 
There are emerging roles for tetraspanins in the processes of viral infections. 
Interestingly, the functions of tetraspanins implicated in viral infection are diverse, as 
discussed here. 
1.6.1 Flaviviruses 
The most exhaustively documented involvement of a tetraspanin in viral infection is 
the role of CD81 in Hepititis C Virus (HCV) infection. CD81 was identified as the 
ligand for the HCV glycoprotein E2 using a cDNA expression library created from a 
sub-clone of human T-cell lymphoma MOLT-4, MR, which showed high E2 binding 
capacity. Monoclonal antibodies recognising epitopes in CD81-EC2 can 
competitively inhibit the binding of recombinant E2 to EBV-transformed B cells 
(Pileri et al. 1998). Recombinant tetraspanin EC2 proteins were used to characterise 
the interaction between the EC2 of CD81 and HCV. African Green Monkey (AGM) 
CD81 differs from human CD81 by only 4 residues yet AGM-CD81 is unable to bind 
to E2 and AGM not susceptible to HCV. PheI86 in human CD81 EC2 is Leu in 
AGM CD81; the mutation of Phe 186 to Leu in human CD81 completely abolishes E2 
binding (Higginbottom et al. 2000). Small molecule inhibitors, designed to mimic 
this region of CD81, have been made and shown to inhibit the interaction with HCV 
providing useful ideas for vaccination development (VanCompernolle et al. 2003). 
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Clearly, CD81 is a cellular receptor for HCV but recent data suggests that CD81 
alone is not sufficient for HCV entry and the relevance of the CD81-HCV E2 
association for viral entry is still in question. There are a number of other candidate 
receptors for HCV in addition to CD81, namely; scavenger receptor class B type 1 
(SR-Bl) (Scarselli et al. 2002), dendritic cell-specific intracellular adhesion molecule 
3 grabbing nonintegrin (DC-SIGN) (Lozach et al. 2003; Pohlmann et al. 2003) and 
the low density lipoprotein receptor (LDLR) (Wunschmann et al. 2000). One study 
has established a need for both CD81 and SR-B I for binding and infectivity of HCV 
in hepatocytes, thus proposing a co- receptor role for CD81 (Bartosch et al. 2003). 
However, in another study the binding of HCV to three hepatocyte-derivcd cell lines 
was not blocked by anti-CD81 (Sasaki et al. 2003). It has also been observed that 
different HCV strains utilise CD81 molecule to different extents (Roccasecca et al. 
2003; Kronenberger et al. 2004); (McKeating et al. 2004). Another study using a 
more diverse range of HCV glycoproteins revealed that mutation Asp196Glu in 
CD81 EC2 reduced the binding efficiency of HCV pseudotypes expressing CH35, 
HJC4 and C6al glycoproteins by 70-96% (McKeating et al. 2004). This data would 
suggest that all HCV pseudotypes require CD81 for infection of HepG2 cells but that 
the interactions between CD81 EC2 and HCV glycoproteins differ between sub- 
species. Perhaps the primary role of CD81 is as an essential component of the 
tetraspanin enriched microdomain (TEM) involved in HCV infection rather then as 
an actual receptor. 
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1.6.2 Retroviruses 
To date, tetraspanins have been implicated in three distinct retroviral infections and 
interestingly, a different member of the tetraspanin family is involved in each case. 
1.6.2.1 HTLV-1 
Cell-cell fusion via syncytium formation is an important factor in viral spread and is 
thought to be one of the main transmission mechanisms of Human T cell Lcukaemia 
Virus (HTLV-1) (Clapham et al. 1983). In an attempt to identify cell surface 
molecules involved in HTLV- I induced syncytium formation, a panel of mAbs were 
tested: M38 (IgGl), M101 (IgGI), M104 (IgGl) and C33 (IgG2a) specifically 
inhibited T-cell syncytium formation (Fukudome et al. 1992). Of these, 3 (C33 and 
M 104 and M 10 1) were found to precipitate CD82. 
When CD82 was cotransfected with HTLV-1 glycoproteins in COS-I cells, a dose- 
dependent inhibition of cell fusion was noted compared to cells transfected with 
HLTV-1 glycoproteins alone (Pique et al. 2000). It was also confirmed that the 
presence of CD82 did not affect production, maturation or incorporation of HTLV-1 
envelope glycoproteins into virions and it has been proposed that CD82 exerts its 
effects by a direct steric hindrance of the envelope-receptor interaction, thus 
inhibiting cell-cell fusion and syncytiurn formation (Pique et al. 2000). 
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1.6.2.2 HIV-1 
By the use of immunogold electron microscopy, alterations in CD63 expression were 
described in Human Immunodeficiency Virus type-1 (HIV-1) infected cells 
compared to non-infected cells. Molecules expressed on the cell surface of H9 cells 
and blood mononuclear cells (MNQ were compared before and after infection with 
HIV-1. CD63, usually predominantly expressed in intracellular compartments, is 
upregulated on the surface of HIV-1 infected cells as well as being selectively 
incorporated into budding structures and newly synthesised virus particles (Meerloo 
et al. 1992; Meerloo et al. 1993). These findings were later confirmed when the virus 
membrane was examined for the presence of cellular proteins, CD63 was amongst 
the cellular proteins acquired by HIV (Orentas et al. 1993). In another study, vesicle 
fractions from non-infected H9 and PBMC cells were shown to contain CD5, HLA- 
DR, HLA-DQ, CD30 and CD44 with only traces of CD63 and CD43. However, in 
vesicles from infected cells both CD63 and CD43 were present and HLA-DQ was 
excluded (Gluschankof et al. 1997). 
Macrophages act as virus reservoirs during HIV-1 infection. Previous work has 
described unidentified organelles within macrophages that harbour the virus particles. 
Expression analysis revealed high levels of CD63 and MHC Il and low levels of 
Lamp 1, hence these organelles resemble the compartments in macrophages where 
MHC II molecules undergo the fmal stages of maturation. These major 
histocompatibility type II compartments (MIIQ are thought to be preferential sites 
for virus accumulation in macrophages. CD63 is also enriched on multivesicular 
bodies (MVB) and it is presumed that HIV-1 particles mimic the mechanisms utilised 
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to make natural internal vesicles (Raposo et al. 2002). Further evidence for the 
involvement of CD63 in HIV- I infection of macrophages has been provided recently 
by the O'Brien group who found that anti-CD63 mAbs inhibited HIV-1 infection in 
macrophages (von Lindern et al. 2003). In these studies, only HIV-1 strains utilising 
the CCR5 co-receptor were inhibited and this phenomenon was only witnessed in 
macrophages and not T-cells (von Lindern et al. 2003). 
1.6.2.3 FIV 
Tetraspanins have been linked to a third retroviral infection by the discovery that an 
anti-CD9 mAb, vpgl5, can inhibit Feline Immunodeficiency Virus (FIV) infection in 
a feline lymphoma cell line (Willett et al. 1994). By pre-incubating the cells with 
vpgl5 or control antibodies followed by addition of FIV, it was observed that anti- 
CD9 antibody delayed reverse transcriptase production by approximately 10 days 
compared to control antibodies, without completely blocking reverse transcriptase 
production. When the antibody was removed this inhibition was lifted (de Parseval 
et al. 1997). The ability of FIV to infect CD9 4' cells (Hohdatsu et al. 1996) implies 
that CD9 is not essential for FIV infection, or at least, that other tetraspanins can take 
over this role. Re-introduction of CD9 into these cells increased infectivity (Willett 
et al. 1997), suggesting that the presence of CD9 facilitates the viral life cycle. It has 
been proposed that CD9 is functioning in the intracellular transportation of viral 
proteins to the cell membrane but further work is required to define its role in more 
detail. 
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1.6.2.4 Paramyxovirus 
Another CD9 mAb, K41, has been discovered to inhibit the infection Canine 
Distemper virus (CDV), a morbillivirus of the paramyxoviridae family. A plaque 
reduction assay was carried out to determine whether K41, or a panel of commercial 
CD9 antibodies, could inhibit uptake of the virus and/or syncytium formation. Both 
the size and number of plaques were reduced in Vero and HeLa cells pre-incubated 
with anti-CD9 (Loffler et al. 1997). No direct binding of CD9 to CDV glycoproteins 
has been detected, suggesting that CD9 is not the cellular receptor for CDV. 
Additional investigations have revealed similarities of CD9 function in FIV and 
CDV. CDV can still bind to the surface of cells in the presence of K41 suggesting 
that CD9 is not involved in the attachment of CDV to cells prior to infection (Schmid 
et al. 2000). Treatment with the antibody also had no effect on the production of 
viral DNA but it was demonstrated that CD9 had an important role in CDV-induced 
cell-cell fusion but not virus-cell fusion. There are a number of examples in the 
literature of tetraspanins being involved in cell fusion events, perhaps the most 
extensively studied example being the involvement of CD9 in mammalian oocyte 
fusion (see Chapter 1.5). Also, our unpublished data suggests that soluble EC2 
domains of both CD9 and CD63 can inhibit Con A-induced fusion of human blood 
monocytes (see Appendix). 
1.9 AIMS 
It is clear from this review of the literature that there is much work to be done in 
elucidating the exact molecular mechanisms of tetraspanin function. The main tools 
currently utilised to study tetraspanins are monoclonal antibodies, gene knock-out 
mice and overexpression of tetraspanins in cell lines by transfection of DNA. Each 
of these methods has their uses, but also a number of possible weaknesses: The use 
of monoclonal antibodies can be misleading due to Fc receptor binding and steric 
hindrance by the bulky immunoglobulin chains; gene knock-out mice are costly and 
time-consuming to generate and ineffective when functional overlap occurs between 
tetraspanins, whereas transgene overexpression could lead to amplification or 
activation of cellular events that would not normally occur in WT cells. Several 
groups have previously successfully used recombinant EC2 proteins in order to study 
tetraspanin function (Flint et al. 1999; Higginbottom et al. 2000; Higginbottom et al. 
2003; Takeda et al. 2003; Zhang et al. 2004). Few primary ligands for tetraspanins 
have so far been identified and the interactions between the tetraspanins and primary 
partner proteins that have been identified, have not been fully characterised. 
Information of this kind would give valuable insights to the functioning of 
tetraspanins at the molecular level. The major aims, therefore, were to clone the two 
recently identified primary ligands for CD9 and CD8 1, EWI-F and EWI-2 (Charrin et 
al. 2001; Clark et al. 2001; Stipp et al. 2001), express them as soluble proteins, and 
using recombinant EC2 proteins, characterise critical amino acids in the EC2 
domains from CD9 and CD81 that may be involved in this interaction. It was also 
planned to characterise the domains in the EWI proteins that engage with CD9 and 
CD81 by cloning individual Ig-like domains as well as full length proteins. Other 
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primary tetraspanin. ligands to be analysed were PSG17 and fibronectin - these two 
proteins were identified as binding partners for CD9 (Longhurst et al. 2002; 
Waterhouse et al. 2002) and it was planned to study the interactions of both proteins 
with CD9 EC2 using the GST-EC2 constructs. 
A secondary aim was to optimise the large scale production of the existing EC2 
constructs and to promote these recombinant proteins as alternative, cheap, quick and 
relatively easily produced tools to study tetraspanin function by collaborating with 
other tetraspanin researchers. It was also planned to increase the repertoire of the 
recombinant proteins by cloning EC2 domains from two further tetraspanins, CD82 
and CD231 (Chapter 3). 
Another part of the work was to attempt to solve the structure of a more complex 
EC2 domain than CD81, by X-ray crystallography (Chapter 4). CD63 fitted into this 
category and was also chosen because of its role in HIV infection. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
General materials 
General laboratory reagents were from Sigma, BDH or Melford, and were AnalaR / 
equivalent grade. 
2.1.2 Solutions and buffers 
Preparation of commonly used buffers is summarised in Table 2. a. Preparation of 
media for the growth of mammalian and bacterial cells is shown in 2. b, and the 
antibiotic stock solution preparations are shown in 2. c. 
a. i 
Buffer Preparation 
BSS (Balanced Salt Solution) 43.36g NaCl, 1.83g KCI, 8.19g D-sorbitol, 3g 
KR04.31-120P 0.7g KH2P04,12.09g Ilepes. pH 7.2 
- 7.4, make up to 51, in 
H20. 
DestainingLolution 70ml glacial acetic acid, 830ml H20. 
ELISA Binding Buffer 1.59g Na2CO3,2.93g NallC03. pIl 9.6 make up to 
IL in 1120. 
Glutathione Elution Buffer 0.154g reduced glutathione dissolved in 50ml of 50 
mM Tris I ICI, pl-18.0 
Hank's Balanced Salt Solution Purchased from Invitrogcn (cat. No. 14170-088), 
(HBSS) contains/L: 400mg KCI, 600mg KH2P04,350mg 
NallC03,8 g NaCl, 48mg Na2HP04, Ig D- 
Glucose, I Omg Phenol Red. 
1x PBS (Phosphate Buffered Saline) 10 x stocWL - 160 g NaCl, 4g KCI, 28.8 g Na2HP04,4.6 gK 2PO4, pH 7.2 - 7.4. 
1x PBS Tween As above + 0.0 1% Tween 20 to the Ix solution. 
TAE 50 x stock/L - 242 g Tris-base, 57.1ml glacial 
acetic acid, I 00ml 0.5 M EDTA, p1l 8.0 
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a. ii 
Buffer Preparation 
SDS-PAGE Running Buffer 10 x stock/L - 30g Tris-base, 144g glycine, 100ml 
10 % SDS. 
SDS-PAGE Loading Buffer (non- 2ml glycerol, 2ml 10 % SDS, 0.25mg bromophenol 
reduced) blue, 2.5n-d stacking gel 4X buffer (see below). 
Add H20 to a final volume of I 00ml. 
SDS -PAGE Loading Buffer As above with 0.5ml P- mercaptoethanol. 
(reduced) 
Separating Buffer 18.17g Tris-base, 4ml 10 % SDS. Adjust to pH 8.8 
using I OM HCI and make up to I 00ml with H20- 
Stacking Buffer 6.06g Tris-base, 4ml 10 % SDS. Adjust to pH 6.8 
using I OM HCI and make up to I 00ml with H O. 
Staining Solution 
! 
id, a c 250ml isopropanol, 100ml glacial acetic acid, 
650ml 1120,2.5 g Coomassie brilliant blue. 
a. iii 
Buffer Preparatio 
Buffers for Native Protein Wash Buffer 6.90g NaH2PO4.1120,17.54g NaCl, 
Purification on -NTA-Ni2+ IL 1.36g Imidazole. Adjust to p1l 8.0 
using NaOH. 
Elution 6.90g NaH2PO4.1120,17.54g NaCl, 
Buffer IL 17.00g Imidazole. Adjust to pH 
8*0 using NaOH 
Buffers for Denatured Protein Lysis Buffer 100mM (13.8g) Nall2P04-1120, 
Purification on -NTA-Ni2+ A I OmM (1.2g) Tris-base, 6M (573g) IL guanidine hydrochloride. Adjust to 
pH 8.0 using MOIL 
Lysis Buffer lOOmM (13.8g) Nall2P04. H20, 
B lOmM (1.2g) Tris base, 8M 
IL (480.5g) Urea. Adjust to p1l 8.0 
using NaOH. 
Wash Buffer IOOmM (13.8g) NaH2P04. H20, 
C I OmM (1.2 g) Tris-base, 8M (573g) 
IL Urea. Adjust to pH 6.3 using HCL 
Elution lOOmM (13.8g) NaI12P04-1120, 
Buffer D lOmM (1.2g) Tris-base, 8M (573g) 
IL Urea. Adjust to pH 5.9 using IICL 
Elution lOOmN4 (13.8g) NaH2PO4-1120, 
Buffer E I OmM (1.2g) Tris-base, 8M (573g) 
IL Urea. Adjust to pH4.5. 
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b. 
Media Preparation 
LB IL (in water): I Og tryptone, 5g yeast 
extract, 10 g NaCl, adjust to pH 7.5 with 
IM NaOH and autoclave 
LB-Agar IL (in water) :I Og tryptone, 5g yeast 
extract, 10 g NaCl, 15 g agar, adjust to 
pH 7.5 with IMNaOH and autoclave 
Soc IL (in water) : 16 g tryptone, 10 g yeast 
extract, 5g NaCl, 5ml (2M) MgS04, 
5ml MgC12,10ml (2M) glucose. 
Table 2a and b. (a. i) Commonly used buffers. (a. i. i) Buffers used in SBS-PAGE, (a. l. l. i) Buffers 
used for purification of His6-tagged proteins on nickel columns. (b) Media used for bacterial cell 
culture 
C. 
Antibiotic Stock Working Concentration 
Carbenicillin 50mg/ml in 50% ethanol 50 pg /mI 
Kanamycin 
_ 
50mg/ml in H20 50 pg /mI 
Table 2. c. Antibiotics 
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2.1.3 Sterilisation 
Bacterial media, glassware, pipette tips and centrifuge tubes were sterilised by 
autoclaving (120 C, 20 minutes, 15 or 20lb/sq. in. ). Antibiotics used in bacterial and 
mammalian culture were sterilised before use by passing through 0.41im filters. 
2.1.4 Molecular biology and cell culture reagents 
Antibodies used throughout the project are listed in Table 2. d and other molecular 
biology reagents/kits are listed in 2. e 
2. d 
Reported 
Name Target 
antigen species 
Isotype Label Source 
specificity 
ALMA-1 CD9 Human Mouse None F. Lanza, 
IgGI Strasbourg, 
I France. 
H5C6 CD63 Human Mouse None D. Azorsa, 
IG NTH. 
Tspanl/2 CD82 Human Mouse None E. Rubinstein, 
IgG France 
BL2 CD82 Human Mouse None Serotec, 
IgGI MCA1311 
Anti-CD231 CD231 Human Mouse None Oncogene 
IgGI Research, 
OP17510OUG 
l4A2. HI CD151 Human Mouse None L. Ashman, 
IgGI Adelaide, Au. 
1.3.3.2.2 CD81 Human Mouse None Ancell 
EAT-2 CD81 Human Mouse None S. Levy, 
I GI Stanford, US 
RGS-His6 RGS-His6 Human Mouse None Qiagen, 
IgGI 34610 
Anti-GST GST N/A Goat IgG none Amersham 
Biosciences, 
; 
27-4577-01 
Anti-GST- GST N/A Goat IgG HRP Abcam, 
HRP Ab6649 
Anti-c-myc Myc Human Rabbit, none Abcam, 
I clonal AbI529 
Go Mouse IgG Mouse Goat HRP Bio-Rad, 172- 
Mouse IgG 1011 
Rabbit Anti- Goat IgG Goat Rabbit HRP Dako, P0449 
Goat 
Donkey Rabbit IgG Rabbit Donkey none Abcam, 
Anti-Rabbit I Ab6701 
Table 2. d. Antibodies 
2. e 
Name Cataloaue number Source 
BugBuster Protein Extraction 
Reagent 
70584 Novagen 
Complete Mini EDTA free PCI 1836170 Roche 
Coomassie Protein Assay Reagent 1856209 Pierce 
ECL Western Blotting Reagent RPN2106 Amersham 
Biosciences 
Full Range Rainbow Molecular 
ight markers 
RPN800 Amersham. 
Biosciences 
L-Glutathione Reduced 40750 Biochemika 
Glutathione Sepharose 4B beads 27-4574-01 Amersharn 
Biosciences 
Hyperfihn ECL RPN3103K Amersharn 
Biosciences 
Multigrade Developer 1757855 Ilford 
Ni-NTA Superflow 1018611 Qiagen 
Nitrocellulose, Hybond N+ RPN303B Amersharn 
Biosciences 
Nucleospin Plasmid Kit 635988 Macherey- 
Nagel 
Polypropylene Columns 34964 Qiagen 
Qiaex 11 Gel Extraction Kit 20021 Qiagen 
Siliconized 1.5ml tubes T4816-250EA Sigma 
Silver Staining Plus Kit 161-046(1-4), 161-0448 BioRad 
Snakeskin Pleated Dialysis Tubing, 
3,500 MWCO 
68035 Pierce 
Unifix, liquid fixer 521 1412 Kodak 
Table 2e. Molecular Biology Reagents 
2.1.5 Oligonucleotide production 
Oligonucleotides were purchased from Sigma Aldrich or MWG. 
2.1.6 Automated DNA sequencing 
DNA sequencing was either perfonned at the in-house sequencing facility using an 
ABI 3 77 or ABI 3 10 Sequencing machine or sent to Lark Technology Inc., UK. 
2.1.7 Instrumentation 
Centrifugation of mammalian cells used a Harrier 15/80, MSE. A bench top Sigma 
113 or a refrigerated Sigma IK15 was used to centrifuge small samples. A Sigma 
3KI5 was used to pellet bacterial cells after lysis and larger bacterial cultures were 
ccntrifugcd in a MSE Falcon 6/300. 
Electroporation used BioRad Genepulser apparatus. For bacterial transfonnation, the 
apparatus was connected to a pulse controller. 
For PCF, the DNA engine, Dyad Peltier Thermal Cycler was used. 
Bacterial fermentation was carried out in a New Brunswick Scientific 20L Fermenter, 
BF4500. 
Sterile mammalian cell culture manipulations were performed in a class II 
microbiological safety cabinet, the Bio 2+, Envair. 
Spectrophotometery (for DNA and protein concentration and measuring OD of 
bacterial cultures) used a Unicam. UV/visible dual beam spectrophotometer. OD 
measurements for 96 well plates (ELISAs, Bradford assays) used an EL800 
Microplate Reader, Bio-Tek Instruments Inc. Visualisation of DNA in agarose gels 
and protein in SDS gels used a MultiImage Light Cabinet and the Alphalmager 
Software, Alpha Innotech Corporation. 
BioRad apparatus was used for running protein and DNA gels. 
A Soniprep 150 sonicator, MSE, was used to lyse bacterial cells. 
2.2 MOLECULAR BIOLOGY - DNA WORK 
2.2.1 Primer design 
Nucleotide sequences were identified on the NCBI website and primers were 
designed to amplify the region of interest. Primers were generally 15-20bps long 
with a Tm around 55*C (roughly determined by counting G and C base pairs as 4'C 
and A and T as 2'Q. 
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2.2.2 General PCR using Taq polymerase 
Unless otherwise stated, PCR using Taq Polymerase (including Reddy Mix and High 
Fidelity Reddy Mix), were performed in the following manner: 
Forward Primer 0.5[tl 
Reverse Primer 0.5pl 
DNA template 1-5[d 
Reddy Mix 6.0ýtl 
dH20 to a total volume 12gl 
Generally, the following conditions were used for PCR cycles: 
Step Time Temperature Cycles 
Initial Denaturation - 2 minutes 94'C Ix 
Denaturation I minute 94*C 
Annealing I minute 50-60*C 25 x 
Extension I minute 72*C 
Final extension 10 minutes 68-72*C Ix 
2.2.3 TOPO-TA cloning 
Specific primers were designed to amplify the DNA region of interest from a full 
length DNA template purchased from IMAGE or Kazusa. 
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For TOPO-TA cloning, 5' primers had a TA overhang to allow insertion into TOPO 
TA vector. Iligh Fidelity Reddy Mix (Abgcne) was used for the PCPL 0.5-4pl of the 
fresh PCR product was mixed with the TOPO vector and incubated for 5 minutes at 
RT. The plasmid was now ready for transformation into TOPIO Chemically 
Compctcnt Cclls (Invitrogcn). 
2.2.3.1 Tmnsformation 
All transformation procedures were carried out on ice. IOPI of competent cells were 
transferred to a prc-chilled 1.5ml tube containing 10-30pg DNA from the TOPO 
Cloning reaction and mixed gently by tapping. This was left on ice for 30 minutes 
before heat shocking the cells at 42T for 30 seconds. The cells were immediately 
placed back on ice and left for 5 minutes. 200-1000pl of SOC medium was added 
and the cells were lcft to grow for I hour at 37*C, shaking at 220RPM. 20-200pl of 
cells werc plated on agar plates containing the appropriate antibiotic (kanamycin or 
carbenicillin) and in the prcsencc of X-Gal. 
2.2.3.2 Colony screcning 
A number of positive (white) colonies and a few negative controls (blue) colonies 
were picked and resuspended in the following PCR mix: 
9.91d 1: 1 Rcddy mix 
I til Forward primer I OnNI 
I jil Rcvcrsc primcr I OnNI 
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Primers spcciric to the insert or internal vector primers were used. 
The gcncral PCR cycle for screening colonies was: 
Step Time Temperature Cycles 
Initial Denaturation 2 minutes 94*C x 
Denaturation I minute 94*C 
Annealing I minute 55*C 25 
Extension I minute 72T 
Final extension 10 minutes 72*C I 
The amplified products were mixed 5: 1 with DNA loading buffer and run on I% 
agarosc gcls containing 0.001 % cthidium bromide made up in TAE buffer, generally 
for 40 minutes at 90V. The gels were visualised on the U. V. light box and the 
presence of a correctly sized band confirmed that the transformation had worked and 
the insert was incorporated in the vector. 
2.2.3.3 Small scale plasmid DNA preparation 
A metal loop was flamed, cooled on agar, and used to pick single colonies containing 
the desired insert which were then suspended in 5ml LB containing the appropriate 
antibiotic. 11csc were left to grow overnight at 370C, RPM 220. The following 
morning the dense cultures were ccntrifuged at 4000 g for 5 minutes to pellct the 
bacterial cells and the supernatant was discarded. Nucleospin Plasmid Miniprcp Kit 
(Machercy - Nagel) was used for all minipreps. The cells were resuspended in 250 
111 of physiological buffer Al. before being lysed by addition of an equal volume of 
Lysis Buffer, A2. ne solution was mixed gently and left to incubate at room 
temperature for 5 minutes. 300pl of neutralising buffer A3 was added to the lysate 
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before centrifugation at 10,000g to pellet the SDS precipitate and cell debris. Ile 
supernatant was loadcd into a QuickPurc column on which the plasmid DNA binds to 
the column's silica membrane. The DNA was washed by centrifuging wash buffer 
through the column and then discarding the flow-through. A buffer to remove 
cndonuclease activity is used and then the DNA is washed twice with an 80 % 
ethanol wash to clean the DNA and then dried to remove residual ethanol which 
might inhibit enzymatic reactions. Finally, the DNA is eluted 25til of ImM Tris, 
p118.0. 
2.2.3.4 Quantification of DNA concentration 
DNA has an maximal absorption at 260nm and an OD reading of I at this wavelength 
corresponds to 50pg of DNA/ml. DNA was diluted 500 fold in water, the absorbance 
at 260nm was recorded and the concentration of DNA was calculated. 
2.2.4 DNA clectrophoresis 
Generally, I% agarose gels with 0.001 % ethidium, bromide made up in TAE buffer 
were used. Gels ran in TAE buffer for 40 minutes at 90 V. Conditions were altered 
slightly for very small or very large DNA fragments. 
2.2.5 DNA sequcncing 
The Nil 3 Forward and Reverse primers from were used for sequencing products in 
lnvitrogcn vcctors unlcss otherwisc statcd. The majority of scqucncing was carricd 
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out using BigDye Tenninator v 3.1 Cycle Sequencing Kit (Applied Biosciences), and 
the sequencing reaction pcrfonncd by the Division of Genornic Medicine's 
Sequencing Facility, F Floor, The Mcdical school. DNA inserts larger than 800bp 
were sent to Lark Technology, Inc. for sequencing. 
For In-house sequencing the following sequencing reaction was set up: 
1040ng plasmid DNA 
3.2 pmo pnmcr 
2.01d BigDyc 3.1 
4.0jil buffcr 
1120 to a total of 20pl 
And the following sequcncing program performed: - 
Step Time Temperature Cycles 
Initial Denatumtion I minutes 96*C Ix 
Denaturation 10 seconds 96*C 
Annealing 5 seconds 50-60*C 25 x 
Extension 4 minutes 60*C 
Cooling_ 10 minutes 4'C Ix 
To precipitate the DNA 50pl of 100 % ethanol and 3. Opl of CH3COONa pH 5.2 was 
added to each tube and this was either incubated on ice for 30 minutes, or frozen at - 
20*C overnight. The DNA was pelleted by centrifugation at 15 000g, 4T for 20 
minutes and then washed with I 001A, 80 % ethanol before a final spin for 10 minutes. 
The ethanol was carcfullY pipetted off and then the pellct was air dried for 30 minutes 
to I hour. T'he DNA was then ready to take to the DNA Sequencing Facility to be 
rcad. 
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2.2.6 Restriction enzyme digestion of DNA 
Restriction enzymes were from Roche or Promcga and were stored at -20*C in 
glycerol to prevent freezing, thereby retaining enzymatic activity. High glycerol 
conccntrations arc also known to modify endonuclcase activity so care was taken to 
keep the volume of diluted enzyme one tenth or below the total reaction volume. 
Standard digestions used 2 units of enzyme for every pg of DNA to ensure complete 
digestion and digestions were generally performed at 37' C for 1-24 hours using the 
appropriate buffer. Following restriction digest the DNA was run on agarose gels to 
check the size of the insert. 
2.2.7 DNA purification from agarose gels 
The kit used for batch purification of DNA products from agarose gels was the Qiaex 
Suspension (Qiagen) and the experiments were carried out according to the 
manufacture's instructions. 
21.8 DNA ligation 
Ligation of DNA into vectors used Ligase enzyme (Roche). A 1: 1 ratio of DNA 
insert to vector is required and amounts were estimated qualitatively by looking at 
agarose gels of restriction digestion DNA. Various ratios of vector to insert were 
prepared as well as a re-ligation control with no insert. The ligation reaction was 
typically carried out for 2 hours at 140C before the DNA was transformed into Mot 
competent cells (Invitrogen) or Omnimax competent cells (Invitrogen) for 
propagation of the plasmid. Colonies were PCR screened and positive colonies were 
mini-prcppcd and sequenced as previously described. Correctly sequenced constructs 
were then ready to be used for protein expression. 
2.3 MOLECULAR BIOLOGY - PROTEIN WORK 
2.3.1 Protein expression In bacterial systems 
2.3.1.1 Expression vectors 
pGEX-2KG vcctor was uscd for production of tetraspanin EC2 domains with an N- 
terminal GST tag. Cloning of EWI full length proteins used Gateway'"m vectors pET 
DEST42 and pcDNA-DEST40 (Invitrogen) for bacterial and mammalian expression 
respectively (see Chapter 5 for specific GatewayTm Methods). 
Cloning of individual Ig domains of EWI proteins used the pET32c and pET26b 
vcctors (Novagcn). 
2.3.1.2 Bacterial strains for protein expression 
131,21 Codon Plus Competent cells and Origami cells (Novagcn) were used for 
protcin cxprcssion. 
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2.3.1.3 Transformation 
Sec 2.2.3.1 
2.3.1.4 Inoculation 
metal loop was flamed, cooled and used to pick single colonies that were 
resuspended in 10ml of LB containing the appropriate antibiotic. The cultures were 
grown overnight at 37*C with 220 RPM shaking to produce a dense inoculate. 
2.3.1.5 Determining optimal protein expression conditions. 
"is method gave 54 conditions and 6 controls to determine which set of conditions 
was best for producing the protein of interest. 
Two 10ml overnight cultures were used to inoculate 400ml of autoclavcd LB. One 
flask was incubated at 37*C and one at 25*C, both shaking at 220 UM. The OD6oo 
was monitored and %vhen ODs 0.2,0.4 and 0.8 were reached 10 xI Oml samples were 
taken at each OD and from each temperature. Three samples from each set were 
induced with 1.0mNI, 0.5mNI and O. ImNI IPTG, the final sample being the non- 
induced control. The samples were left to produce protein for 2 hours, 4 hours or 
overnight before centrifugation at 4500g for 10 minutes to pellet the bacteria. The 
pellcts were thcn frozen at -20'C prior to analysis. 
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2.3.1.6 Biomass scale - up 
Once the optimal conditions to express the protein were determined, a scalc-up of 
protein production was performed. 
Each 10ml overnight culture was used to inoculate 400ml of autoclavcd LB, with 
added antibiotics, in 2L conical flasks (this gives the bacterial cells optimal room for 
acration). I'lic cultures were then grown at the optimal temperature and until the 
dcsircd OD600 was reached before induction of protein production using the pre- 
determined concentration of IPTG. The cultures were then left to grow for the 
appropriate time. 
2.3.1.7 Harvesting cells 
Cultures were transferred to 750ml centrifuge tubes and centriftiged at 4500 g for 20 
minutes. The supernatant was removed, the cell pellet washed by resuspending in ice 
cold Ix PBS and then the mixture was transferred into 50ml tubes and centrifuged as 
before. Again, the supernatant was removed and the pellet stored at - 20 * C. 
2.3.1.8 Biomass fermenter 
The Biomass krincritcr holds 25L of culture and so dense 500ml inoculates were 
required. This was achieved by setting up the 10ml of overnight culture, as before, 
and then transferring I ml into 500ml of LB and leaving this to grow for a further 24 
hours. 
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The inoculate was loaded into the fermenter by use of a peristaltic pump and the 
correct antibiotics were injectcd through a port in the fermentcr. Samples were 
collected through a small valve to monitor the OD. When the correct OD was 
reached, IPTG was injected in the same way as the antibiotics. The cells were 
harvested by collecting the culture in IL centrifuge tubes and centrifugation at 4000 g 
for 20 minutes, followed by washing the pellet in PBS and transferring to a 50ml tube 
before centrifuging again. The cell pellets were stored as before. 
2.3.1.9 Defrosting the cell pellet 
Cell pcilcts were always defrosted on ice with frequent vortcxing to help speed up the 
process. 
2.3.2 Isolation of soluble GST-tagged protein by affinity purification 
2.3.2.1 Lysing the cell membrane and removal of the insoluble fraction 
The cell pellet was rc-suspended in 10 - 20ml of BugBuster (Novagen) with added 
protcase inhibitors; Icupcptin, aprotinin, and pepstatin (to a final concentration of 
I Ojiglml) and I mM PNISF. The cells were lyscd by gently rolling for I hour at room 
temperature. The nuclear fraction and cell components were removed by 
centrifugation at 14 OOOg for 10 minutes, and the supernatant contains the soluble 
protein fraction. 
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2.3.2.2 Storage of columns 
Glutathione Sepharose beads were stored at 4*C in Ix PBS with 20 % ethanol in 
paraffin scaled columns. After clution of protein from the beads, excess PBS was run 
through the column to wash the beads before filling the column with 20 % ethanol 
solution. Storcd in this way the beads lasted for 2 or more years and were continually 
reused for purification of the same protein construct. 
2.3.2.3 Preparation of beads 
The glutathione Sepharose beads were washed 3 times in an excess of PBS to remove 
any residual ethanol that can interfere with enzymatic reactions. This was carried out 
by vortexing fresh beads until they were completely resuspended before adding the 
desired amount (typically 1.33ml beads per 1.6 L culture volume) to a 25ml tube. 
Each wash entailed filling the 25ml tube with PBS, centriguging at 500 g for 3 
minutes and then carefully pouring off the supernatant. 
2.3.2.4 Adherence to beads 
The standard conditions for allowing adherence of GST fusion proteins to the 
glutathionc beads was I hour at RT or overnight at 4*C. 
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2.3.2.5 Loading the column 
15ml columns (Qiagcn) were used routinely for protein purification. The columns 
were prc-washed with detergent, typically Triton X-100, and the beads were loaded 
into the columns and allowed to settle. 
2.3.2.6 Washing the column 
To remove unbound protein and other contaminants from the sample, 3 column 
volumes of PBS were washed through. 
2.3.2.7 Elution of protein 
Protein was elutcd by addition of 0.5ml Glutathione Elution Buffer fractions. The 
eluatcs were collected in 1.5ml tubes and assayed for protein content using the 
Bradford Assay. Fractions were continued to be collected until the protein content 
could no longer be detected, typically 8-15 fractions. 
2.3.3 Purification of Ilis6-tagged proteins under native conditions 
2.3.3.1 Soluble protein release 
AfIcr thawing on ice the Pellet was resuspended in 5ml BugBuster (Novagen) for 
every Ig of cell pcllct and PCI (Roche). This was left to lyse on a rotator at RT for I 
hour bcfore centrifugation (13,000g, 20 minutes, 4'Q to pellet the cell debris. 
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2.3.3.2 Periplasmic protein purification 
This method was used to purify pcriplasmic proteins from 10ml culture volumes and 
was scaled up accordingly for larger preparations. 
Tle cell pcllct was defrosted slowly on ice and then resuspended in 0.5ml 30 mM 
Tris-IICI p1l 8.0,20 % sucrose with lpl EDTA, pH 8.0 and appropriate protease 
inhibitors. The cells were mixed for 10 minutes at RT and then centrifuged for 10 
minutes at 10,000g at 4*C, and the supernatant was discarded. In order to break the 
cell wall and release the pcriplasmic proteins, the cell pellet was thoroughly 
resuspended in ice cold 5mMMgSO4 for 10 minutes with gentle stirring. 
Ccntrifugation to pellet the cells and to isolate the periplasmic fraction in supernatant 
was performed at 130OOg for 20 minutes at RT. 
2.3.3.3 Binding to and clution from the Ni-NTA resin 
The binding capacity of the Ni-NTA resin is 5-10mg/ml and the volume of beads 
was adjusted accordingly for each purification. The beads were washed 3 times in 
wash buffer by centrifuging at 500g for 5 minutes, before being mixed with the cell 
lysate for I hour at RT. After this incubation period the lysate - Ni-NTA mixture 
was loaded into a column and the ilow through collected for SDS-PAGE analysis. 
The column was washed with 2 column volumes of wash buffer and the flow-through 
collected for SDS-PAGE analysis. 0.5ml fractions of elution buffer were used to 
clutc the protein from the beads and this process was continued until Bradford assay 
of the clutcd fractions failed to show presence of protein. 
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2.3.4 Purification orilis6-tagged protein under denaturing conditions 
T*ha%N, cd cell pellets were resuspended in 5ml of Buffer B for every Ig of cell pellet. 
The lysis reaction was left to take place at RT, with stirring for I hour or until the 
solution became translucent. The lysate was centrifuged at 10 OOOg for 30 minutes to 
pellet the cell debris and the cleared lYsate (supernatant) was mixed with I- 2ml of 
washed Ni-NTA beads (2.2.3). Binding of His6-taggcd protein to the Nickel beads 
took place for I hour at RT. The lysate- resin mixture was carefully loaded into a 
column and the flow-through collected. This was saved for SDS-PAGE analysis. 
Buffer C was used to wash the column twice, 4ml each time and then the protein was 
cluted using 0.5ml fractions of Buffer E. The protein content of each fraction was 
assayed in a Bradford Assay. 
2.3.5 Estimation of protein concentration using the Bradford assay 
In a 96 well plate, 200pl of Bradford Reagent was mixed with I PI of the protein 
sample of interest or the same volume of BSA standards, typically the range of 
concentration of BSA standards was l0mg/ml - 0.5mg/ml. After thorough mixing, 
the absorbancc of the wells at 595nm wavelength was read on the plate reader. The 
concentrations of the standards were entered, a standard curve was automatically 
created and the concentrations of the unknown samples were calculated. 
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2.3.6 Protein dialysis 
Proteins generally needed dialysing to remove the glutathionc or imidazole from the 
clution buffers following purification on glutathione Sepharose or NTA-Nil* beads 
respectively. Protein fractions of similar concentrations were pooled and carefully 
pipettcd into a short piece of dialysis tubing scaled at one end with a plastic clip. A 
second plastic clip was used to scal the open end and the sample was placed in I OL of 
PBS and left to equilibrate for 4 hours at 4*C with stirring. After 4 hours the PBS 
was replaced and then repeated twice more to be sure that the concentrations of 
cluting agent were negligible. SDS-PAGE was used to accurately determine protein 
conccntrations following dialysis. 
2.3.7 SDS-PAGE 
Unless otherwise stated, 12.5 % acrylamide were used and were prepared according 
to the following formulations: 
Sepamting gel 
2.4ml dH20 
3. Oml 30% acrylamide solution 
1.9ml separating buffer 
II 2pt Ammonium Persulphate (APS) 
5.0jil TEMED 
Stacking gel 
I. Oml dH20 
300pl 30 % acrylamide solution 
444pl stacking gel 
28pl 10 % APS 
5. Opl TEMED 
64 
The separating gel was poured into the BioRad plates, held into position by the 
clamp. Once set, the stacking gel was poured on top and a 10 or 15 lane comb was 
positioned into the stack. When the second gel was set, the comb was removed and 
the gels were positioned in the tank and immersed in running buffer. 
Samples were boiled in the appropriate loading buffer (generally reduced loading 
buffer unless a structurally sensitive antibody was being used in a Western blot). 
SDS-PAGE gels were run at 60V for 30 minutes or until the proteins had passed 
through the stacking gel, and then 130V for 60 minutes. 
2.3.7.1 Coomassie staining 
The gels were carefully taken out of the clamps and stained by immersing in an 
excess of Coomassic Brilliant Blue for one hour. De-staining the gels to remove non- 
specifically bound Coomassie was performed by discarding the Coomassie, adding 
an excess of de-staining solution and a piece of sponge to absorb the dye and help to 
speed up the process. For optimum results de-staining was carried out overnight 
before analysis the following morning. 
2.3.7.2 Silver staining 
Silver staining was performed as per the manufacturers' instructions. Firstly the gels 
were fixed in Fixative Enhancer Solution made by mixing 50 % v/v methanol, 10 % 
v/v acctic acid, 10 % v/v Fixative Enhancer Concentrate*, and 30 % v/v distilled 
water. The gels were fixed for 20 minutes or overnight with gentle agitation. The 
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gels were washed by rinsing twice in excess distilled water for 10 minutes each time 
with gentle agitation. To stain and develop the gel the following components were 
mixed in a glass beaker widi a Teflon coated magnetic stirrer 5 minutes before use: 
35ml deionised water, 5ml Silver Complex Solution*, 5ml Reduction Moderator 
Solution*, 5ml Image Development Reagent* and immediately before use 50ml of 
Development Accelerator Solution* at room temperature was added. This was 
poured over the gels and gently agitated for 10 - 20 minutes until desired staining 
was reached. The reaction was stopped by placing the gels in 5% acetic acid for 15 
minutes and then rinsing in water. 
* solutions from Silver Stain Plus Kit, BioRad 161-0449 
2.3.8 Western Blotting 
SDS-PAGE gels were arranged in the Western blotting clamp with nitrocellulose 
membrane on the anode side. Protein transfer conditions were 250mA for one hour 
on ice, or 30mA for six hours. 
2.3.8.1 Probing the membranes with antibodies 
Membranes were blocked in PBS-T containing 5% w/v milk powder for I-2 hours 
at RT and primed with primary antibody at the manufacturers' suggested 
concentration diluted in blocking buffer. Incubation was at RT for I hour followed 
by three, five minute washes in PBS-T. The membranes were then incubated with 
secondary antibody labelled with horse radish peroxide (HRP), used at 1/3000 (the 
dilution recommended by manufacturer) in blocking buffer. Incubation was at RT for 
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I hour. Thorough washing in PBS-T took place to remove unbound and non- 
specifically bound secondary antibody. Control blots were performed by omitting 
the primary antibody to determine any non-specific or background binding of 
secondary antibody. 
2.3.8.2 Developing the Western blot 
A 1: 1 ratio of ECL reagents (Amersham) were mixed and immediately poured over 
the membrane. After I minute the membrane was taken out, drained, wrapped in 
clear plastic and taped into a film cassette protein side up. A sheet of 
autoradiography film was immediately placed over the membrane and exposed for 30 
seconds to five minutes. The film was immersed in developer solution until bands 
became visible, washed in excess water and fixed in fixative solution until the film 
turned transparent. The fixative solution was washed briefly in water and the fihn 
lcft to air dry. 
2.3.9 General ELISA method 
ELISAs were performed in flat-bottomcd Maxisorb 96 well plates (Nunc) unless 
othcr%visc stated. All washes were pcrfonned by filling the wells with Ix PBS-T, 
nicking off and blotting on some paper towel. All incubations were for 1- 2 hours at 
room tcmperature. 
Generally the wells were coated with 1001d of a lOpg/ml protein solution in binding 
buffer and incubated at 4*C overnight. Next morning, the excess protein solution was 
flicked off and the wells were washed before blocking with 2001A of blocking buffer 
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for 1-2 hours at RT. The wells were washed 3 times and incubated with primary 
antibody dilutcd in blocking buffer (see individual experiments for dilutions). 
Following washing the secondary antibody labelled with HRP at 1/3000 dilution was 
added and after the incubation period the plate was washed 5 times and was then 
ready to be developed. For each 96 well plate one TMSO tablet (Sigma) was 
completely dissolved in Iml of DMSO before adding 9ml citrate phosphate buffer 
and 21d 11202.1001d of this reagent is added to each well. The reaction is left to take 
place (typically 1-10 minutes) by shaking at RT. When a substantial level of colour 
was obtained in the control well the reaction was quenched by addition of 15 PI 
112SO4. An absorbance reading at 450nm for each well was read on an ELISA plate 
reader. 
2.4 CELL CULTURE METHODS 
2.4.1 Cell Passage, harvest and cell count 
Unless otherwise stated, all cells were grown in DMEM and 10 % FCS supplemented 
with 100jig/ml penicillin and lOOpg/mI strcptomycin in a 37*C incubator with 5% 
C02. 
Adherent cells were harvested by adding 2ml 5mM EDTA in HBSS (without calcium 
and magnesium) or Cell Dissociation Solution (Sigma) followed by a 3-5 minute 
incubation before gently pipetting the solution across the Petri dish to remove cells. 
Culture medium was added to a total volume of 10ml and the cells were isolated by 
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centrifugation at 400g for 4 minutes. The cell pellet was resuspended in fresh 
mcdium and the cells wcrc platcd as required. 
A hacmocytometer was used to count cells. The density (cells/ml) of a cells 
suspension was calculated by counting the number of cells in the central 5x5 
squares. 100 cells counted was equal to 106 cells/ml. 
2.4.2 Freezing of cells 
Confluent cells on a 100 mm Petri dish (typically 10 x 106 cells) were harvested and 
re-suspended in I ml of freezing mix comprising of 10 % v/v DMSO and 90 % FCS. 
Cell freezing chambers were used to slowly freeze the cells (I *C per minute) before 
transferring to liquid nitrogen dcwars for storage. 
2.43 Thawing of cells 
Cells were defrosted rapidly by immersing in a 37 "C water bath immediately after 
being taken from the storage dewar. Once the cell suspension had just thawed it was 
poured into fresh media, centrifuged to pellet the cells as described earlier, before 
being resuspended in appropriate media and plated. 
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2.4.4 Transfection of Plasmid DNA 
2.4.4.1 Electroporation of plasmid DNA 
CHO cells at 70-90% confluency were harvested in cell dissociated solution. One 
plate (_IX106 cells) was used for each electroporation event and after pelleting, the 
cells were resuspended in 0.8ml and added to a pre-chilled I. Sml tube containing 
50jig of chilled DNA. The DNA and cells were then transferred to pre-chilled 
cuvcttes and incubated for 10-30 minutes on ice. The cells were then pulsed with 
290 V, 960 [tF and then transferred back onto ice. After 30 minutes incubation on ice 
the cells were divided between 5 plates containing the normal growth media. The 
cells were lcft to grow for 24 hours before addition of the selective media containing 
40.100pg/ml gencticin. 
2.4.4.2 Lipofectamine transfection procedure 
Cells were plated on 6 well plates (Nunc) to 50-60 % confluency and left to adhere 
overnight. The DMEM used for the remainder of the protocol is without serum. 
Preparing DNA per well: 
AI jig of the DNA of interest was mixed with I OOjtl of DMEM and 6pl of plus 
reagent and incubated for 15 minutes at RT. 
B Add 4jil of Lipofcctamine to I 00pl of DMEM, mix and leave for 2 minutes at 
RT. 
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Solutions A and B were combined, vortcxcd and incubated at RT for 15 minutes. 
Preparing cells: 
I'lic cell media was removed before adding 8001d of DMEM (-FCS) with 2001d of 
the DNA complex prepared as above. After 4-5 hours incubation (37*C, 5% C02) 
the supernatant was removed and 2.5ml DMEM (+FCS) was added. Cells were 
grown for 48 hours before being assayed for protein expression. For stable 
constructs, 40-100 pgIml of Gencticin was added to the cells after the initial 48hrs 
and then lcft for 2-3 weeks with half media changes as and when required. 
2.4.4.3 Calcium phosphate transfection procedure 
Tlis procedure was for cells growing on 100 mm plates and was performed on cells 
that were 30 - 60 % conflunt. Fresh media was added to each plate and left to re- 
condition for 1-2 hours. 
Solution A. In a 1.5ml tube, 10 - 20pg of DNA was mixcd with 62pI of CaCI2 and 
madc up to 500pl with dH20. 
Solution B. 5001d 2x PBS in a 15ml tube 
Ile 15ml tube containing solution B was vortexed continuously whilst solution B 
was added in a drop wise manner. The solution was incubated at RT for 30 minutes 
in which time it tuned slightly opaque due to the formation of calcium phosphate- 
DNA co-prccipitation. Aftcr a final vortcx the solution was cardully addcd to the 
plates whilst swirling gently. Cells were harvested afIcr 48 hours. 
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2.4.5 Isolation of protein from mammalian cells 
Cells were harvested as previously described and resuspended in 50gl of cell lysis 
buffer containing protcase inhibitors. The cell suspension was incubated for 10 
minutes on ice, at RT or at 37'C to lyse cells. The cell lysate was centrifuged at 
100OOg for 10 minutes to pellet the nuclei and the supernatant was transferred to a 
fresh tube and assayed for protein content by the techniques described above. 
2.4.6 Whole cell ELISA method 
Conflucrit cells were harvested and counted as described in 2.3.1. A cell suspension 
of density 106 cclls/mI was made up and 1001d plated per well in 96 well plates 
(method adapted from (Schobcr ct al. 2002). The cells were left to adhere overnight 
and the following day antibody probing and development was carried out in the same 
was as described in 2.3.9. 
2.4.7 Fluorescent activated cell sorting (FACS) 
All centrifugation steps are at 400g for 4 minutes unless otherwise stated. 
All washes are carried out as follows: The cells were centrifuged and resuspended in 
1001d PBS with gentle pipetting up and down, before centrifugation as before. 
Sub-conflucnt cells were dissociated in 50mNI EDTA in HBSS and centrifuged at 
400g for 4 minutes. Cells were counted and resuspended at 106cclis per ml in BSA 
(Basic salt solution and 0.2 % w/v azide) and then plated at a concentration of 105 
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cclis per well of a 96 well plate (100pl / well). Cells were centrifuged and 
resuspended in primary antibody diluted in HBSS with I% w/v BSA to block. Cells 
were then incubated on ice for 30-60 minutes and then washed twice. A 1/1000 
dilution of appropriate secondary antibody, conjugated to FITC and diluted in HBSS 
with I% . v/v BSA, was added and incubation was for I hour on ice in the dark. The 
cells %vere washed twice as before, resuspended in 300 pI HBSS and read 
immediately on a FACS calibre using the Cell Quest program and FLI basic settings. 
Five thousand cells per experiment were counted and results were analysed using 
WinNIDI software. 
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CHAPTER 3 
RECOMBINANT TETRASPANIN EC2 PRODUCTION AND 
FUNCTIONAL STUDIES 
3.1 INTRODUCTION 
3.1.1 Tetraspanin EC2 domains 
The tetraspanin EC2 domains are arguably the most intriguing and well researched 
region of this family of transmembrane proteins (see Chapter 1.2). Tetraspanin EC2 
recombinant proteins have been used to study the properties and functions of this 
domain here in Sheff"ield (Higginbottorn ct al. 2000; Higginbottorn et al. 2003; 
Garcia-Lopez et al. 2005). and elsewhere (Zhu, G. Z. ct al. 2002; Ellerman et al. 
2003). 
3.1.2 Production of tetraspanin EC2 domains using the pGEX system 
In order to assist the production and purification of proteins in E coli, several vectors 
have been developed that express the desired protein as a fusion with another more 
easily purified protein. Fusion proteins can also prevent proteins from forming 
insoluble aggregates and also can enhance the stability of the protein (for review see 
(Cabrita et al. 2004). In Sheflield, tetraspanin EC2 proteins are expressed with N- 
terminal GST tags using the pGEX vector system (Amersham). The pGEX 
cxprcssion system was developed in 1988 (Smith et al. 1988). The same group had 
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previously expressed an enzymatically active, 26kDal, GST (Sj26) from S japonicum 
in F. coU and other groups had demonstrated that mammalian GST isozymcs can be 
purified by affinity chromatography on immobiliscd glutathione, followed by 
competitive clution with excess free glutathione (Simons ct al. 1977; Simons et al. 
1981). This property was found to also be true for Sj26 (Smith et al. 1988) which 
suggested to the designers that a vector with a Sj26 fusion protein would be 
extremely beneficial for the rapid, single-step purification of foreign polypeptides 
linked to Sj26. In addition, the GST tag improves the solubility of the fusion protein 
so that non-denaturing purification procedures can be used. The first vector of this 
type, pGEXI, was successfully used to express stable eukaryotic-GST fusion proteins 
(Smith ct al. 1988). A more advanced pGEX vector, pGEX2T, was then produced 
encoding the cleavage recognition site for thrombin immediately 5' to the multiple 
cloning site to allow for removal of the GST fusion protein if desired (Smith et al. 
1988). Further engineering of the pGEX vector was carried out to create pGEX-KG, 
which included a glycine-rich linker region containing the sequence PGISGGGGG 
located immediately following the thrombin cleavage site (Fig. 3.3). This glycine 
linker acts to increase the efficiency of thrombin cleavage by allowing greater 
accessibility of thrombin to its recognition sequence (Guan et al. 1991). 
ne desirable properties of optional GST removal, ease of purification and increased 
solubility of fusion protein when tagged with GST, were all factors that lead to the 
decision to use this vector system to express the tctraspanin EC2 constructs. 
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3.1.3 AINIS 
The previous success of using recombinant EC2 proteins and the need for additional 
tools to study these complicated transmembranc proteins were motives for us to: A) 
optimise the current methods of production of our existing EC2 proteins; B) to 
attempt to clone and express the EC2 domains from CD82 and CD231; Q to use 
these proteins to study the interactions with primary tctraspanin ligands; D) to 
promote these proteins as novel and useful tools in the study of tetraspanins by 
collaborating with fellow tctraspanin researchers. 
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3.2 MATERIALS AND METHODS 
pGE-X"-KG vectors containing EC2 domains from CD81, CD9, CD63 and CD151 
were constructed previously in our laboratory. Full length CD9, CD81, CD63 and 
CD151 cDNA were kind gifts from D. Azorso, S. Levy, C. Murdoch and L. 
Ashman rcspectiN, cly. The EC2 domains were initially cloned into the pGEX-2T 
vector (Amcrsham Bioscienccs) using BamlfflEcoRl restriction sites (Flint et al. 
1999) and transferred to pGEX-KG vectors using EcoRl/HindIII restriction sites. 
Full length CD82 and CD231 cDNA were obtained from the I. M. A. G. 13 
Consortium, clones 2959683 and 4801388 respectively. For directional cloning 
into the pGEX-KG vector, 5' oligonucleotides were designed with the EcoRI site 
followed by TA overhang immediately upstream from the beginning of the EC2 
domain. 3' oligonucleotidcs had stop codons followed by HindIII sites. Both 
inserts and plasmids were cut with EcoRI and HindIII and ligated as described in 
Chapter 2. 
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3.3 RFSULTS 
3.3.1 Production of recombinant EC2 domains 
The production of the CD9, CD81, CD63 and CD151 tctraspanin EC2 proteins 
was continued for use in the current work and in collaborations (Chapter 7). 0.5ml 
aliquots; of GST-EC2 proteins were cluted from the glutathionc-Scpharosc affimity 
columns and each aliquot was assayed for its protein content using Bradford 
reagent. Typically, the EC2 proteins were elutcd in a total volume of 6ml. At this 
stage the samples were in clution buffer, IOmM reduced glutathione and 50rnM 
Tris, p118.0, and so required dialysis into PBS. Aliquots of similar protein 
concentration were pooled. For each sample, there were generally two pools; one 
that Nvas of higher concentration and one of lower. Following dialysis, the 
concentration of each sample was determined by separating SpI aliquots of each 
sample on SDS-PAGE gels along with known concentrations of BSA (Figure 3.2). 
Spot densitometry was then used to determine the protein concentration in each 
sample (Figure 3.2). Wherc possible, structurally sensitive antibodies were used to 
authenticate the tctraspanin proteins (Figure 3.3). It is apparent from Figures 3.2 
and 3.3 that the GST-EC2 constructs are not 100% pure. In each sample there is 
some free GST (26kDal) the GST-EC2 protein (-35kDal) and what is presumably 
a degradation product (-3OkDal). It is also noticible in the western blots that there 
is some free EC2 protein at around lOkDal that is recognised by the structurally 
sensitive antibodies. 
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Protein Lane Content Protein 
mg/ml 
1- - -- -- --- -T-g/ 
MI 
10 Molecular % eight n/a 
marker 
Human ( D151 6.2 
medium 
2.5 Human ( D151 high 7.4 
1.0 12 Human ( D151 lo, ^ 3.4 
5.9 13 Iluman ( DO high 3.1 
1.4 14 Human CDO lo" 1.9 
8.2 15 Human ( D81 high 12.1 
2.8 16 Human CDSI I oA 3.3 
17 GST 2.8 
"I Figure A. - knal-tsis of recombinant tetraspanin EC2s b% SDS-PACF. Following affinitN 
purifi%: ation Ilic I (" rc,: ombinant protcm-ý (high 
'and lo%ý ct mk: ew rations r0ols) %%ere 
dialý%ed apmýi PBS and then separated on SDS-lA('YF gels run kinder reducing conditions and 
stairk-d %%ith Coornassic (A) to detennine the concentration ofeach sample. Table B sho%%s the 
contents ofeach lane and the concentration detennined bý s1vt densitornetrý. 
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Figure 3.3 1 etra%panin recombinant protein analýscs using NNestern blot-ting. 15 pg of the 
tetnispanin proicinN %%ere Wded on NDS-PAUF get., mid run in the presence of P-mercaptoethanol 
prior it) blotting. Membranes %%ere blocked in 5% %% % milk in PBS-T. In A. blots were probed %%ith 
I 3WO dilution of' anti-6ST-IIRP diluted in blocking buffer. Figure B shows Western blots of 
ictraspanin FC2 constructs run on SDS-PAGE gels in the absence of reducing agent. Specific 
mAhs %%ere usc& At \IA-I (hCD9). 115C6 (CD63), 1.3.3.2.2 (CD8I) and 14A2 (CD151) each at 
1,1000 dilution in blocking buffer followed bý 1 3000 dilution of anti-mouse IgCy diluted in 
blocking buffer. 
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3.3.2 Procclim expressýom In m 20 L BicTermemter 
Protein expression in a 20L biofcrinenter and in 21, conical flasks in a shaking 
incubator were compared to evaluate the optimum method for GST CD63-EC2 
production. I. Oml fractions of GST-CD63 EC2 prepared in a shaking incubator 
were clutcd from a glutathione Sepharosc column of gave a yield of 0.85mg/ml. 
The protein produced in the biofermenter gave a yield of over 2.6mg/ml Fig. 3.4 
A). This is over a3 fold increase in protein produced in the biofcrmenter 
compared to production in 2L conical flasks in shaking incubators. 
A Coomassic-staincd gel allowed comparison of the composition of recombinant 
protein produced and the method of production i. e. relative amounts of GST-CD63 
EC2 (-36 kDal), GST alone (-25 kDal) and other degradation bands that are 
present. Ile Coomassie gel (Fig. 3.4 B lanes 3 and 4) shows similar banding 
pattern bct%vcen whole cell lysates and GST-CD63 EC2 produced by both 
mcthods, showing that production in the biofermenter does not affect the quality of 
the recombinant protein (top band only: - -42 % GST-CD63 produced in the 
biofermcnter versus - 40.5 % in shaking incubator). For functional assays, the 
concentration of EC2 protein was determined using all bands above the 25kDal 
GST alone band. The samples were used in functional assays with the 
contaminating GST present, but a GST control was always used to rule out any 
possibility that the frcc GST was having any affcct. 
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FiXure 3.4. Conipmrinon of G%T-(*9)62 FU2 producaion in 1he %hgking incublator and 
hi4ifernienter. 'I oI bacterial culture from cach production method "as assaýed for amount of 
ic%: onibinani prolcin I lie cell% %kere 1ý%ed ý%ith BuglIuster and NOole cell 1ý', Jtes %wre loaded onto 
cqual amount o(glutathione Scpharow. OS 1 -CD61 FC2 %%as cluted with reduced glutathione. 2 pI 
frorn each clution step %%as mixed Aith 200 pI tit' Bradtord reagent and the absorbance was read at 
it) ,5 nm. ., % standard curw "as calculated 
from kmmn amounts of 11SA. and the concentration of 
clution %olume% from latvratorý and b1ofennenter productions N%erc detennined and plotted on an 
clution profile (A) A Ctionlassic-stained gcl sho"s the coniliosition kit' recombinant protein made 
b\ the mo methods. 10 pg nil of(iS 1 -CDO FC2 constructs \%ere loaded (14). 
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3.3.3 Cloning CD82 mmd CD231 EC2 dommins 
Primcrs %N, crc designed with 5' EcoRl and 3' Ilind]II restriction sites and a 5' TA 
overhang for incorporation into the TOPO cloning vector (Table 3.1). 
Rnaricalom Sttrt/ TA Primtr 
Site stop 
CDSI F GAATTC TA TACTTCAACATGGGCAAGC 
(5'-3') 
-- CDC R AAGM TCA GTTCTCCTGCAGCAGCCACG 
V-31 
CD231 F GAATTC TA TT-rGTGTITCGTCATGAGTC 
(5,41 
-- CD231 R AAGCTr TCA GTTAGTCTCCATGAAACTAGTTACC 
Table 3.1. Tetnupsmim EC2 prime for cBom1n& Imto Che pGEX-KG vector. The primers listed 
%%ith their respective overhangs were designed and ordered from MWG. 
Ile cDNA of interest were supplied in plasmids in bacteria that had been streaked 
on LB agar containing 50 pgIml ampicillin. Colonies were re-streaked onto the 
same medium and left overnight at 37*C to obtain single colonies. Plasmids were 
extracted and the DNA of interest was amplif ied using the specific primers. 
For cloning of PCR prcOucts into the TOPO-TA vector, single DNA bands at the 
correct heights on an agarose gel are required. A band for CD82 was generated 
easily using the recommended conditions for the proofreading enzyme PlatinumV 
Pfx; an annealing temperature of 55*C for 30 scconds/cycle (Table 3.2). CD231 
rcquircd furthcr optimisation by changing the annealing temperature and 
incrcasing the time for annealing and extension. When the annealing temperature 
was at SOT for 45 seconds and the period of extension was increased to 4 minutes, 
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a single band at the right size was obtained for CD231 EC2 (Table 3.2 A&B and 
Figurc 3.5). 
A. 
PCR m5iture Volume/pl 
10 x Vfx amplifying buffer 5.0 
1 OmNl dNTP mix 1.5 
5OMNI N19SO4 1.0 
1: 1 mixturc primers 1.5 
Tcmplate DNA 1.0 
Platinum pfx DNA pol 1.0 
d1120 To 50 pi 
IL 
PCR condifloms Temp (*Q 
CD82 
Temp (*C) 
CD231 
Time (s) 
CD82 
Time (s) 
CD231 
DENATURE 94 94 15 is 
ANNEAL 50-55 55-60 30 45 
EXTEND 68 
_68 
60 
CYCLES 25 CYC LES 
Teble 3.2. PCR conditions for smplificaflon of CD231 mad CD32 EC2. The composition of the 
reaction buffer for the PCR of each construct is listed in Table A. The conditions that produced 
single, discrete bands at the correct height are outlined in Table B. 
The remainder of the PCR reaction mixture that gave single, discrete bands at the 
correct size on the agarosc gel was used in the TOPO cloning reaction. The TOPO 
cloning reaction was carried out and transfonned into TOPIO cells. 10-50pl of 
each transformation was spread onto pre-warmed LB agar plates containing 
I OpgIml X-gal (for blue/white screening) and 50pgImI of carbcnicillin or 50pg/ml 
kanamycin (thc TOPO vcctor has rcsistance to both antibiotics allowing for 2 
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rounds of selection). Around 40 white colonies had grown on both CD231 and 
CD82 transformants. 
Figurr 3.5. PCR amplification of the EC2 domains from CD82 and CD231. I-he PCR reaction 
, ý%as performed on a temperature gradient ý%ith I'm temperatures ranging from 50-55 *C for CD82 
and 55-60T for CD231. at IV inter%als. For both domains. all five temperatures gave single 
discrete hands at the right height (- 350400bp). In lane 1, there is a DNA marker and lane 12 is a 
no-template control. 
Six white colonies were picked from each plate, grovm ovemight in LB containing 
the antibiotic that was not used in the LB agar, plasmids were extracted and 
digested with EcoRl to verify the presence of the insert (Fig. 3.6). The TOPO 
%ector contains FcoRl restriction sites immediately up- and down-stream from the 
PCR product cloning site. The inserts were sequenced in the 
TOPOT" vectors to 
ensure that the full insert is present and of the correct sequence and orientation. 
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Figure 3.6. Restriction dig"t o( CD82 and CD231 EC2 DNA from TOPO-TA. After cloning 
the iilwrt% into the I OPO- IA% ector (In% itrogen), colonies ýNere screened for the presence of the 
interest before being suenced to check the correct direction and sequence of the cloned DNA. 
FOPO- FA vector has FcvRI restriction sites flanking the inserted DNA. The miniprepped DNA 
-A-&% digested %%ith EcoRl for 3 hours at 37*C and reaction mixtures were run on aI% agarose gel. 
After identification of correct inserts in the TOPO vector, a double digest of both 
I'0110-clone and pCjFX-KG vector was performed. The digestion reactions were 
set up according to Fable 3.3. 
Component Volume pi Component Volume/pi 
TOPO Clone 10 pGLX-KG 8 
Multicore 2 Multicore 2 
Water 1 6.5 1 Water 8.0 
iI: 
IlindIll IIIý HindIll 11 
EcoRl 0.5 111 EcoRl 0.5 
Fable 3.1. Component% of the Illindill, EcoRl double digest of CD231 and CD82 DNNA from 
f*()Po-T'% and the inwri in p(; F. X-K(; expression vector. Correctlý sequenced 10110-1A 
% coor, containing the I wid ('D82 - cre digested ý%ith the cornivnents described in the two 
IcIt hand k: olunin% and the p(Il: X ý ector as des-mbed in the t"o fight hand columns. (HindIII was 
added alone to the JOPOJA %ector for 2 hours before addition of the FcoRl. This is to ensure 
correct cutting bý the FcoRlas there are additional EcoRIsites in the'FOPO-TA %ector). 
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Fhe digestion was left for 2 hours at 37*C. EcoRI was added to the TOPO clone I 
hour allcr the IfindIll to aid correct cutting as there are additional EcoRI sites 
flanking the insert. The reaction mixtures were run on high purity gels, the 5 Kb 
cul vector and 350-400bp EC2 DNA from CD82 and CD231 (as shown by *) were 
excised from the gel and the DNA purified (Figure. 3.7). 
Hgurv Yý. Ilindill. EcoRl double digest of CD82 and CD231 DNA from TOPO-TA and the 
p(J'\-KG' expression %ector - FOPO-I'A \ectors containing CD213 and 
CD82 FC2 inserts were 
, figeNted vith 11indIll and EcoRl t'0r a total ot'-, hour-, at -17 
C. Reaction mixtures were nin on high 
pun" agarose gels and the 350-400bp FC2 inserts (*) as well as the cut pGEX woor (*) were 
c\ci-. ed and the DNA purified. read% for ligation. 
The punfied. cut vector DNA was ligated with CD82 and CD231 tetraspanin DNA 
for 2 hours at 14T. 5pl of each ligation reaction mixture was used to transform 
100 pi DH5a competent cells. CD82 and CD231 colonies grew on the plates with 
inscrt: vector ratios of 3: 1 and 1: 1. respect Ive Iv. Presence of the insert was 
examined b-, a direct PCR screen ofthe colonies using CD82 or CD231 specific 
primers. Positive colonies were picked, the plasmid was purified and the DNA 
digested with FA-oRHIindIII to confirm the presence of the inserts in the pGEX 
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vector (Figure. 3.8), The DNA was sequenced in the pGEX vector to ensure no 
ensuing mulations had occurred and to verify the correct orientation and reading 
frame of the insert. 
Figure 3.8. Double digest of p(; EX-K(; vector to confirm the presence of CD231 and CD82 
inserts. I olltming ligation ofthe inscris excised frorn the I-OPO-TA vector with the cut p6l: X- 
KO %wor. the ligation reactions %%ere uwsformed into DI-15ct cells and the plasmids were purified. 
., % 
double digest %ith 11intAll and FcoRl %as perfornied to confirm that the ligation had worked and 
the insert %as present. The reactions %%ere run on I 0,, o agarose gels. 
3.3.4 Expressing CD82 and CD231 recombinant protein 
A method to purifý- the FC2 domains from CD9, CD81, CD151 and CD63 has 
already been established (Flint et al. 1999). BL21 Codon Plus E. coli cells are 
transformed with the p6FX vector and a 10ml overnight inoculum added to 400ml 
1.13 and grown until ODw = 0.8 -IA before induction with 0.1 mM IPTG. The 
bacterial cells are then left to express the protein for 4 hours before being harvested 
89 
by centrifugation. This, therefore, was the first method of choice when attempting 
CD231 and CD82 protein expression. Colonies grew on the antibiotic selection 
plates, suggesting that the transformation had worked and the plasmid had been 
taken up. Colonies were picked and grown as described for the other taraspanins. 
T1c ccll pcilets were lysed with BugBuster and protein purification, using the 
glutathionc Scpharose column, was performed. Samples eluted from the column 
with free, reduced glutathionc were assayed for the presence of GST-tagged 
protein using Bradford Reagent. The first attempt showed no eluted protein. The 
%holc expression procedure was repeated using freshly made LB-Agar plates, 
reduced glutathione and IPTG but there was still no production. It was then 
decided to decrease the temperature to 25*C and to use 1.5mNI IPTG to induce. 
Samples from die purification procedure were Tun on an SDS gel and stained with 
Coomassic to test for the presence of correctly sized proteins (Figure. 3.9). There 
appeared to be evidence of some protein at around the correct weight (35 kDal) for 
CD82 in the cluted samples 2-4 although the Western blot for CD82 appeared 
negative in these lanes. 
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Figure 3.9. (-oomm%%ie gel sho% ing expression of CD231 and CD82 in shaking incubators at 
1.!; m%l IPM induction. Cells were IN-sed and GSF-W2 proteins %%ere puritied on 
glutathionc Scpharww column, Sample% fTx)m various stages in the purification procedure %%, ere 
Ivitecl in Ioading hullcr and run on SDS-PAGF before staining in Cm, )rnassic. 
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3.3.5 Protein expression In the 20L Bidermenter 
CD63 EC2 is poorly expressed compared to the smaller CD9 and CD81. 
However, improved yields arc obtained when expressing CD63 EC2 in the 20L 
biofcnncntcr compared to production in the laboratory in a shaking incubator 
(average values were 0.85mg/ml compared to 2.6mg/mI respectively, Figure 3.2). 
As CD231 and CD82 arc more similar in size to CD63 than CD9 and CD81, it was 
decided to attempt expression in the biofermenter. 500ml of inoculate was made 
up as described in Materials and Methods and added to the 20L biofermentcr. 
When OD6w reached 0.6, IPTG was added to a final concentration of 0.1mM 
proceeded by growth at 37*C for 4 hours. 
There was a band at 25kDal in the CD231 and CD82 purified protein and 
glutathione Sepharose bead samples (Figure. 3.10), this is likely to be GST. There 
arc no other clear, additional bands in the CD231 purified protein column (lane 3) 
but there is a band at 35kDaI for CD82 (lane 7). However, this was not rccognised 
by the commercial CD82 antibodies in a Western blot and yields were extremely 
low (0.2mg, 1L). It became evident that a more efficient method was required. 
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Figure !. 10. Coomx%%ic %tained gel %hoA ing ( D231 and ( D82 FC2 production in a 201- 
hio(ermenter. ( c1l, %%ctc har\c, tcd and Iýscd the nicthod fOr protein c\preoion in a NhakinL 
n, wbatot W% I -ta"Ld pmems \%ere puntled on glutathione-Scpharow heads. Samples from 
%, jr, oti, t., tgc,, in the purificallon procedure \%ere N)Hed in loading huffer and nin on SDS-PAGl-' 
bef'Ore tving Cixmmsw stained. 
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3.3.6 Protein purification from the insoluble fraction 
It is common for complex recombinant protein expressed in bacterial cells to 
become trapped in insoluble aggregates known as inclusion bodies. Despite the 
fact that the other tetraspanin EC2 domains are not insoluble, it is possible CD82 
and CD231 EC2 proteins have different properties. Indeed, it could explain why 
they arc not being detected in BL21 cells. To solubilise inclusion bodies, 
guanadinum-IICI and urca arc required. This, of course, denatured the proteins, 
which then needed to be re-foldcd before being affinity purified. 
Figure 3.11 shows the whole insoluble fraction from BL21 cells transformed with 
CD82 (Lane 1) and CD231 (Lane 3), and the cluate from glutathione Sepharose 
columns loaded with the whole cell lysatc, washed, and protein eluted with 
reduced glutathione. Although there are some bands in the eluate in lane 2, these 
,. %-crc not rccognised by the anti-CD82 antibody. There is no evidence of any GST- 
tagged protein in lane 4. 
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3.3.7 The use of Origaml cells to produce CD82 and CD231 EC2 domains 
Origami cells have thiorcdoxin reductasc (trxB) and glutathione reductase (gor) 
mutations that create a lower c)loplasmic redox. potential, favouring the formation 
or disulphide binds. The mutations arc carried on plasmids that are selectable on 
kanamycin and tetracycline; thererore these strains are compatible with the pGEX 
vector that is ampicillin resistant. As this was the first time that these cells were 
to be used ror tetraspanin EC2 production, an expression-optimisation experiment 
%%-as perrormcd allowing a total or 54 differcnt conditions to be screened (Table 
3.4). Competent Origami cells were transformed with pGEX-KG vectors 
containing the CD82 EC2 or CD231 EC2 insert. Cultures were grown on LB agar 
containing 15jig/ml kanamycin, 12.5pg/ml tetracycline and 50pg/ml carbenicillin. 
Overnight cultures (10ml) were grown with the same selection and used to 
inoculate 400ml LB with selection antibiotics added. 
The cultures were grown at 25*C or 37*C, and to a range of OD6oo values (0.2,0.4, 
0.8) before being induced with 0.1,0.5 or I. OmNI IPTG. Finally, the cultures were 
lcft to express the protein for 2 hours, 4 hours or overnight, before being harvested 
by centrifugation. Non-induced controls were included for background protein 
analysis purposes. Ilic samples were lyscd with BugBuster and centrifuged to 
leave the whole ccll lysatc. As a quick screen to check that some protcin had been 
expressed, a range of samples were chosen at random for immunoblotting. I PI of 
each sample was dotted on to the nitrocellulose three times. Using anti-GST 
antibody, it was observed that all of the samples tested had a greater amount of 
GST compared to the background (non-induced) sample (Figure 3.12). 
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Sample 0 tomp OD600= VPTGYmM time/hrs 
--tamp 
Sample# 
1 37 0.2 0.1 2 25 -- - 28 
2 37 - 0.2 0.1 4 25 29 ------ 
3 37 0.2 0.1 ON _25'____ '' ____30___ 
4 37 0.2 0.6 2 _25- ___31 
6 37 0.2 0.5 4 25 32 
6 37 0.2 0.5 O/k 25 33 
7 37 0.2 12 
' 
25 34 
8 37 0.2 1' - ___4: ----- -- -- - 25-- 35-- 
9 37 0.2 1 ON - - 25 36 
10 37 0.4 0.1 2 25 37 
111 37 0.4 0.1 4 25 38 
12 37 - 0.4 0.1 ___25 __39_____ 
13 37 0.4 0.5 2 25 40 
14 37 ___ 0.4 0.5 4 25 _____ 41 
16 37 0.4- 0.5 OIN 25'_ -42-- 
16 37 0.4 12 25 43 
17 37 0.4 14 44 
18 37 0.4 1 PIN 25 45 
19 37 - 0.6 OA' 2 ____ ------- 25 46 
20 37 0.6 0.1 4 25 47 
. 21 __ _37- , ----0.6-- *-"- - -O. I---------b/ýý-- __25_____ ___48__ 
22 37' - - - 0.6 0.5 2 ___25___ 
23 37 
____ 
0.6 0.5____ __25___ --60- 
24 ý 37 0.6 0.5 O/N 25 61 
25- 37 0.6 1 
26 37 0.6 14 25 63 
27 37 0.6 1 01W____ 26- 64 
Table 3.4. Conditions for GST-231 EC2 and GST-82 EC2 production in Origami cells. 
400mls of LB plus selection was inoculated %%ith 10mls of overnight cultures of Origarni cells 
u=rormcd %ith pGEX-KG-CD82 EC2 or pGEX-KG-CD231 EC2. Flasks were left to shak-c at 
31'C or 25*C until the above mentioned 0136w values were reached. For each set of conditions, 
loml of the culture was taken out and induced %ith the appropriate concentration of IPTG before 
being left to express the Protein for the indicated time. 
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GST 01010 
04 aI* 
0 21 61010 
ýICZ 
r ad 
046 01110 
Figure 3.12. Dot blot sbowing GST-92 EC2 production in Origami cells. 400ml of LB plus 
wlection was akwulated - ith I Onil of o% emight cultures of Origanii cells transfonned %%ith pGEX- 
K(, -( D92 1 C_' or p(, l-X-KG-CD_", I FC2. Flasks %%m left to shake at 37*C or 25*C until the 
abo%c mentioned 01),.., values, %%ere reached. For each set of conditions. 10ml of the culture was 
taken out and induced %%ith the appropriate concentration of IPTG before being left to express the 
protein foc the indicated time. All of the samples %%ere Iysed %ith BugBuster and initiall). a 
selection %%, ere immurwhioned onto nitrocellulose, blocked in 5% w/v milk PBS-T and probed %%ith 
anti-6ST-lIRP (1,13000 diluted in blocking buffer) to ensure that there was a level of GST-tagged 
proteins in the induced samples abo%c the background levels (non-induced). 
As there did appear to be GST protein present in the induced samples, it was 
decided to immunoblot the remaining samples to see if there was anv correlation 
bct%%ccn the conditions used and the amount of protein produced. This is a crude 
mcthod and was performed as a rough guideline only. In each square of the grid, 2 
xI VI dnip were placed for each condition and blots vvere developed in the usual 
manner using an ant 1-6 S I' anti tx-)d-, - (Figure 3.13). A number of observat* ions can 
he made from the blot. Firstly, it is clear that overnight expression at 37*C has 
dctrinicntal Olects on protein pioduction as shown by the diminished spots in the 
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ovcmight squares compared to the 2 and 4 hour results. This effect is not seen 
with proteins expression at 25*C. For proteins expressed at both temperatures, 
induction at OD6oo = 0.8 appears to be unfavourable as less GST-tagged protein is 
identified in these squares compared to induction at OD6w 0.2 and 0.4. The 
optimum expmssion appears to always be after induction at ODOO = 0.2. At 37*C, 
using 0.5mM IPF6 and expressing for 2 or 4 hours, or using I. OmM IPTG and 
cxpressing for 2 hours are all noticeably good conditions, as are overnight 
expression at 25*C %k Ith 0.1 mM or 0.5mM induction. 
37 *C 
25 *C 
v 
0.1 mM IPTG 0.5 mM IPTG 1.0 mM IPTG 
0 01.4 0. -4 
2 hr 4 hr 0, N 2 hr 4 hr O/N 2 hr 4 hr O/N OD6oo 
. , f 
0 * a 
Am 'I a 0 
T 
0 e 
l 
0 . 0 lb 0 
0 % 0 0 t ., 
00 e 's 
. 
NI 
control 50 20 100.5 
0.2 
0.4 
0.8 
0.2 
0.4 
0.8 
10 
mg/ml GST 
Fiturt 1ý01 h101 4h"ing PrOduction of CST-CD82 FC2 in Origami cells. All of the IN-sed 
%ampics frtwn I able 3,4 %%ere blotled onto nitrocellulo-w in duplicate. Fhe nitrocellulose was 
'then 
bitxkW in 5% milk in PBS- I and probed %%ith anti-OS F-11RP (13WO diluted In blocking buffer). 
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IIo%%c%cr. dot blots do not gnve anN information about the quality of protein 
prixcluced i. e. the ratio of'GST-FC2 : GST alone. In order to gain this information 
. SDS-l'A(Il- gels are required. 
Fhe candidate samples identified by the dot blot 
nmed \\ith glutathionc-Sepharose beads in 1.5nil tubes. GST and GST- 
Jutathione in a batch purification tagged protein %%ere cluted with reduced u 
procedure and aliquots %%ere run on an SDS-PAGE gel and stained with 
Coomassle. Figure 3.14). Because ofthe increased degradation effects seen when 
gro%% ing at 1 TC %% e concentrated solelý oil tile samples grown at 25'C. 
I he densitomem program measures the density of all bands In each lane and gives 
them a rwrcentage %alue. Fhe program was set to measure 2 bands, the 25kDal 
(ISI and . 
3,5kDal GST-CD82 FC2. and to give a value of each band as a 
Ivi-centage. as sho%%n t'or the CD82 band (Figure 3.14 and Table 3.5). 
0.5 mM IPTG 0.1 mM IPTG 
4- 
l. igurv 3.14. ()ptimi%ation of GN 1 -CD82 FC2 proteins in Origami cells. Different samples 
pl,: kcd otit ti-om the immunoblot (I iý II I) N%erc run on 'SOSTAOI and Comiussle stained to look 
a, the conlixisition ofthe recombinam protem. 
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4""Now 4"Mmomp --- 
oftowmwo - 
Lane 1 2 3 4 15 
Value % 35.0 28.9 28.1 = 
Table 3.5. Densitometry measurement3 of the percentage of GST-CD82 EC2 relative to GST 
taken from the coomassic In Figure 3.14. Ile densitornetry of the bands in each lane were 
calculated using the Alpha-Im3ger. Percentage values of GST-CD82 EC2 are shown for lanes 
corresponding to those in Figure 3.14. 
From this, it was evident that growing at 25*C, inducing with 0.5mM IPTG when 
the culture density reaches OD600 0.2 and expressing the protein for 2 hours were 
the optimum conditions. Even though there was apparently more total protein 
produced using other conditions, the maximum amount of GST-CD82 EC2 relative 
to GST is desired. A Wcstem blot probed with TS82 showed that the GST-CD82 
EC2 was rccognised by this antibody as well as a faint band at lOkDal that is 
presumably cleaved CD82 EC2 alone (Figure 3.15) and was undetectable on 
Coomassic-staincd gels. 
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- 35 kDal 
GST-CD82 FC2 
400M 
-10 kDal 
(is 1 GST-CD821 CD82 ECI FC2 
Figure . 
1.15. %%esteru blot sho%ing recognition of the GST-CD82 EC2 b., the anti-CD82 
,, ntitmd-.. T%82. Urr%hlý pnoJuced(iSl-CD82 EC2 (IOpg) and a GST (]Opg) control %%ererunon 
transferred onto nitrocellulose and blocked in 5% milk in PBS-T before being probed 
,A ith I S82 (I 5M diluted in blocking butler) followed by anti-mouse IgG-HRP (1 /3000 in diluted 
in blocking butler). 
'Fhe same optimisation of GST-CD231 EC2 protein was performed in Origami 
cells but the immunoblots were negative for any GST-tagged protein produced 
despite presence of CD231 DNA in the Origami cells as shown by PCR of DNA 
firorn a plasmid purification of a sample of the culture medium taken after 
induction. CD231 specitic primers were used and a band at the correct size was 
w. en when the PCR product %%as run on an agarose gel, suggesting that although 
p(il: X-(-1)231 FC2 is being tak-en up by the Origarni cells, it cannot be expressed. 
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3.3 DISCUSSION 
This chapter describes the successful development of a strategy to produce high 
levels or tctraspanin EC2 domains on a large scale, the successful cloning of a 
further two tetraspanin EC2 domains (CD82 and CD231) into the pGEX-KG 
expression vector and the expression and purification of GST-CD82 EC2. Some 
aspects of protein production in bacterial cells are discussed below. 
3.3.1 Recombinant protein production in F- coli 
lie gmm-ncgativc bacterium Escherichia coli is a versatile host for the production 
of hcterologous protein. Eukaryotic proteins can be expressed and purified on a 
large scale with relative case in a host whose genetics are far better characterised 
than any other microorganism. However, there are limits to the potential of 
expressing cukaryotic proteins in F. colt, although with recent advances in 
biotechnology, the majority of these limits are gradually being overcome. All in 
all, E colt is the initial host of choice when commencing recombinant protein 
production. Expression of CD9 and CD81 EC2 domains give the largest yields, 
probably because these extracellular loops are the smallest in the tctraspanin 
family, having just four cysteines that are predicted to form two disulphide 
bridges. 7lic remainder of the EC2 domains made here are larger and more 
complicated with additional disulphide bridges that are necessary for protein 
folding. This would certainly help to explain the lower yields of CD63, C151 and 
CD82, and of the complete lack of expression of CD23 1. 
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3.31. Rare codon usage 
One limitation in the expression of beterologous proteins in E coli is the 
differcncc in tRNA usage between the organism from which the heterologous 
protein is dcrived and that of E coli. If the tRNA required for high level synthesis 
of a lictcrologous protein is rare in E coli, stocks may quickly become depleted 
and consequently the synthesis of the hetcrologous protein will be stalled. Due to 
this reason, the EC2 proteins that were previously produced in Sheffield 
(Iligginbottom et al. 2000; Zhang et al. 2004), including the CD9 mutants, were 
expressed in BL21 CodonPlus competent cells (Stratagene). These cells contain 
extra copies of the rare tRNA encoding genes that are frequently used by GC-rich 
organisms, the argU and proL genes. These genes encode tRNAs that recognise 
the argininc codons AGA and AGG and proline CCC, respectively. 'Me BL21 
CodonPlus cells are cil'icient at expressing tetraspanins CD9, CD81, CD63 and 
CD151 but no expression was detected for CD82 and CD231. Given the fact that 
these two proteins contain additional disulphides, it was presumed that the folding 
was too complicated for this type of expression system and so it was decided to use 
Origami cells (Novagen). Origami cells are specially engineered cells that have a 
lower cytoplasmic rcdox potential that is more favourable for the formation of 
disulphide bridges (discussed in more detail in Chapter 6). This strain worked for 
the expression of CD82 EC2 but CD231 remained undetected. It is possible that 
CD231 rcquires more rare codons than CD82 and therefore using an Origami cell 
line (or similar) that contains, in addition to the lower cytoplasmic redox: potential, 
more copies of the rare tRNA genes may aid CD231 expression. Due to the low 
redox potcntial in specially engineered cells such as Origami cells, it is possible 
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that nascent proteins form disulphide bridges too readily with incorrect partners, 
leading to protein aggrcgation. If this were the case then the best solution would 
bc to attempt CD231 EC2 expression using CodonPlus cells and a periplasmic 
leader sequence (discussed in more detail in Chapter 6). 
The percentage yields of GST-EC2 produced vary between constructs but in 
general 40-60% of the total protein is GST-EC2. The remainder is GST alone 
(25kDal) and there is always another unknown band at around 30kDal that one 
would presume to be a degradation product. Ideally we would like to make 
samples that contain 100 % GST-EC2 with no GST or degradation products. 
Ilowcvcr, the system we have set up enables us to make large amounts of 
recombinant protein in E coli in a quick, cheap and efficient manner at a sacrifice 
of having the GST contaminants. So long as a GST control is used alongside all 
experiments with these recombinant proteins, the effects of the GST alone can be 
ruled out. As already mentioned, the GST-EC2 recombinant proteins have already 
proved to be useful tools for studying tetraspanin protein functions. There arc a 
number of advantages of using these recombinant proteins over antibodies; binding 
of the antibody Fc region to Fc receptors on whole cells can stimulate a range of 
immune responses that could mask the desired cffects; of the mAbs (Jefferis et al. 
2002; Radaev ct al. 2002); mAbs are large molecules compared to GST-EC2 
recombinant proteins (1 50kDal compared to - 40kDal) and will cause more steric 
hindrance at the cell surface which may also lead to inaccurate results; as the 
recombinant tctraspanins are produced in E coli they are cheaper and quicker to 
produce than mAbs and no animal sacrifice is required (this latter point is of 
particular interest to the sponsors of this work, The Ilumanc Research Trust). The 
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GST-EC2 proteins arc extremely useful for studying binding interactions of 
tctraspanins. They can be used directly in ELISA experiments to determine 
%%hahcr or not they bind to particular ligands (e. g. HCV binding to GST CD81- 
EC2 proteins but not mutant proteins (Iligginbottom ct al. 2000) and Chapter 4). 
The EC2 recombinant proteins can also be used in whole cell assays, generally to 
inhibit a tetraspanin function, e. g. the sperm-egg fusion assays (Higginbottom et al. 
2003), the inhibition of monocyte fusion (V. Parthasarathy, F. Martin, A. 
Iligginbottom, G. W. Moseley, P. N. Monk, U. Partridge - unpublished data), and 
the inhibition of IIIV-I infection in macrophages (Chapter 7). The exogenous 
tetraspanins could be binding to molecules on the cell surface that the endogenous 
proteins would normally bind to, thereby disrupting the formation of the 
tctraspanin web. Alternatively, the EC2 domains could be forming homo- or 
hctcro-dimcrs with cndogcnous tetraspanins, therefore preventing their proper 
functioning. In addition to functional studies, these GST-EC2 recombinant 
proteins can also be used in structural studies (Kitadokoro et al. 2001; Kitadokoro 
ct al. 2001). 
Afthough the rccombinant proteins have their uses in studying tctraspanin proteins, 
one has to appreciate that there arc limitations. Single domains of proteins are 
quite unlikely to function in the same way as intact proteins and it is likely that the 
other tctraspanin domains arc required for the proper functioning of the EC2 
domain. It has alrcady been shown the ECI plays a role in the expression of EC2 
(Niasciopinto et al. 2001). Viewing the EC2 proteins as peptide inhibitors or 
simply, useful tools to study the binding properties of EC2 domains and to inhibit 
the function of EC' .1 domains in whole cell assays is a more accurate concept. 
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CHAPTER 4 
LIGAND BINDING BY TETRASPANIN EC2 DOMAINS 
4.1 INTRODUCTION 
As previously described in Chapters I and 3, recombinant tctraspanin EC2 
domains can be used as tools to study the interaction of EC2 domains and their 
binding partners. This chapter describes the binding experiments using our GST- 
EC2 domains and two proteins that have been reported to bind to CD9, PSG17 
(Waterhouse et al. 2002) and fibronectin (Longhurst et al. 2002). 
4.1.1 AINIS 
The aims of this Work- were to use our recombinant GST-EC2 domains in ELISA 
and FACS experiments to determine whether the 
interactions between CD9 and the 
rcported ligands take place via the 
EC2 domain of CD9. In the event of CD9 
binding to one or both ligands, it was also planned to 
investigate the structural 
requirement of CD9 in the interactions 
by using the CD9 EC2 mutants. 
Additionally, the specificity of the reported interactions 
for CD9 was to be 
investigated using the repertoire of tetraspanin EC2 proteins. 
0 
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4.2 MATERIALS AND METHODS 
Murine PSG17-Myc-His6 and control protein, murine PSG19-Myc-His6, were 
gifts from Gabriela S. Dveksler, Department of Pathology, Bethesda, US. PSG19- 
Myc-IIis6 had previously been shown not to bind to murinc CD9 (personal 
communication with collaborator). Human plasma fibronectin was purchased 
from Invitrogen (F2006) and biotinylated human fibronectin was a gin from Simon 
Foster, Department of Molecular Biology and Biotechnology, University of 
Sheffleld, UK. 
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4.3 RESULTS 
4.3.1 Investigation into the binding between PSG17 and GST-CD9 EC2. 
ELISA was used to investigate the binding between PSG17 and tetraspanin EC2 
domains. It was previously reported that murine CD9 binds to PSG17 and due to 
the high sequence similarity between murine and human CD9, it was predicted that 
human CD9 EC2 should also bind to PSG 17 since human CD9 EC2 inhibits mouse 
spcnn/cgg fusion to a similar extent as mouse CD9 EC2. To determine the 
concentration of tctraspanin EC2 proteins required to produce the best binding 
cffcct, mouse and human CD9 EC2 constructs were titrated against a fixed 
concentration (20 pg/ml) PSG17-Myc-His6, and bound PSG17 was detected using 
a rabbit anti-Myc antibody and an anti-rabbit IgG-HRP conjugated secondary 
antibody. Figure 4.1 shows the effects of concentration of tetraspanin EC2 
constructs on the binding to PSG 17. 
From Figure 4.1, it is clear that maximum amount of binding of both mouse and 
human CD9 to PSG 17 is seen at the highest concentration used, 20pg, and so this 
concentration of tetraspanin EC2 proteins was used throughout these experiments. 
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ar 
[CD91 (pgiml) 
Figure 4.1. HISA to determine the optimum concentration of tetraspanin EC2 domain% to 
u%c in the binding A raiwc oI , onccntranoný of Inou..; C and 1111111an ('I)k) W-201LIL! 1111) 
, filtited in binding butler. %Nere adhered to aii FLISA plate oýernight. After blocking in 5'o milk in 
Nis- I. PSOI 'AINc-litso (at a fixed concentration of -"Opg nil) 
in blocking buffer Aas added. 
Uollo%%ing incubation and %%a-shing. binding . %as detected LlSing an anti-\l\c antibod\ (1 1000 
dilution in blocking buffer) follo\\ed bý anti-rabbit-IIRI) 0 3000 diluted in bltvking buffer). 
. -kb--1rtxuwe at 
450nni \%as recorded on aii ITISA plate reader. The graph sho\\s the percentage 
increase in binding of Mott". and hurnan CDL) relati\e to the buffer control. 
H Is.. \,, \\ere Ivrt'()niled to detennine %\hether the binding bemeen human CD9 
and llls(, 17 %%as significant. and to imestigate %%liether the binding is specific tor 
CD9 or %%hether other tetraspanins can also bind to PSG17. The results are 
presented in Figure 4.2 as percentage increase in binding compared to the buffer 
control from each c\periment. 
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T f, tra-I ii rl i il FC2 
II ý-- III(IIi. II, II. III, tI--%%III_, (IIt hilid III _, ,fI, 
"(, I-. iIItII, N(. II)Iý,, II. III ý-, (ý, IIkI1 .11 ýA 11111 
I I, 
-, 
d, I I. Iý 11 , 111 iIIIý: JIIIt, IIIdIII 1ý 11 LI 114. ' 1, L, II)LIIIC1 . 11 k)iIi: Iý11 
adhere it, thc Nurlacc ot 1: 1 ISA plates bt: t'()re blocking in PBS-1' k%ith 5 lo milk and addition 
or diluted to 20pg'nil in blocking buffer. After thorom: i- 
\%xshing. binding ý%as detected b\ an anti-\I\c antibod\ (1 1000 dilution in blocking buffer 
tollo\%ed bý anti-rabbit-IIRP 0 30W dilution in hltvking buffer). Absorbance at 4- ii 50nm \%&, 
rvct)rdcd (in an II IS.. \ plate reader. Results are e\presst: d as percentage Increase in binding of PSO 
pmeins to tetrwpanins compared to the buffer control +- Slý \1 
k1l ofthe tetraspanin F('2 domains tested sho%%ed greater binding to PS(j 17 than 
t tic negat I% e contro L PSO 19. and bind ing in aII cases ý%as greater than %%hen butTer 
alone %%. tN substituted t'or tetraspanin FC2 domains. 1-he trend in binding is as 
follow,: m('DI, ) -h('I)I) -h('1)8 I -('DI 5 1. Statistical analýsis bemeen %aiucs 
obtaincd for PSG 17 and PSG 19 revealed that only the binding of PSG 17 to murine 
CD9 was significant. The human CD9 mutant constructs that lack the crucial 
cysteine residues involved in disulphide bridge formation had an apparent lesser 
binding to PSG17 that wild-type tctraspanins. The binding was not reduced to 
background lcvels and C181A (n=5) did not exhibit significantly less binding to 
PSG 17 than NVT human CD9. 
A second batch of PSG17 was sent by the collaborators and because it was a 
different batch of PSG17, it was decided to repeat the ELISA using EC2 proteins 
to ensure that the new batch of protein was acting in the same way. ELISA was 
perfomcd as described in 2.3.7, and again the results are displayed as percentage 
increase in binding to PSG17 compared to the control using buffer alone to coat 
the wells. Figure 4.3 shows the results, and again, each value represents the 
average from three parallel experiments. GST was also used and so results were 
compared to the background GST control values to check for any significance. 
The new PSG 17 protein showed a lower binding to the tetraspanin proteins than 
the previous batch (mean value for mCD9 binding to PSG17 previously was 
339.6% compared to a value of 160.4% with the second batch of PSG 17). In these 
cxpcriments mCD9 (or the other tctraspanins tested), did not show significant 
binding to PSG 17 when compared to the binding of GST alone. 
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Figure 4.3. Bar chart %himing the binding of a neA batch of PS(117 to tetraspanin EC2 
dornaim. -'Opý TW M letraNpaim, 
I( 
-' 
domairis dilmed in biriding bUffer. or binding buffer alorle. 
\%crc Icti to idhere to the -. surface of II ISA plates bd`6re adding 20pg nil PS(j17-\1)c-I1isb. After 
tborough %kx-ýhing -and b1twking in 5 'o milk in PBS-L binding \%as detected using anti-\Iýc 
antlbodý diluted 1 1000 in blocking buffer. follo, %ed bý anti-rabbit-[IRII diluted 1 '3000 in blocking 
buffer Osorbance at 45()nni was recorded on an 1-1 ISA plate reader. Results are e\pressed as 
pcr%: cntagc increasc in binding cif PSG pn-iteins to tetraspanins compared to the buffer control. 
I lumber of c\pcrinients -1. in triplicate). 
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4.31 Whole cell ELISA to investigate the binding between CD9 transfected 
CHO cells and PSG17 
One possible explanation for the very low binding of both batches of PSG17 to 
human CD9 EC2 relative to mouse CD9 EC2 may be the that human CD9 EC2 
docs not fold propcrly. To investigate this, we used full length human CD9 instead 
of EC2 domains, in the form of CHO cells transfccted with hCD9 and non- 
transfcctcd CHO cells as controls. Anti-CD9 antibody, ALMA-1, was used to 
confirm, the presence of human CD9 in the transfected cells. In each well of a 
stcrile 96 well tissue culture plate, IX 104 CHO cells were plated and left to adhere 
overnight. PSG 17 or PSG 19 was titrated across the plate and left to bind for one 
hour followed by careful washing and detection of binding using an anti-Myc 
antibody. The results are displayed as: 1) the percentage increase in binding of 
PSG 17 relative to PSG 19 in CD9-transfccted CHO cells and non-transfected cells 
(Figure 4.4); or 2) the percentage increase in binding of PSG17 and PSG19 to 
CD9-transfected cells relative to the binding to non-transfected cells (Figure 4.5). 
Thc results were analysed using an unpaired t-test but no significance was shown 
for either comparison. 
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ýirurv 4.4. HAr charl it) %ho%ing r"ult% from Ahole cril FLISA experiments im"tigating the 
hinding (if PMX rvlxti%v to control protein in ( IN-transifected ( 110 cells and non- 
tramfected celk ( 11( 1 'CII, %%IIII tull ! C1101 IIIIIII. In ( DQ ol 11,1T)-tr. I1I'Ie,: Icj cells 
ýkcrc 111,1d, xcd ý%Ilh ditlerent %: o1wentrations ot J',., s(jl7 or PS011) protein W-]WýAg nill. diluted in 
1114N%, and inmuNitcd tin ice for I twur Afier thonnigh \%ashing. binding %%as detected using an 
anti-\Iýc antitxxlý diluted 1 1000 in MISS tolltmed bý anti-rabbit-11R]" diluted 1 3,000 in IIBI%S. 
Atw4)rtwk-c %%&% recorded tin an 1- 1 ISA plate reader and the results are e\prrs, --, cd in this bar chart 
w the pm-entagc irwrr&,; c in binding oll"S(117 relati%c to PSGIQ in rKin-transfixted (\X)and Cl )4) 
transtecied ('110 cell% murnbcr tit c\jvnrncnt-ý Is. in triplicate). 
115 
100000 10 0001 000 0,000 
300- 
200 
0- 
za 100 r_ 
FD 
0 
[PSG], pg/ml 
= PSG 17 ý PSG19 
Figure 4.3. liar chari %h4vA ing the rv-. ult% (rom %hole cell tI Is% experiment% im emigating 
the hinding of and control protein to ( D9-tran%cfecled and non-tran%fected celk 
( fit ) C11% tr. III,? L-, IcJ %%]it) hill length human CDO or non-tran, tected cells i%cre incubated %%ith 
JI HercIIII. Al ,4 Mi. C1111.01011% tit P*, ( iI- or PSO 1 1) i: ontroi pioicin (0- 1 OOpg nil I diluted in IIB, %S 
AtIct i1xim-ugh %%&%hing. binding %%&-. delecled using in anti-\Iýc antitx, -Jý diluted it) I l(XN) in 
liltiss t-Ollmed bý anti-rabbil-IMP diluted I I(XX) in MISS 1-he results are c\prr,., sed in this bw 
cham as. the pmentage inctmw in binding of' PS617 or PSON lo Cl W-transfec led ('110 cells 
relati%c to ruin-tran%lecicd i\\1 CIRII ccl I% (number of c, iperiments ý 3. in triplicate I 
I it) 
100000 10000 1 000 0000 
4.3.3 Imemigation into the binding (if CD9 F. C2 and fibronectin by ELIS. A 
An interaction hcMeell fibronectin and CD9 had tven rclx)rted bý Jennings and 
co-%%orkcr-, (1-onghurst ct al. 2002) and so %%e attempted to demonstrate th's 
binding using our OS I -CD9 FC2 recombinant protein. GS 1 -F. C2 proteins %kere 
Knind it) the plate and fibronectin %ka,, added and atler thorough %%ashing, bound 
libronectin %k; is detected using anti-tibronectin antitWies (Figure 4.7. a). In 
control %%elk either CDI) or tibronectin %%as bound to the %Neils and detected %%Ith 
their rc,. Fvctl%c antlK-ýdics (Figure 4.7. b). I'here ý% as no e%idence of binding of 
tibronectin to (is F-CIW FC2 despite the control clearlý dernonstrating that CD9 
%k as prest nt on the 1.1 ISA plate sur6ce. The I-I. IS.. Ns %%ere also repeated the other 
%ýaý round bý binding tibronectin to the plate and incubating %%Ith tetraspanin FC2 
pniteins. but there "as still no e% idence of binding. 
117 
04 
ý) t) - 
B 
10, 
00 
CD9 
C D81 
GST 
= anb-FN 
M anb-CD9 
Figurr 4. ". Bar chart% %hoAing i1 1%% % analý%i% of libronectin binding to WA I-( Dq FC. I. 
II \%crv u%cd it, c\alimic thc k DIJ to fibroneoin k 
CIN 1 C2. ( IS 14,1118 11 i-onc ýkcre Nmnd it, the mells ot an I1 11, piatc and alier 
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%econdarý antiNxlý diluted it) I IOW in blotAing bUtl'CT 0, A)rKince at 450nm \kas recorded tin an 
II ISA plate trader B) G1sI-('DQ 1-C2 (10ýLg nil) and IA (20pg ml) were adhered tocontrol \%ells 
\nli-( IW antiNxi 
'\ 
(1 500 diluted in blocking huffer) \%a. % added it) the CIW wells and anti-FNN 
anttt%wJ% (1 1000 diluted in h1twking huftcr) %%-as added it) the FN' wells. K-sth follo%%ed b\ anti- 
nunkv Igiv-1IRP (I lo(x) in MxAing butler). Ah, -, A1rt%am-c wa% reconled at 
45onm tin an 1-1 ISA 
platc rvadcr (nurnhcr of c\Fwrirnent% ý 1. in triplicate) 
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4.3.4 FACS anah sis of fibronectin binding to CD9 transfected CHO cells. 
Chine%c hanister ovarv cells (CHO) transfected with full length human CD9 were 
tested flor their ability to bind to biotinylated fibronectin by FACS assay. CD9- 
('110 and ('110 cells transfected %%tth a control protein, C51-2, were used. Figure 
4.8 sho%%s some examples of the fluorescence profiles ofthe control experiments. 
When protx-d with anti-C'D9 mAb, CD9-CHO cells show a high percentage of 
cells in the gated fluorescence region (4.8. a, 97 %) and, as expected, there is a 
much lo%%cr [wreent of ('51.2-('110 in this region (4.8. b, 19.9 %) as does an 19-G 
control anlIK)dy (4.8. c. 6.7 1' o) 
a. CD9-CHO &AL", I A- I hl'5U-010 & ALNIA-1 
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Hyurr 4.8. F'Iuorr%cent proffles of CD9 (a) and control transfected ('110 cells (b) %ith anti- 
D9 mAh. Al %I A-I and an IgC control antibtWý (c). liar%ested ('110 cell-, N%ere incubated 
ý%ith \1 \1 vi iI ý00 in IIIISS) or in IgO control antilvdN (I 5(X) in MISS) for I hour on ice 
follo\ked bý %,.. tshing and incuhation %%Ith anti-mouse lg6-Fll'C (I IOM in HBSS) for I hour on 
ice Flixrcs. 4ccrice %%-&% mc&,; ured using the FI. - I Basic sciting on a flo%% cytometer. 5000 cells per 
cxpcnmcnt%%crccounIcd. I'hctiguresho\%-., týpicalcxaniplesol'thecontn)ic\rvrinients. 
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Figure 4.9 shows that there was no specific binding of fibronectin to CD9 
transl'ected CHO cells compared to C51-2 transfected cells. Both populations of 
Oft) cells were incubated with avidin-FITC to test whether there was a high 
background ofavidin-FITC binding to ('51.2 transfected cells and although avidin- 
FI R' did appear to be "sticky-, there was an average of 25 % avidin-FITC 
background tor C51.2-CHO but a 40 % avidin-FITC background was obsen, ed for 
CD9-CII0. I'hese results further highlighted that there was no specific binding 
between CD9-CII0 and fibronectin in these assays. 
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Figure 4.9. FACS amisms to stud, * binding of biotinýlated fibronectin to full length C139- 
tranifected ('110 cells. I tar-, ested Cl 10 cells transtected %% ith CDQ werc Incubated %% ith ; Opg ml 
bI Ot III ,N 
lated fibroncctin in I IBSS and incubated on ice for I hour. Binding was detected using 
a% idin-I'l FC (II M) in I HISS). CI 10 cells transtiocted %%ith C51_2 (a G-protein coupled receptor 
in%ol%ed in the complement cascade) %%eyv used as controls and results are expressed as the 
percentage increase in binding relati%c to background (cells incubated with midin-FITC onlý). 
Number of c\pcnments = 2. in quadruplicate. 
Further FACS c\periments \%ere perfornied using unlabelled fibronectin at 
concentrations ranging from 10-200ýig/rnl. This was done to tr) and avoid the high 
background binding of a% idin-FITC to CHO cells. Foliowing incubation %% Ith 
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CD9 C5L2 background 
fibronectin. cells were probed using a mouse anti-hurnan fibronectin mAb and anti- 
mouse IgG-IIRP conjugated secondary antibody. Control experiments where both 
rK)pulations of ('110 cells were incubated with secondary antibody alone were 
included to establish non-specific, background fluorescence levels. Binding was 
calculated as the percentage change of cells in the fluorescent region compared to 
background fluorescence levels (taken as 100 %). Figure 4.10 shows that there 
was no Increase in fibronectin binding to CD9-CliO relative to controls. 
150-1 
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Figure 4.10. FACS xssaý% to %tud) binding of fibronectin to full length CD9-transf"ted ('110 
cells. I v's xssaý s %%erc fvrt'Ortned as, described in I igure 4.1) bill lising non-biotiný lated 
t thronectin wW at concentrations ot'2(X)- 10 Vg; ml. Background levels ofsecondar) antibod) alone 
\,. crc taken to be IM *o and the relative percentage binding of fibronectin was calculated for each 
c\pc, rinwnt. in -2. in quadruplicatc). 
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4.4 DISCUSSION 
Waterhouse et al. demonstrated that PSG 17 binds to cells expressing murine CD9 
but was unclear whether CD9 was acting as a direct receptor or as a co-receptor for 
PSG 17 (Waterhousc et al. 2002). Using our GST-EC2 recombinant proteins, we 
set out to investigate the role of CD9 EC2 in this interaction. We demonstrated 
that PSG 17-Ntyc-Ilis6 (a murine CEA subfamily member) did indeed bind directly 
to our mouse CD9 EC2 recombinant protein (P>0.05), but there was no significant 
binding to the homologous human CD9 in our assays. The variation between 
different batches of PSG 17-hfyc-His6 provided by our collaborators together with 
the observation that other taraspanin proteins tested, including human CD9-EC2, 
did not significantly bind directly to PSG17, meant that this work could not be 
continued. In parallel to this work done in Sheffield, further characterisation was 
performed on murine CD9 and its interaction with PSG17 (Ellerman ct al. 2003). 
In this report murine GST-CD9 alone was used and they, like us, showed that this 
bound directly to PSG 17. In addition, they demonstrated that the observed binding 
of mCD9 EC2 to PSG 17 involved the Ser-Phe-G In (173 -175) moti f in murine CD9 
that is essential in sperm-egg fusion (Zhu, G. Z. et al. 2002). They also showed 
that prc-incubation of murine eggs with PSG 17 before addition of sperm inhibited 
spcrm-cgg fusion. suggesting a role for PSG17 and therefore the CEA family in 
ooc)-tc fusion (Ellerman et al. 2003). Tlicre was increased binding of human CD9, 
CD81 and CD151 EC2 to PSG17 compared to both GST and buffer controls, 
although these results were not significant. It is a possibility that human CD9 EC2 
may not be properly folded relative to mouse EC2 and that the recognition 
scquencc is masked or not formed thereby preventing binding between human 
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CD9 EC2 and PSG17. However, human CD9 EC2 shows potent activity in other 
systems e. g. CD9 EC2 inhibits monocyte giant cell formation from human 
monocytes but mouse CD9 EC2 is ineffective (Takeda et al. 2003). The fact that 
the same human CD9 EC2 is also functional in sperm-egg binding assays 
(Higginbottom, et al. 2003) suggests that a different binding site is involved in this 
interaction. Many PSGs are predicted to bind to integrins because they contain the 
Arg-Gly-Asp (RGD) motif. Intriguingly, PSG 17 does not contain the RGD motif. 
Therefore, it is a strong possibility that whereas many PSGs bind to integrins and 
are, perhaps, associated with tetraspanins via a TEM, murine PSG17, with the 
absence of an RGD motif, binds directly to murine CD9. There is no human 
ortholog of PSG 17 and so it is possible that the direct involvement of CD9 in PSG 
functioning is a pathway present only in murine cells. 
Although it has been reported that CD9 EC2 is responsible for the direct 
interaction with fibronectin (Cook et al. 1999; Longhurst et al. 1999; Cook et al. 
2002), when we attempted to repeat these experiments, no binding was detected 
using our GST-EC2 CD9 recombinant proteins in ELISAs, nor could we detect 
binding between fibronectin and CHO cells transfected with CD9 in FACS 
experiments. Although we tried to replicate the experiments performed by 
Jennings and co-workers as closely as possible, it is feasible that slight differences 
in conditions and/or reagents used could account for the observed differences. 
Alternatively, it is possible that the results by Jennings and co-workers have been 
misinterpreted and fibronectin is actually associating with beta integrins and not 
CD9. The initial work by Jennings and co-workers was done using CHO cells 
that had been transfected with full length CD9 and mock transfected cells as a 
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control (see Chapter 1.3). Adhesion and spreading of CHO cells on FN was 
modulated in CD9 transfected cells compared to mock transfected cells, despite no 
apparent change in 01 and P3 integrins expression levels (Cook et al. 1999). 
However, CD9 could be functioning here by aiding the binding of integrins to 
ECM components by incorporating them into TEMs -a process that would not 
necessarily require an altered expression of integrin proteins, just a change in 
location. Indeed, it is possible that CD9 EC2 is involved in the process of binding 
to integrins and therefore in its absence, integrins are not integrated into the TEM 
and cannot, therefore, associate with fibronectin. This would certainly explain 
why we do not see binding between GST-CD9 EC2 and fibronectin in our ELISAs 
and perhaps differences in transfection levels of CD9 in our CHO cells may 
account for the contrast in our FACS results. Short peptides based on CD9 EC2 
are reported to bind to fibronectin and partially inhibit the binding of full length 
CD9, although it is not stated in the original report whether these findings were 
significant (Longhurst et al. 2002). 
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CHAPTER 5 
STRUCTURAL STUDIES OF CD9 AND CD63 EC2 DOMAINS 
5.1 INTRODUCTION 
5.1.1 X-ray crystallography 
X-ray crystallography is the most common method used to solve the three- 
dimensional structures of proteins (Branden et al. 1999). It is a complicated 
procedure involving a large amount of mathematical manipulation but the main 
concept of X-ray crystallography is that the negatively charged electron clouds that 
orbit atoms have the ability to diffract X-rays. When a crystal is bombarded with 
X-rays, every atom in the molecule will individually diffract the X-rays and, in 
doing so, produce a spot on a film. The result is an electron diffraction pattern 
composed of diffraction spots from each atom within a molecule. Computer 
analysis and interpretation of the electron diffraction pattern reveals the positions 
of the electrons, and hence the atoms, within a molecule. Electron diffiraction by 
single molecules is weak and so crystals are used to amplify the signals. Protein 
crystals contain many molecules precisely ordered and orientated in three 
dimensions. The smallest, unique part of a crystal is called the asymmetric unit 
and contains one or more copies of the protein. Rotation of one or more 
asymmetric units forms the unit cell, which is then translationally repeated to form 
the crystal lattice. Each unit cell diffracts X-rays identically and so the diffracted 
beams from all the unit cells within a crystal add together to prodpce strong, 
detectable X-ray beams (reviewed in (Branden et al. 1999; Rhodes 2000). 
However, the first major hurdle to be crossed before the 3D structure of a 
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macromolecule can be determined by X-ray diffraction from crystals, is to obtain a 
singular, perfect protein crystal which has dimensions of 0.2-0.4 mm in at least 
two of the three dimensions (Fig. 5.1). 
Clear Drop 
Skin. -Precipitate 
Precipitate 
q* Precipitatel-Phase 
-La 
Ouasi Crystals 
c roc 1-Y "tal 
Or it 
Noodle Clti,, t(, r 
Plates 
r)m Rod Clu%ter 
Single Crystal 
Figure 5.1 Typical observations in a crystallisation experiment. This figure is from Hampton 
Research (http: //wNN, w. haiiiptonrcsearch. coiii/stipport). The figure shows the different types of 
observations one would expect to see in hanging drops after an initial screening experiment. 
Different crystal forms are shown ranging from a clear drop to different form of crystalline 
precipitate and eventually the ultimate goal, a single crystal. 
Identifying favourable conditions for protein crystallisation to occur is a 
substantial task. There are many variables (pH, temperature, organic solvent etc. 
etc. ) and the exact conditions required for crystalisation differ from protein to 
protein. In fact, protein crystallisation is considered by many scientists to be more 
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of an art than a science! To aid initial crystallisation experiments, a number of 
crystal screens are available. These screens generally contain around 50 
formulations with varied precipitating agents, pH and divalent cations, that were 
initially selected from incomplete factorial experiments, where variables were 
tested at random for their ability to allow protein crystallisation (Carter et al. 1979; 
Carter et al. 1988). There are now a number of these kits commercially available 
that are excellent places to start when commencing protein crystallisation trials. 
5.1.2 NMR 
Nuclear Magnetic Resonance (NMR) spectroscopy is a powerful method for 
studying the biological properties of macromolecules (Branden et al. 1999). It is a 
complex set of techniques based on the properties of subatomic particles, namely 
protons and neutrons. Protons and neutrons possess a quantum property called 
spin. In many atoms that have even numbers of protons and neutrons (12 C), the 
spins from protons and neutrons pair together and there is no overall spin. 
However, if the number of protons or the number of neutrons is odd, then the 
nucleus possesses spin. The most common, naturally occurring atomic isotopes 
that possess spin are 1H and 31p; less abundant isotopes with a nuclear spin (13C, 
15N) can be incorporated into a biomolecule by isotope labelling. In the presence 
of a magnetic field, the spins of the nuclei align in two or more different energy 
levels. The frequency of the radio waves required to produce the spin (or 
resonance) depends on the chemical environment of the atoms i. e. other atoms that 
are connected. As soon as the radio frequency excitation is stopped, the nuclei 
return to lower energy levels in a process called relaxation, and, in doing so, 
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transmit a radio frequency resonance response that is picked up by the NMR 
spectrometer. This response is then amplified and used to produce a spectrum that 
can be interpreted to determine information about the chemical environments of 
atoms within a molecule. In the case of ID IH NMF, the different resonance 
frequencies picked up in the spectrum represent the different chemical 
environments of the IH atoms, and are known as chemical shifts. IDIH NMR is 
commonly used to determine whether a protein is folded. The IH frequencies of 
all residues in unfolded proteins are very similar and the spectrum is recognised as 
having little dispersion. If there is some folding, different chemical environments 
of lH atoms can be identified. Like crystallography, a highly concentrated and 
pure sample produces better results but crystals are not required, and a ID 
spectrum to evaluate whether or not a protein has any structure can be performed 
in an hour (Branden et al. 1999). 
5.1.3. AIMS 
In 2001 the crystal structure of CD81 EC2 was solved (Kitadokoro et al. 2001). 
The EC2 domains of tetraspanins are variable, and structural information of 
another EC2 containing additional cysteines that are predicted to form disulphide 
bridges, was considered advantageous. The main aim of this work, therefore, was 
to attempt to determine the crystal structure of CD63 EC2 in order to gain a better 
insight to the function of CD63, especially its role in HIV infection (Chapter 7). 
CD63 EC2 contains a total of 6 cysteines that are predicted to form 3 disulphide 
bridges. Due to problems encountered when attempting to concentrate the cleaved 
CD63 EC2 (5.3.1), a collaboration with Dr Christopher Liu was established. This 
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collaborator provided Iyophilised His6-CD9 EC2 and was willing to make some 
CD63-His6 EC2. Although the structure of CD9 EC2 was not one we originally 
planned to attempt to solve, since the protein was available in large quantities, we 
decided to have a preliminary attempt whilst awaiting the CD63 EC2 protein. 
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5.2 MATERIALS AND METHODS 
5.2.1 GST cleavage from CD63 EC2 
In addition to the reagents listed in Chapter 2, thrombin protease (Amersham. 
Pharmacia Biotech, USA. Product number 27-0846-01) was also used in the work 
described in this chapter. 
5.2.1.1 Small scale batch cleavage of GST from CD63 EC2 
Siliconised 1.5ml tubes were used throughout these experiments to prevent the 
hydrophobic, cleaved CD63 EC2 from being absorbed onto the plastic. A known 
quantity of purified GST-CD63 EC2 was allowed to bind to glutathione Sepharose 
by incubation for I hour at RT. The beads were saturated with GST-CD63 EC2 to 
prevent non-specific binding of the cleaved CD63 EC2 (Iml of glutathione 
Sepharose beads binds 10mg of GST fusion protein). The glutathione Sepharose, 
with GST-CD63 EC2 attached, was pelleted by centrifugation (all centrifugation 
steps were 500 g for 2 minutes) and washed twice with 200ml of PBS. Thrombin 
protease at a concentration of I unit/pl was added to a final concentration of 10 or 
I unit(s) per mg of fusion protein, and the volume was made up in 200-500PI of 
PBS. The reaction was gently agitated at RT for 2 hours, 4 hours, 6 hours or 
overnight. Glutathione beads were removed by centrifugation. The supernatant, 
now containing CD62 EC2 (plus a negligible amount of thrombin), was removed 
into a fresh, siliconised tube. 5gl samples were taken at each step to monitor the 
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cleavage and purification process by Coomassie staining of SDS-PAGE gels and 
Western blotting. 
5.2.2 Setting Crystals 
Crystal screening kits were from Hampton Research, CA; Crystal Screen (50 
conditions), Crystal Screen 11 (48), PEG ION (48), or from Nextal Biotech; the 
SMI (96), the Classics (96), the pHClear (96), the PEGs (96), the AmS04 (96) and 
the MDPs (96). The Robot used to set crystals in 96 well plates was from Nextal 
Biotech. 
5.2.3. Hanging drop vapour diffusion method for protein crystallography 
To each well of a 24 well-plate, 500-700pl of the fonnulation was added. I [il of 
protein was pipetted onto the surface of a siliconised coverslip and mixed together 
with I pI of the formulation from the well. The rim of the well was coated with 
sealant (oil) and the coverslip was inverted over the well with the drop hanging 
over the pool of formulation (Fig 5.1). To ensure sealing, the coverslip was moved 
around a little in the oil. The drops were examined under a microscope every 2-4 
days for the presence of crystals. 
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Figure 5.1. Hanging drop vapour diffusion method for protein crystallisation. This was the 
predominant method for crystal growth that was used. 24 well plates were used to set the crystals. 
500-700pl per well of a commercial screening formulation, or a follow up trial formulation, was 
added. On a siliconised coverslip, I ýtl of the same fon-nulation was mixed with I ýd of the protein 
solution. The coverslip was inverted so that the drop was left suspended above the well. Oil was 
used to create and air-tight seal between the coverslip and the well. 
5.2.4. Automated crystallisation screening 
Automated crystallisation screening was performed (NeXtal suite) using 0.33[d of 
protein solution and 0.33pl of formulation from the reservoir in the well. This 
drop sits on a raised ledge in the well rather than hanging above it. Once the robot 
had set up each of the 96 wells in this manner, a plastic sheath was pressed over 
the plate to seal the wells. 
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5.2.5. Production of His6-tagged CD9 and CD63 EC2 
[The production of His6-tagged EC2 constructs was carried out by a collaborator, 
Christopher Liu (Howard Hughes Medical Institute, Centre for Cancer Research, 
Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA)]. 
cDNAs were kindly provided by Martin Hemler (Dana-Faber Cancer Institute, 
Harvard Medical School, Boston, MA). The following oligonucleotides were used 
to amplify the EC2 domains: 
Construct Oligo (5' - 3') 
CD9 F CGCTAGCTAGCTCCCACAAGGATGAGGTGATTAA 
CD9 R CCGCTCGAGGTGGAATTTATTGTCGAAGACCTC 
CD63 F CGCTAGCTAGCAGAGATAAGGTGATGTCAGAGTTTAATAAC 
CD63 R CCGCTCGAGCTCATTMCCTCAGTTAGCCC 
The EC2 domains were cloned into the NheI and Xhol restriction sites of the 
pET24a (Novagen) vector and sequenced to check for effors. BL21/pLysS 
competent cells (Novagen) were used for protein expression. The recombinant 
proteins were purified from inclusion bodies by guanadinium/urea extraction 
followed by partial purification by Ni-NTA chromatography (Qiagen). The 
solubilised protein was analysed by reverse-phase C 18 HPLC with protein content 
monitored as absorbance at 229nm. HPLC protein peaks were collected and 
analysed for tetraspanin content by dot-blot. Tetraspanin protein was Iyophilised 
and stored at -20*C before being sent to the UK. 
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5.2.6. NMR 
It was decided to perform ID IH NMR on the CD63-His6 EC2 to ensure that the 
protein was folded. CD63-His6 EC2 was diluted to 4mg/ml in dH20 and loaded 
into a Bruker DRX500. The ID proton NMR spectrum was run with presaturation 
of the water and a halm echo (2.6m total echo time) to improve convolution 
difference, I second recycle time, 128 scans. The spectrum was processed with a 
convolution difference to further remove the water signal, and 5Hz line 
broadening. 
134 
5.3. RESULTS 
5.3.1 Batch cleavage of GST from CD63 EC2 
An initial experiment was performed on small quantities of GST-CD63 EC2 to 
determine the amount of thrombin and the length of time required to cleave GST 
from GST-CD63. I unit of thrombin should cut > 90 % of 100ýtg of a GST-fusion 
protein in PBS at 22*C for 16 hours (according to manufacturers' instructions). 
Optimum conditions for the cleavage of GST from CD63 were determined (Table 
5.1 and Figure 5.2). 
Lane Ithrombinj Units Time Buffer 
1 0.1 2 PBS 
2 0.1 4 PBS 
3 0.1 T- PBS 
4 0.1 OIN PBS 
5 1.0 2 PBS 
6 1.0 4 PBS 
7 1.0 6 PBS 
8 1.0 OIN PBS 
9 0.1 6 Tris 
10 1.0 6 Tris 
I1 0.0 6 PBS 
12 0.0 6 Tris 
13 PBS 
Table 5.1. Optimisation of conditions to cut GST from GST-CD63 EC2 using thrombin. To 
determine optimum conditions, 100ýtg aliquots of GST-CD63 EC2 were cut with LOU (IOU/mg) 
and 0.1 U of thrombin protease. Ile reactions were stopped (by freezing the samples) after 2 
hours, 4 hours, 6 hours or overnight incubation at RT. GST-CD63 EC2 was typically dialysed into 
PBS, pH 7.4. To test whether this buffer was suitable for proteolysis to occur, a control of GST- 
CD63 EC2 in Tris, pH 8.0, was also included. The samples were made up to 100ýtl in the 
appropriate buffer. 
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Figure 5.2. Western blot of samples from optimisation of GST-CD63 thrombin cleavage. I Oýd 
of the samples corresponding to those in Table 5.1 were run on SDS-PAGE, blotted and blocked in 
5% milk in PBS-T and then probed with an anti-GST antibody, I /1000 dilution in blocking buffer. 
Anti-mouse IgG-HRP was added (1/3000 diluted in blocking buffer) and the blot was developed 
using ECL reagent (Amersham). Lanes II and 12 show uncut GST-CD63 EC2 and lane 13 is GST 
alone. B. 
The Western blot using anti-GST antibody shows 2 bands present in the uncut 
protein, the top band being GST-CD63 and the lower GST alone. All of the 
samples with thrombin present (lanes 1-10) show one band, GST alone, suggesting 
that the reaction has worked in all cases. The samples in PBS (lanes 1-8) appear to 
have cut more efficiently than the samples in Tris, and there does not appear to be 
a preference for 1.0 or 0.1 units of thrombin. 
Different amounts of GST-CD63 EC2 were cut with thrombin protease to test the 
effectiveness of this method of thrombin cleavage on higher concentrations of 
protein (Figure 5.3). 
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Lane 1 2 3 4 5 6 7 8 9 10 11 12 
Amount of 200 400 85 200 400 85 200 400 85 200 400 85 
protein (Iýg) 
Reaction time 2 2 2 4 4 4 16 16 16 uncut uncut uncut 
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Figure 5.3. Western blot of samples from the second optimisation of GST-CD63 thrombin 
cleavage experiment. 0.1 U of tluombin was added to different concentrations of GST-CD63 (as 
described in the table) and the volume was made up to I 00ld and left for 2 hours, 4 hours or 16 
hours before stopping the reaction by freezing the samples. 20gl of each sample was run on SDS- 
PAGE and blotted. Following blocking in 5% milk in PBS-T, anti-CD63 antibody, H5C6 (at 
1/1000 dilution in blocking buffer) was added. After washing, anti-mouse IgG-HRP was added at 
1/3000 dilution in PBS-T and the blot was developed in ECL reagent (Amersham). 
As shown by the blot in Figure 5.3,0.1 U of thrombin can cut up to 400pg of GST- 
CD63 EC2 and so this is the concentration used from now on. When the reaction 
was left for 16 hours, there was a clear reduction in the amount of CD63 EC2, 
probably due to protein degradation. However, at 4 hours there was still a 
substantial amount of uncut CD63 and so the reaction required at least 4 hours 
incubation. Interestingly, the Western blot also shows two bands at around the 
35kDal mark. Perhaps one is a dimer or even a trimer of the l2kDal CD63 EC2 
and the other is GST-CD63 EC2. 
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After the optimal cleavage conditions had been determined, the method for 
removing the cleaved GST from the sample was developed. Initially, glutathione 
Sepharose was added to the sample at the same time as the thrombin, as free GST 
and GST-CD63 EC2 would bind specifically to the glutathione beads and could be 
removed by centrifugation, leaving the CD63 EC2 and thrombin protease in 
solution. However, this method did not yield any cleaved protein, probably 
because the cut CD63 EC2 was binding non-specifically to the Sepharose beads. 
instead, it was decided to first bind the intact GST-CD63 EC2 to the beads for one 
hour before adding the thrombin. Also, the amount of glutathione Sepharose used 
was carefully calculated so that it was completely saturated by the GST-CD63 EC2 
protein, to reduce the non-specific attachment of cleaved CD63 EC2. The binding 
capacity of glutathione Sepharose beads is 10mg GST tagged protein per ml of 
slurry (according to the manufacturer), therefore, 100pg of GST-CD63 EC2 
requires lOpI of slurry. After mixing the GST-CD63 with the beads for I hour 
followed by the addition of thrombin for 4 hours, the free CD63 EC2 was collected 
by centrifugation. The beads were then washed once in PBS. Samples of the 
supernatant, wash buffer and glutathione beads were evaluated by Western blotting 
and silver staining SDS-PAGE gels. The Western blot revealed that the majority 
of GST-CD63 EC2 had been cleaved using this method; there was very little CD63 
attached to the beads or in the PBS wash (Figure 5.4). The silver stained gel also 
revealed that the sample was extremely pure, as no other protein bands were 
detected. The protein concentration of cleaved CD63 was 0.2mg/mI as determined 
by Bradford assay. 
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Figure 5.4. Western blot of samples used to optimise purification of cleaved CD63 EC2 from 
the reaction mixture containing GST. 100ýLg of GST-CD63 EC2 was mixed with 10pl of 
glutathione Sepharose slurry and left to bind for I hour at RT before addition of 0.1 U of thrombin. 
The beads were pellet by centrifugation at 400g for 2 minutes and the supernatant contained 
cleaved CD63. The beads were washed in PBS and centrifuged again, the wash buffer was saved 
and the beads were resuspended in 100pi PBS and saved for analysis. 20ýd of the supernatant, 
wash buffer and beads were run on two SDS-PAGE gels. A) One gel was blotted and probed with 
H5C6 (as described in Figure 5.3). B) silver stain of the second gel. 
After taking an aliquot of the purified, cleaved protein, the remainder of the sample 
was stored at 4*C. The following week, the sample was used in an experiment to 
remove the thrombin using p-aminobenzamidine agarose. This agarose has a 
binding capacity of 7-10mg of thrombin per ml of slurry. The amount of thrombin 
present in the sample was in the ng range. AI Opl sample of the cut GST-CD63 
EC2 was removed for analysis, and 5ýd of p-aminobenzamidine agarose was added 
to the sample and mixed at 4'C for 2 hours. After this incubation period the 
agarose was pelleted and the supernatant was carefully collected and analysed by 
SDS-PAGE stained with Coomassie, along with the sample taken before treatment 
with p-aminobenzamidine, with GST and a lOkDal protein used as markers 
(Figure 5-5). 
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Figure 5.5. Effects on thrombin removal from cleaved CD63-EC2 using p-aminobenzamidine 
agarose. The solution ofCD63-EC2 and thrombin protease from Fig. 5.4. was kept at 4'C for 48 
hours before the attempted removal of thrombin using p-aminobenzamidine agarose. Samples 
before treatment and after were run on SDS-PAGE and Coomassie (A) or silver-stained (B) along 
with a GST control and aI OkDal protein. 
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The first Coomassie stained gel (Fig. 5-5 A) did not show any sign of a lOkDaI 
protein either in the sample before treatment with p-aminobenzamidine, or in the 
post - treatment sample. A second gel (Fig. 5.5 B) was run and this time silver 
stained in an attempt to detect any I OkDal cleaved CD63 EC2. Again, this gel was 
negative. It appeared that the cleaved CD63 EC2 was unstable and degraded when 
stored at 4*C for a couple of days. Any cleaved protein made after this was made 
for immediate use. As the protein was so unstable, it seemed sensible not to 
attempt to remove the thrombin from the solution since it accounted for less than 
0.1 %total protein. 
5.3.2 Column purification of cleaved CD63 EC2 
Crystal trials generally require 10mg/ml of protein as a starting point, preferably in 
water. However, only 100-2001d are required for the initial screens. The cleavage 
procedure is only around 5% efficient (for every lmg of GST-CD63 EC2, only 
about 50pg of CD63 EC2 is purified). In an attempt to increase protein yield for 
crystal trials, it was decided to use 15ml columns. The columns were siliconised 
and left to air-dry before being loaded with glutathione Sepharose saturated with 
10mg of GST-CD63 EC2 (in approx. 15ml). At this point, in order to concentrate 
the final product, the non-bound volume in the column was drained out. This 
should be PBS as all of the GST-CD63 EC2 and GST alone should have bound to 
the glutathione Sepharose. The thrombin was added in 500pl PBS, and the 
cleavage reaction was performed in the column. After the reaction the column 
was drained into siliconised 1.5ml tubes and washed three times in PBS. Reduced 
glutathione was then added to Sepharose and collected after a5 minute incubation. 
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If only GST eluted from the column then we would assume that the cleavage 
reaction had worked and all the CD63 EC2 present had been cut from GST. 
Figure 5.6A shows the first Coomassie stained gel. The fraction taken after the 
cleavage event (lane 5) as well as washes (lanes 2-4), all contained the cleaved 
CD63 EC2 band, but they also contained high amounts of GST. In an attempt to 
remove this GST, 1001d of glutathione Sepharose was added to the eluted 
fractions, the theory being that this would bind and "mop up" the cleaved GST. 
Figure 5.63 shows that although some of the GST had been removed there was 
still -50 % contamination with GST. Due to these problems in purifying large 
quantities of cleaved CD63 it was decided to use His6CD63-EC2 for 
crystallisation trials. 
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Figure 5.6. Silver stained SDS-PAGE showing samples from the optimisation of column 
purification and GST cleavage from CD63 EC2.10mg of GST-CD63 EC2 was mixed for I hour 
at RT with 15ml glutathione Sepharose slurry in a pre-siliconised l5ml column. Thrombin protease 
(I U/mg) was added to the column and the reaction left for 4 hours at RT with gentle stirring. The 
column was drained and the eluted fraction and PBS washes were saved and run on SDS-PAGE 
and then silver stained (A). Glutathione beads were added to these samples in an effort to remove 
the GST. 100ýd of glutathione Sepharose slurry was added and incubated for an hour at room 
temperature before centrifugation at 400g for 2 minutes to pellet the beads. PBS washes were 
performed in the same way and the samples run on SDS-PAGE and silver stained (B). 
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5.3.3 His6-CD9 EC2 crystallisation trials 
A vial containing 2mg of Iyophilised His6-CD9 EC2 was reconstituted in 200 [LI 
dH20 to give a final concentration of 10mg/ml. Hanging drop trials were set up 
using formulations from: Crystal Screens I (CSI) and II (CSII), PEGIon Screen 
(PI) and Structure Screen I (SSI). Table 5.3 lists the contents of the reagent 
formulation that gave crystalline precipitate or small crystals in the initial screen. 
Screen Salt Buffer / pH precipitant description 
CSI 3 None None OAM CP 
NH3H2PO 
CS1. 0.2 M NH3SO4 0.1 m % w/v PEG Quasi crystals 
15* C2116AsO2Na. 3H20 8000 (5.7b) 
PH 6.5 
CS1 0.2 M CaC411604 0.1 m 18 % w/v PEG CP 
46 C2116AsO2Na. 3H20 8000 
vH 6.5 
CSII 3 None None 25 % v/v CP 
Ethylene 
Glycol 
CS11 0.5 M NaCl 0.1 m 2% w/v CP (5.7a) 
16* Na3C6H507.2H20 Ethylene Imine 
pH 5.6 Polymer 
CS11 None 0.1 M MES pH 6.5 1.6 M CP 
20 MgS04.7H20 
CSII 0.05 M CsCl 0.1 M MES pH 6.5 30 % v/v CP 
24 Jeffamine M- 
600 
PI 20* 0.2 M pH 5.9 20 % w/v PEG Microcrystals 
Mg(HC0092.2H20 3350 (5.7c) 
PI 24 0.2 M pH 7.8 20 % w/v PEG CP 
LiC21-1302.21-120 3350 
PI 25 0.2 M pH 7.7 20 % w/v PEG- CP 
(CH3CO2)2Mg. 41420 3350 
PI 29 0.2 M CH3CO2K pH 7.8 20 % w/v PEG CP 
3350 
PI 40 0.2 M pH ý. I 20 % w/v PEG CP 
Na2HP04.2H20 3350 
SSI 0.2 M CaC12 0.2 M 20 % Propan-l- Needle-like 
II* CH3COONa. 3H20 01 crystals (5.7d) 
pH 4.6 
Table 5.3. His6-CD9 EC2 crystal screening. Crystal screen I and 11 (CSI and CSII), Peglon (PI) 
and Structure screen I were used for CD9 EC2 crystal trials. The tale lists the conditions that gave 
crystals (C) or crystalline precipitate (CP). * denotes conditions shown in Fig. 5.7. 
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Figure 5.7. Results from the initial His6-CD9 EC2 screen. Crystal screening kits (I lampton) 
were used to determine crystallisation conditions for his6-CD9. I ýLl of 10mg/ml His6CD9 in dllO 
was mixed with lptl of each formulation and were set as hanging drops above 700PI formulation. 
The conditions in these well are listed in 'Fable 5.3, a= CSII 16, b= CSI 15, c= PI 20, d= SSI 11. 
(all crystal pictures are 20 - 100 x magnification). 
Figure 5.7 shows some of the more interesting wells identified in the first screen. 
Figure 5.7. a is a good example of crystalline precipitate. Figures b-d contain more 
separate entities that resemble better crystal-like structures with a corresponding 
decrease in pH of formulation used. Figure b) shows Quasi-like crystals (pH 6.5), 
the bodies in c) resemble microcrystals (pH 5.9) and there are needle-like clusters 
in d), (pH4.6). The latter well looked the most promising and so further trials were 
set up based on the formulations of SSI 11. 
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5.3.3.1 CD9 EC2 crystallisation trials 11 
The variables were; 10-30 % propan-l-ol in 2% intervals (11 conditions), 
CH3CO2Na, pH 4.0,4.6 and 5.0, and CaC12 at concentrations of 0.1 M, 0.2 M or 
omitted, giving a total of 99 conditions (Table 5.4). The needle-like crystals were 
not seen again in this trial (Figure 5.8. and Table 5.4). Some crystals did grow in a 
tiny bubble within one well (26 % propan- I -ol, CH3CO2Na, pH 5.0,0.2 M CaC12). 
but it was not possible to repeat the conditions that forced the growth of these 
crystals, and the crystals themselves were not suitable for diffraction studies 
(Figure. 5.8. c). Another well was very interesting in this screen (18 % propan- I -ol, 
CH3CO2Na pH 4.6,0.2M CaC12). This contained large needle-like crystals and 
Quasi/microcrystals in the same well but unfortunately these were not large 
enough for diffraction studies and there was also substantial precipitate 
contamination in this well (Figure 5.8. d). 
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P % 
propan-1- 
01 
CH3C02Na 
pH 
[CaC121 
M 
Description 
1 10 4.0 0.2 CP (Fig5.8s) 
2 12 4.0 0.2 Clear 
3 14 4.0 0.2 P 
4 16 4.0 0.2 P 
5 18 4.0 0.2 P 
6 20 4.0 0.2 P 
7 22 4.0 0.2 P 
8 24 4.0 0.2 CP 
9 26 4.0 0.2 CP 
10 28 4.0 0.2 CP 
11 30 4.0 0.2 CP 
12 10 4.6 0.2 CP 
13 12 4.6 0.2 P 
14 14 4.6 0.2 P 
15 16 4.6 0.2 P 
16 18 4.6 0.2 Large needle like crystals + Quasi/microcrystals + 
P (Fig. 5.8d) 
17 20 4.6 0.2 CP 
18 22 4.6 0.2 CP 
19 24 4.6 0.2 CP 
20 26__ 4.6 0.2 P 
21 28 4.6 0.2 P 
22 30 4.6 0.2 P 
23 10 5.0 0.2 P 
24 12 5.0 0.2 P 
25 14 5.0 0.2 Clear 
26 1 16 5.0 0.2 Clear 
27 18 5.0 0.2 Clear 
28 20 5.0 0.2 CP 
29 22 5.0 0.2 CP 
30 24 5.0 0.2 CP 
31 26 5.0 0.2 Small crystals forme3 within a bubble, CP (Fig 
5.8. c) 
32 28 5.0 0.2 CP 
33 30 5.0 0.2 CP 
34 10 4.0 0.1 CP 
35 12 4.0 0.1 CP 
36 14 4.0 0.1 CP 
37 1 16 4.0 0.1 P 
38 18 4.0 0.1 P 
39 20 4.0 0.1 P 
40 22 4.0 0.1 P 
41 24 4.0 0.1 P 
42 26 4.0 0.1 CP 
43 28 4.0 0.1 P 
44 30 4.0 0.1 P 
45 10 4.6 0.1 CP 
46 12 4.6 0.1 P 
47 14 4.6 0.1 P 
48 16 4.6 0.1 CP 
49 18 4.6 0.1 CP 
50 20 4.6 0.1 Clear 
51 22 4.6 0.1 CP 
52 24 4.6 0.1 P 
53 26 4.6 0.1 P 
54 28 4.6 0.1 P 
55 30 4.6 0.1 P 
56 10 5.0 0.1 Infected 
57 12 5.0 0.1 Infected 
58 14 5.0 0.1 Infected 
59 16 1 5.0 0.1 P 
60 19 1 5.0 0.1 P 
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61 20 3.0 0.1 p 
62 22 5.0 0.1 p 
63 24 5.0 0.1 CP 
64 26 5.0 0.1 CP 
65 28 5.0 0.1 p 
66 30 5.0 0.1 p 
67 10 4.0 0.0 p 
68 12 4.0 0.0 Hair 
69 14 4.0 0.0 p 
70 16 4.0 0.0 CP 
71 18 4.0 0.0 CP 
72 20 4.0 0.0 p 
73 22 4.0 0.0 Clear 
74 24 4.0 0.0 p 
75 26 4.0 0.0 CP + outlines of globular regions (rig5.8b) 
76 28 4.0 0.0 CP 
77 30 4.0 0.0 CP 
78 10 4.6 0.0 CP 
79 12 4.6 0.0 CP 
80 14 4.6 0.0 p 
81 16 4.6 0.0 p 
82 18 4.6 0.0 p 
83 20 4.6 0.0 Infected 
84 22 4.6 0.0 p 
85 24 4.6 0.0 p 
86 26 4.6 0.0 p 
87 28 4.6 0.0 p 
88 30 4.6 0.0 p 
89 10 5.0 0.0 p 
90- 12 5.0 0.0 p 
91 14 5.0 0.0 p 
92 16 5.0 0.0 p 
93 Is 5.0 0.0 p 
94 20 5.0 0.0 p 
95 22 5.0 0.0 p 
96 24 5.0 0.0 p 
97 26 5.0 0.0 p 
98 28 5.0 0.0 CP 
99 30 5.0 0.0 CP 
Table 5.4. CD9 EC2 further trials. The first set of further trials were based on SSI II conditions: 
0.2MCaCI2, CH3CO2NapH4.6,20%propan-l-ol. The variables are listed in the table, along with 
a description of the contents of the well taken 2 weeks after the trials were set up. P= Precipitate, 
CP = Crystalline Precipitate. 
5.3.3.2 His6-CD9 EC2 crystallisation trials III 
The remainder of the His6-CD9 EC2 was used in trials with two other conditions 
that were pulled out of the original screen, these being 20 % PEG 3350 and 
Mg(HC02)2, 
) pH 5.9 (Fig. 5.7. c), or CH3CO2K, pH 7.8. A concentration range of 
PEG 3350 from 10 - 25 % with 
Mg(HC02)2 pH 5.8 and 6.4, or CH3CO2K pH 7.0 
and 7.8, were used (Table 5.5). There was some crystal growth in the 
Mg(HC02)2 
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pH 5.8 plate in well with 20 and 25 % PEG 3350 (Fig. 5.8. e and f, respectively) but 
these were not large enough to test by X-ray diffraction. 
% PEG 
3350 
0.2 M 
Mg(HCOO)2/ 
0.2 M 
CH3COOK 
pH Description 
1 10 Mg(HC02)2 5.8 P 
2 15 M9(HC02)2 5.8 1 CP 
3 20 Mg(HC02)2 5.8 CP 
4 25 Mg HC02)2 5.8 CP 
5 10 Mg(HC02)2 
- 
6.4 CP 
6 15 Mg(HC02)2 6.4 CP 
7 20 Mg(HC02)2 6.4 Small crystals around the edge of the 
well, P in centre (Fig. 5.8. e). 
8 25 Mg(HC02)2 6.4 Multiple, small, necdle-like crystals 
scattered throughout the well (Fig. 5.8. f). 
9 10 CH3CO2K 7.0 CP 
10 15 CH3C02K 7.0 CP 
I1 20 CH3CO2K 7.0 Clear 
12 25 CH3CO2K 7.0 P 
13 10 CH3CO2K 7.8 P 
14 15 CH3COOK 7.8 P 
15 20 CH3COOK 7.8 P 
16 25 CH3COOK 7.8 1P 
Table 5.5. Final trials with His6-CD9 EC2. Two further conditions picked out in the initial 
screen were: - 0.2 M Mg(HC02)2 pH 5.8,20 % PEG3350 and 0.2 M CH3CO2K p1l 7.8,20 % 
PEG3350. These were chosen because they both contain PEG3350. The remainder of the His6- 
CD9 EC2 was used to screen around these conditions. Small crystals were formed in wells 7 and 8 
(Fig. 5.8. e) and f), respectively). Unfortunately, these crystals were too small but could provide 
useful information for future trials with this protein. 
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Figure 5.8. Further trials with His6 CD9-EC2. Figures a-d are the results of further trials 
centred around the conditions that gave the needle-like crystals, SSI (see Table 5.4. for description). 
Pictures e) and f) are taken from the results of the second further trials, centred on PEGIon (Table 
5.5. ). 
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5.3.3. CD63 crystallisation trials 
An automated system was used to set up sitting drops of CD63-His6 EC2 and the 
600 different formulations (Nextal Biotech, US). In the first screen, the conditions 
listed in Table 5.6 gave small crystals after the first few days and so further trials 
were based around these formulations. 
Screen Formulation Description Further trials 
PEG 0.1 M MES pH 6.5,25 % Rod shaped 0.1 M MES, pH 5.0-8.0 in 0.5 
w/v PEG 1000 crystal. intervals. 
25 % and 35 % PEGIOOO 
PEG 0.1 M MES, pH 6.5,20 % Rod shaped As above but with PEG2000 
12 PEG 2000 crystal. 
SMI. 0.1 M HEPES, pH 7.5, 2 rod shaped 0.1 M HEPES pH 6.0,7.5,8.0,8.5. 
1.26 M (NI44)2SO4 crystals. 0.6 M, 1.26 M, 2.5 M (NI14)2SO4 
Attached. 
SMI 0.2 M Li2SO4. H20,0.1 M Single crystal 0.1 M Tris pH 7.0 - 9.0 in 0.5 
12 Tris, pH 8.5,1.26 M but similar to intervals. 0.1 M, 0.2 M Li2SO4. H20 or 
(NH4)2SO4 SMI 11. without Li2SO4-H20,0.6 M, 1.26 M 
I or 2.5 M (NH4)2SO4 
SM1 0.1 M CH3CO2Na. 3H20, 2 small, cuboidal. 0.1 M CH3CO2Na. 3H20 p1l 3.0 - 5.5 
25 pH 4.5,1.0 M crystals. in 0.5 intervals. 0.5 M, 1.0 M, 1.5 M, 
(NH4)2HP04 1 2.0 M (ýý)21-11? 04 
Table 5.6. Conditions from the first screen of CD63-Ifis6. The robot was used to screen 6 
formulation kits (96 formulations/kit) for the ability to produce CD63 EC2 crystals. The table lists 
the best conditions around which further trials were performed. 
From these trials, crystals grew in the HEPES and 2.6M (NH4)2SO4 wells at pH 
7.5,8.0 and 8.5. However, when tested for X-ray diffraction, they produced a salt 
crystal diffraction pattern. 
The PEG 12 screen grew a reasonably sized crystal and this was mounted for X- 
ray diffraction studies. The crystal turned out to be salt, but it was noted that, upon 
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trying to mount the crystal, there was a skin across the drop that when pierced, 
released a large amount of precipitate. It appeared that the skin had developed 
preventing the drop from reaching equilibrium and therefore, preventing the 
fonnation of potential crystals. Using a fme acupuncture needle, the 0.33 pl drops 
were carefully tested for the presence of a skin and if one was found it was 
removed, the well resealed and the contents of each well left to reach equilibrium 
once more. 
Two days later, the drops were viewed again, and the contents noted. Table 5.7 
lists the conditions of the wells in which crystals grew and gives a description of 
the crystals fonned. These crystals are shown in Figure 5.9. Fortunately, all of 
these crystals were large enough to diffract X-rays. 
Screen Formulation Description 
PEG 1 0-2M NaF, pH 7.1,20 % Small, cuboidal crystals around the 
w/v PEG 3350 perimeter of the drop (Fig5.10. c and d) 
PEG 3 0.2 M NI-1417, pH 6.2,20 % Clusters of small crystals around the 
PEG 3350 perimeter and some larger ones in the 
centre of the well. Jagged edges (5.10. g 
and e) 
PEG40 0.2 M Na2HP04.21-120, pH Two crystals, crossed at one end. 
9.8,20% PEG 3350 Rocket like shape (5.10. f) 
PEG44 0.2 M (NI14)2HP04, pH 7.9, Fern-like crystal. Lots of tiny 
20% PEG 3350 projections from two large, crossed over 
crystals (5.10. h) 
CS1 0.1 M CH3COONa. 3H20, Multiple, fern-like crystals (5.10. a and 
pH 4.5,1.0 M (NH4)2HP04 b. ) 
Table 5.7. Chemical formulations of wells where crystal forms were observed in the second 
screening experiment. 
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Figure 5.9. Crystals from screening CD63-His6 EC2. Magnification is between 20 and 100. 
For a description of the contents of the well see Table 5.7. 
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All of the crystals described in Table 5.7 were loaded onto the X-ray diffractor but 
they all produced the characteristic diffraction pattern from salt crystals. 
As mentioned previously, around 50 % of the drops had developed a skin, thus 
preventing equilibrium between the contents of the drop and the reservoir being 
reached. The only way to remove the skin from the sitting drops produced by the 
robot was to peel back the film and use a needle to lift away the skin before re- 
sealing. This was a complicated procedure that took time, however, the drops were 
0.331d in volume and undoubtedly a large amount of evaporation would have taken 
place in the time taken to remove the skin. This may have been having some effect 
on crystal growth. It was therefore decided to manually set some crystal trials 
using the Hampton screens. These drops were larger (2gl) and individually sealed, 
thus reducing the exposure time if a skin should develop. Unfortunately, no crystal 
growth was detected by this method. 
5.3.5 One dimensional 1H spectrum of CD63-His6 EC2 
The collaborator who made the CD63-His6 EC2 proteins used circular dichroism 
to verify the presence of alpha helices. To ensure that the protein had regained its 
structure after Iyophilisation it was decided to perform I D-NMR spectrometry on 
the sample. This was also done to confirm that protein crystals had not failed to 
grow simply because of lack of structure. 500pI of a 4mg/ml solution of CD63- 
His6 EC2 was used to obtain a one dimensional spectrum (Figure 5.11). 
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Figure 5.11. One dimensional 1H spectrum of CD63-His6 EC2.500pl of CD63-His6 EC2 at 
4mg/ml in dH, O was placed in a glass capillary tube and centrifuged briefly to ensure that all the 
protein was at the bottom of the tube. The tube was then loaded into a Bruker DRX500 and 
subjected to 50OMHz proton frequency. The ID proton NMR spectrum was run with presaturation 
of the water and a hahn echo (2.6m total echo time) to improve convolution difference, Is recycle 
time, 128 scans. The spectrum was processed with a convolution difference to further remove the 
water signal, and 5Hz line broadening. 
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From the spectra obtained, the opinion from an expert in the field (Dr. Jeremy 
Craven, Department of Molecular Biology and Biotechnology, University of 
Sheffield) was that the protein did have some alpha helical content and was 
therefore highly likely to be folded. The peaks highlighted by the arrows in Figure 
5.11 show chemical shifts of hydrogen atoms, a phenomenon which only takes 
place in structured proteins and not in random coils. This initial experiment 
strongly suggests that the protein is still folded. This, therefore, rules out the 
possibility that CD63-His6 EC2 crystals are not growing because the protein is in a 
random coil formation. 
156 
5.4. DISCUSSION 
The initial aim for this structural work was to cleave GST from GST-CD63 EC2, 
concentrate the purified, cleaved CD63 and use this protein in crystallisation trials. 
CD63 EC2 was successfully cleaved from GST and purified by batch purification. 
The cleaved product was considered extremely pure since only the II kDal band 
corresponding to cut CD63 was visible on a silver stained SDS-PAGE of the 
sample. However, once GST was cleaved, CD63 became very unstable and 
proved to be problematic to work with. The problems that were encountered, such 
as apparent "sticking" of GST to plasticware, were probably due to the 
hydrophobic patches present in the EC2 of CD63. To avoid this problem, pre- 
siliconised plasticware was used but this did not prevent loss of cleaved CD63. 
Instead, CD63-His6 EC2, provided by a collaborator, was used for the 
crystallisation trials. 
The prerequisite for X-ray crystallography is a single crystal with two or more 
dimensions being 0.2 mm or longer and this, in many cases, is the rate limiting 
step in structural studies. The conditions that cause a protein to crystallise are 
specific for the individual protein and variables include pH, ionic solvent and 
temperature. Commercially available sparse matrix screens have been developed 
to aid initial screening experiments and further developments of robots to set-up 
the screens using minute volumes of protein, means that hundreds, if not thousands 
of different screens can be performed each day. In many cases, however, proteins 
still do not crystallise. Recent data from various proteome structural genomics 
projects reveal the extent of this problem. The Human Proteome Structural 
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Genomics pilot project, (http: //www. proteome. bnl. gov/progress. html) found that 
out of 120 soluble proteins expressed, only 19 (16 %) gave suitable crystals for 
diffraction studies. Other projects have resulted in comparable levels of success in 
gaining diffraction-quality crystals: the Berkeley Structural Genomics Centre 
(b": //www. strgen. org/status/-P-rogresstotals. html) crystallised 19 % of the soluble 
expressed protein, a study by Lesley et al. (Lesley et al. 2002) showed 
crystallisation. conditions for 31.2 % and only 3.1 % of proteins grew diffraction 
quality crystals in a study by the Joint Centre for Structural genomics 
(httv: //www. icsg. org/scrints/Drod/home. html). 
In the case of crystallising a protein domain, as we did here, it is possible that the 
protein itself could be a good variable. Indeed, earlier studies have shown that if it 
is not possible to crystallise the target protein, homologous proteins from another 
species could serve as a good alternative. The difference ofjust a couple of amino 
acids can change the properties of a protein and allow crystallisation to occur in the 
standard screens. Strategic point mutations and truncations or deletions have also 
been used to encourage crystallisation, as have addition of fusion proteins to the 
target protein, (reviewed in (Dale et al. 2003). Producing new constructs that 
include or exclude amino acids on either side of the predicted domain structure 
would be a wise next step, although time constraints did not permit these 
experiments in this project. 
Affinity tags are used primarily to aid purification of the protein but can also act to 
stabilise and solubilise the target protein. There are conflicting reports about the 
usefulness of tags in protein crystallisation. However, at the Centre for Genomics 
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and Protcomics at the UCLA, 60 % of the protein crystals that diffracted, and 57 % 
of the structures solved, used proteins with C-tenninal His6-tags (Goulding et al. 
2003) so it is probably advisable to continue the use of His6-tagged protein for any 
further work. 
1- pH and buffer 
2 Ionic strength 
3_ Temperature 
4 Concentration and nature of precipitant 
5 Concentration of macromolecule 
6 Purity of macromolecule 
7 Additives, effectors and ligands 
8_ Organism source of macromolecule 
9 Substrates, enzymes, inhibitors 
10 Reducing/oxidising environment 
11 Metal and other specific ions 
12 Rate of equilibrium and rate of growth 
13 Detergents 
14 Gravity, convection and sedimentation 
15 Vibrations and sound 
16 Volume of crystallisation sample 
17 Presence of amorphous or articulate material 
18 Surfaces of crystallisation vessels 
19 Proteolysis 
20 Contamination by microbes 
21 Pressure 
22 Electric and magnetic fields 
23 Handling by investigator and cleanliness 
24 Viscosity of mother liquid 
25 Heterogeneous nucleating reagents 
Table 4.8. Factors that could affect protein crystal growth (McPherson 1990). 
As the probability of growing protein crystals is enhanced as the concentration of 
protein is increased, the recommended starting concentration is 10-100mg/ml. The 
concentration of GST-CD63 EC2 used was only 5mg/mI making it less likely that 
crystals would grow. 
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The I D-NMR spectrometry graph revealed that the protein had structure, probably 
containing alpha-helices. This data was promising and 2D-NMR techniques could 
be a real possibility to continue the work in the future. 
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CHAPTER 6 
CLONING AND EXPRESSION OF EWI PROTEINS 
6.1 INTRODUCTION 
6.1.1 EWI Proteins 
In 2001, three independent groups identified two novel primary binding partners 
for CD9 and CD81, namely EWI-F and EWI-2 (Chaffin et al. 2001; Clark et al. 
2001; Stipp et al. 2001). The EWI proteins are a subfamily of the IgSF, but the 
other 2 members of the EWI family do not bind to CD9 or CD81 (Clark et al. 
2001; Stipp et al. 2001). EWI-F and EWI-2 consist of 6 and 4 Ig-like domains, 
respectively. It has been demonstrated that these proteins exist in association with 
CD9 or CD81 in the presence of Triton X-100, thus fulfilling the requirements of 
Aprimary tetraspanin binding proteins' (Chapter 1.2). Each of the three studies 
pinpointed the EC2 domain from CD9 and CD81 as being responsible for the 
interaction with EWI proteins. However, critical amino acids in the EC2 domains 
and EWI proteins that are involved in the association had yet to be identified. 
6.1.2 AIMS 
We decided to use our tetraspanin EC2 constructs to attempt to further characterise 
the interactions between CD9 and CD81 and the two ligands, EWI-2 and EWI-F. 
Using WT and mutant CD9 and CD81 GST-EC2 recombinant proteins, we aimed 
to identify critical amino acids in these regions that are involved in the interaction. 
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In order to gain a complete understanding of the involvement of EWI proteins with 
tetraspanin complexes, it was necessary to make numerous constructs of the EWI 
proteins: Constructs of the four members of the human and mouse EWI family 
were required for expression as full length, native protein in mammalian cells as 
well as soluble, recombinant protein expression in bacterial cells. It was also 
planned to identify the Ig-like domains in EWI-2 and EWI-F responsible for 
binding to CD9 and CD81, and so individual Ig-like domain expression in bacteria 
was also planned. The GatewayTm System (Invitrogen Life Technologies, CA) was 
chosen to aid the cloning procedure (see 6.1.3. ). 
6.1.3. GatewayTm Technology 
Invitrogen developed GatewayTm Technology as a highly flexible and powerful 
approach to cloning multiple proteins based on bacterial X recombination (Gujral 
2003). Briefly, the DNA of interest is amplified by PCR and recombined into a 
donor vector to create an entry clone, which is in turn mixed with one of a number 
of destination vectors in a5 minute bench-top reaction, to produce an expression 
vector that is ready to be transformed or transfected. 
In ?, recombination, attB and aul' sites recombine to generate attL and altR 
recombinant sites, and vice versa. Bacteriophage X has three enzymes that catalyse 
the recombination events: Integrase (Int), Excisionase (Xis), and E. coli Integration 
Host Factor (IHF). These enzymes recognise the att sites and act to bring together 
these sites, cleave them and covalently attach the DNA. 
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Figure 6.1. Gateway' Cloning Reaction. To allow entry of the insert into the GatewayTM 
system, a CACC overhang is designed at the 5' end of the forward primer. This will combine with 
the GTGG overhang of the pENTR/SD/D-TOPO vector in a reaction catalysed by TOPO isomerase 
(yellow star). Following transformation of the pENTR/SD/D-TOPO reaction mixture with fresh 
PCR product and plasmid isolation from correctly sequenced constructs, the LR clonase reaction is 
performed. Here, the cloned insert is shuffled into either destination vector by recombination of the 
attL sites in the entry vector with atIR sites in pET-DEST42 or pCDNA-DEST40 in a reaction 
catalysed by LR clonase. The diagrams of the destination vectors show selection genes. promoter 
sites and carboxy-terminal tags. 
MD 
P-- 318 
1., 0-337 
163 
The first recombination reaction is to create an attL-containing entry clone. The 
quickest entry into the GatewayTm system uses pENTR/TOPO vectors to create 
entry clones which replace the need for donor vectors. pENTR/TOPO vectors 
have attL sites flanking the multiple cloning site. The destination vectors contain 
attR sites to allow recombination with the entry vectors. The pENTR/SD/D- 
TOPO vector was used here as it contains a T7 gene 10 translational enhancer and 
a ribosome binding site for optimal expression in both prokaryotic and mammalian 
hosts. To enable directional cloning into the pENTR/SD/D-TOPO vector, forward 
primers must contain the CACC overhang at the 5' end which will base pair with 
the GTGG overhang sequence in the ENTR vector (Figure 6.1). 
Following the directional TOPO cloning to create an entry vector, clones are 
analysed by PCR to identify positive transformants using the M13 forward or 
reverse primer. Positive PCR clones are then sequenced to ensure the insert is 
correct. The vector is then ready to be mixed with a destination vector of choice. 
There are a number of GatewayTm destination vectors available for bacterial, 
mammalian and insect expression. For this study the bacterial vector pET- 
DEST42 (cat # 12276-010) and mammalian vector pcDNA-DEST40 (cat # 12274- 
015) were used (Fig 6.1). Both have C terminal V5-His6-tags and were chosen for 
the following reasons: 
1) Due to an absence of antibodies, purification and identification of the proteins 
via the His6-tags was necessary. 
2) The recombinant tetraspanins are GST-fusion proteins and so making EWI 
constructs as His6-tagged proteins would not interfere with the detection of 
tetraspanins. 
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3) Since the carboxy-tenninal in the native protein contains a TM and IC region, a 
tag on this side was chosen. It is more likely that an N-terminal tag could interfere 
with the interaction with CD9 and CD81. 
Once the DNA has been cloned into the destination vectors, an expression vector is 
formed which can then be either transformed into E. coli or transfected into 
mammalian cell lines. 
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6.2 MATERIALS AND METHODS 
Full length EWI-F cDNA (clone KIAA1436) was ordered from Kazusa DNA 
Research Institute, China. EWI-2 was ordered from the IMAGE Consortium, 
clone 3613821. The primers for full length cloning were designed and purchased 
from Sigma-Aldrich (Table 6.1). These primers are suitable for protein expression 
in both eukaryotic and prokaryotic cells. When the ATG initiation codon 
immediately follows the CACC necessary for directional cloning, then the ATG is 
properly spaced from the RBS within the entry vector, allowing proper translation 
of the PCR product in prokaryotic cells - both the 5' primers were designed in this 
way. For proper eukaryotic translation, a Kozak consensus sequence is required. 
A number of sequences are possible for this but aG or A position at -3 and aG at 
+4 is critical for fiinction e. g. (G/A)NNATGG. The 5' primers also fitted this 
description and the critical (G/A) and G residues are highlighted in bold type in 
Table 6.1. Stop codons were omitted as inclusion of the C-term His6-tags were 
required. 
Oligo name overhang sequence 
EWI-2 5' C ACC ATG GGC GCC CTC AGG C 
EWI-2 3' CAC AAA TA6 GGT GTC CAG G 
EWI-F 5' C ACC ATG GGG CGC CTG GCC T 
EWI-F 3' GGG ATA CTT GAA GGC GTT C 
Table 6.1. Oligonucleotides designed for full length, soluble protein expression in the 
GatewayTm system. The C-tenn transmembrane region was not included so that the protein could 
be expressed as a soluble protein. 5' primers required the CACC overhang to allow recombination 
into the entry vector, immediately followed by the initiation codon, ATG. This format makes the 
insert in the same reading frame as the ribosome binding site in the entry vector, thus allowing 
expression in prokaryotic cells. The A at position -3 (A of ATG is taken as position + 1) and the G 
at +4 (both highlighted in bold), create a Kozak consensus sequence to allow expression in 
eukaryotic cells. 
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6.2.1 LR clonase reaction 
The LR clonase reaction was performed to recombine the entry vector containing 
the gene of interest with the destination vectors. The following components were 
added to a 1.5ml tube and mixed at room temperature: 
Component volume 
Entry clone (15 Ong) 1-5 gl 
Destination vector (15 Ong/jil) I [d 
5X LR clonase reaction buffer 2 Itt 
TE buffer, pH 8.0 To 8 gl 
The LR clonase was thawed on ice and 2gl was then added to each reaction tube 
and vortexed briefly to mix. The reaction was then incubated at RT for one hour 
before being terminated by addition of proteinase K and incubation at 37*C for 10 
minutes. The destination vector now contained the gene of interest and was 
transformed into DH5a competent cells following the protocol given in Chapter 2. 
[N. B. From here onwards the protocols were the same as the protocols given in the 
general Methods and Materials with regards to isolating DNA and identifying 
positive clones by PCR and restriction digests. All inserts were sequenced before 
being transfected or transfonned into expression hosts. ] 
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6.3 RESULTS 
6.3.1 Prokaryotic expression using the Gatewaylm system 
In order to obtain a GatewayTm entry clone, the first requirement is a blunt end 
PCR product that runs on an agarose gel as a single, discrete band of the correct 
size. Thermostable, proofreading polymerase, Platinum(ID Pfx, (Invitrogen), was 
used initially. A gradient PCR block was used to test a range of Tm temperatures 
from 55-65*C. EWI-2 PCR product gave single, discrete bands at all the 
temperatures tested (Figure 6.2). However, EWI-F produced several bands that 
perhaps corresponded to the different immunoglobulin-like domains (Figure 6.2). 
PCR conditions were optimised and eventually a single band was produced (Figure 
6.2) by using the conditions depicted in Table 6.2. 
PCR mix components (pl) EWI-2 EWI-F 
Reddy mix 10 10 
Forward primer 0.25 1.0 
Reverse primer 0.25 1.0 
DNA template 0.5 2.0 
dH20 9.0 6.0 
Annealing temp (*C) 5 -65 65 
Table 6.2. PCR conditions used to obtain single bands. In order to clone the inserts into the 
TOPO vector, PCR products should run as single, discrete bands at the correct size. The table lists 
the conditions used to obtain these. 
The PCR products were run on high purity agarose gels and the DNA purified 
from the gel. For cloning into the pENTR TOPO vectors it is recommended to use 
1-5ng of aI kb PCR product or 5-1 Ong of a2 kb PCR product. The purified EWI- 
2 DNA was estimated to be at 20ng/pl and EWI-F at 30ng/gI. The DNA was 
therefore diluted 1: 10 and 4 pl used in each TOPO reaction. The TOPO reaction 
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using the pENTR/SD directional TOPO vector and the cloning reaction was 
transformed into One Shot cells by using the chemical transformation described in 
Materials and Methods. 12 colonies from each construct were picked and named 
(EWI-)2 (1-12) and (EWI-)F (1-12) and the plasmid DNA was isolated. 
Commercially available M13 forward and reverse primers were used to analyse the 
plasmids by PCR to confirm the presence of the insert. Positive samples were 
sequenced using the M13 forward and M13 reverse primers for each sample. The 
sequences are only reliable for the first 900bp so it was necessary to design internal 
primers to get a full read. The oligonucleotides used for internal sequencing are 
listed in Table 6.3 
Construct Starting 
position 
Forward/reverse oligo 
EWI-2 856 Forward CTATGCTGAGCGATTGG 
EWI-F 851 Forward CCAAGAATGTGTCTGTGGCT 
EWI-F 1768 Reverse CAGCCATATGAGAACAGAG 
Table 6.3. Internal primer design for EWI DNA. In order to read the whole DNA sequences it 
was necessary to design internal primers. The table lists the oligonucleotides and the starting 
positions. 
6.3.2 Sequencing results 
The entry plasmids EWI-2: 4 and EWI-F: 2 were found to contain the correct 
inserts. The LR clonase reaction was performed to transfer the gene of interest 
from the entry clone to a destination vector in order to generate an expression 
clone. The first destination vector used was pET-DEST42. The reaction mixture 
from the clonase experiment was then ready to transform into competent E. coli. 
DH5a cells were used and positive colonies were identified firstly by PCR 
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screening using the insert-specific primers, and secondly, by sequencing of 
samples that were positive in the PCR using M13 forward and M13 reverse 
primers. From this second screen, EWI-2: 2 and EWI-F: 3 were sequenced and 
found to be correct and so were used to transform BL21 cells. Two colonies were 
picked and inoculated overnight so that optimisation of protein conditions could be 
carried out. For each condition listed in Table 6.4,50pl of inoculum was added to 
I ml LB with 50[tg/ml carbenicillin and grown for 2 hours. For each expression 
construct, a non-induced control was grown for 4 hours. Whole cell lysates were 
analysed on Coomassie stained gels, (Figure 6.3). 
'A. B. 
Figure 6.2. PCR amplification of EWI insert from cDNA clones. The first PCR reaction used 
Platinurrit Pfx and gradient block with TM between 55-65'C in 2'C intervals. EWI-2 gave single 
bands at the correct height (1.5 kb) at all annealing temperatures but these conditions were not right 
for the production of EWI-F (2.5 kb) and a banding pattern was obtained (A). The polymerase was 
changed to HighFidelity (Abgene) and PCR conditions were altered to obtain a single, discrete 
band at 2.5 kb for EWI-F (B). 
There was no evidence of any protein 70kDal corresponding to full length EWI-2. 
However, in the EWI-F optimisation from colony 2, one band at the correct size 
was seen (Figure 6.3). The conditions for band number 7 were: induction with 
I. OmM IPTG and growth for 4 hours. 
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Lane # 1 2 3 4 5 6 7 8 9 10 11 12 
JIPTG] M 0.1 0.1 0.1 0.1 1.0 1.0 1.0 1.0 0.5 0.5 0.5 0.5 
time 2 hr 3 hr 4 hr ON 2 hr 3 hr 4 hr ON 2 hr 3 hr 4 hr O/N 
Figure 6.3. Coomassie stained SDS-PAGE gel showing whole cell lysates from the trial 
expression of EWI-F in BL21 cells. Correctly sequenced, full length EIWI-2 and EWI-F in the 
pET-DEST 42 vectors were used to transform BL21 cells. Difterent concentrations of IPT6 were 
used to induce protein expression and then the cells were left to express for 2 hours, 3 hours, 4 
hours or overnight. Cells were harvested and whole cell lysates were run on SIDS gels next to a 
non-induced control and stained with Coomassie. The Coomassie stained gel shown here is of 
EWI-F. [* = 135kDal band that could be EWI-F]. 
The same EWI-F plasmid was used to re-transform some fresh BL21 cells in order 
to scale up the protein production using these identified conditions. EWI-2 was 
also expressed in the same way to check the possibility that protein concentration 
was too low for detection in the small scale trial. Bacterial pellets weighing >5g 
were obtained from both preparations and the protein was purified by the 
denaturing His6-tag purification method. Samples eluted from the column were 
immediately tested for protein concentration but found not to contain protein. To 
verify that the protein had not been produced but then lost during the purification 
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procedure, samples from the lysed cell pellet, column flow-through, beads and 
eluted fractions were run on SDS-PAGE gets. Coomassie staining did not show 
correctly sized proteins (Figure 6.4) and Westem-blots were negative for His6- 
tagged proteins. 
12 345678 
EWI-F EWI-2 
Lane 1 2 3 4 5 6 7 8 
Co-ntents lysed 
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flow- 
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EWI EWI-F EWI-2 
Figure 6.4. Coomassie stained SDS-PAGE showing various stages of the EWI-F and EWI-2 
purification procedure. Whole cell lysates from 131-21 cells transfected with His6-tagged EWI-F 
or EWI-2 were loaded onto Ni-NTA beads (Qiagen). Samples from the purification procedure 
were run on an SDS-PAGE gel and stained in Coomassie. 
W* 
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6.3.3 Investigation on the effects of temperature on the production of EWI 
protein 
Up to this point, all of the protein induction experiments had been carried out at 
37*C. It was decided to investigate the effects of lowering the growth temperature 
during expression of EWI protein. For this assay, 3 overnight inoculums for each 
protein were diluted 1: 40 into fresh LB. All of the flasks were grown for the first 2 
hours at 37*C to bulk up bacterial density before being induced with IMM IPTG. 
One flask of each protein was grown at 3 7,25 and 22*C and left to grow for 2,4 or 
6 hours or overnight. Coomassie stained gels and Western blots probed with anti- 
His6 antibody did not detect any cloned protein. 
All attempts to detect the expression of EWI proteins were focused on soluble 
protein expression or protein being secreted from the cells. It is possible that the 
proteins were being expressed but accumulating in insoluble inclusion bodies 
within the cell that were not solubilised during native purification. Lysing the cells 
using guanidinium/urea and thereby unfolding the proteins, will release the 
contents of inclusion bodies. However, Coomassie stained gels and Western blots 
of samples prepared in this way were negative and so EWI protein was not 
accumulating within inclusion bodies. 
6.3.4 EWI protein expression in mammalian cells 
Eukaryotic protein expression was the obvious next step after having exhausted the 
possibilities in the prokaryotic system. Although the yields of protein produced 
173 
arc generally lower from cukaryotic cells, these organisms have more sophisticated 
methods for producing proteins that have complex folding. Since the EWI proteins 
are of human origin, is it possible that they are too complex to be produced in 
prokaryotic cells. The same entry vectors used for the prokaryotic cloning were 
used again, this time in an LR clonase reaction with destination vector pcDNA- 
DEST40 (Figure 6.1). This vector is for cloning and expression of C-terminal 
fusion proteins in mammalian cells. Following the LR clonase reaction the 
reaction mixture was transformed into DH5a cells. Plasmid DNA was isolated in 
the usual way and analysed for the presence of the insert. A PCR screen, 
performed using the insert-specific primers, confirmed that the cloning had 
workcd. 
6.3.5 Lipofectamine transfection 
In the first attempt at transfecting the EWI DNA, Lipofectamine Plus (Invitrogen) 
was used. Three cell lines: COS; CHO and HEK cells were transfected with 500ng 
and I OOOng of each DNA and an additional 2500ng of the larger EWI-F. After 24 
hours the CHO and HEK cells had grown to - 90 % confluency. The COS cells, 
however, had only reached around 40 % confluency. After 48 hours, the 
supernatant was removed for protein assays. The cells were harvested and lysed 
for Western-blotting and silver staining. For each cell type there was a non- 
transfccted control and 5 different transfections carried out (Table 6.5). 
The supernatant was used in an immunoblot to detect His6-tagged protein. 
However, the immunoblot and Western blot did not recognise any His6-tagged 
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protein. Silver-stained gels of the cell lysates showed evidence of some EWI-F 
(105 kDal) in CHO cell lysates, sample number 4 and 5 in Figure 6.5. A protein of 
this molecular weight does not appear to be present in the non-transfected control. 
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Figure 6.5. Expression of full length EWI-F in CHO, COS and HEK cells. Lipofectamine 
reagent (Invitrogen) was used to transfect full length EWI-F or EWI-2 DNA into CHO, COS and 
HEK cells. Whole cell lysates were run on SDS-PAGE gels and silver stained. 
After preparing more DNA, the transfections were repeated using 2.5ýtg of each 
DNA and this time harvesting cells 2,3,4,5 and 6 days following transfection but 
again no recombinant protein was detected with anti-His6 antibody. A final 
attempt at transient Lipofectamine transfection used up to 30OOng of DNA but no 
expression of the desired protein was detected. 
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6.3.6 Stable transfection using Lipofectarnine 
Stable transfection can also be achieved by using the same plasmid vector, by 
selection with the antibiotic, geneticin. CHO cells were used initially with the 
same transfection protocol as for transient transfection, but 48 hours post- 
transfection, geneticin was added. The antibiotic kills non-transfected cells that do 
not carry the plasmid containing resistance to geneticin. After the first week of 
growth in the presence of the antibiotic selection, cell death of non-transfected 
cells was observed. Over the next few weeks the surviving cells were cultured, 
performing only half media-changes when necessary and within four weeks there 
were sufficient amounts of EWI-F and EWI-2- transfected cells to test for 
expression (the fact that the cells grew in selective media suggests that transfection 
of the resistance containing plasmid had occurred). One plate of each cells 
transfected with each insert was left to propagate and the remaining cells were 
harvested in trypsin and lysed in order to assay for protein expression. Gel 
analysis and Coomassie staining did not show any bands of transfected proteins in 
the cells nor in the supernatant, and the negative result was confirmed with anti- 
His6 and anti-V5 probed Western blots. 
A new batch of COS-7 cells were tested for transfection and expression of EWI 
proteins since these are chimpanzee cells that are more similar to human cells and 
should therefore be better equipped to express human protein. Both stable and 
transient expression experiments were performed in tandem, using Lipofectamine 
plus reagent. After 48hrs the cell lysates and supernatants from the transient 
transfection tested negative for EWI protein. Following addition of geneticin, any 
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non-transfected cells were left to be killed by the antibiotic and any transfected 
cells were cultured for 21 days. The assays were negative for transfected protein 
expression in both the stable and transiently transfected cells. 
6.3.7 Calcium phosphate transfection of EWI-2 and EWI-F 
Calcium phosphate transfection was attempted to rule out the possibility of 
Lipofectamine being incompatible with this DNA for whatever reason. 48 hours 
post-transfection, the cells were harvested in the usual way. An immunoblot of the 
supernatants and a Western blot of the cell lysates was negative. 
6.3.8 DNA electroporation of EWI-2 and EWI-F 
Since chemical transformation experiments had proved unsuccessful, the decision 
was made to use electroporation. methods to transfect the cells with DNA. CHO 
cells were used since they appeared to be the most robust. Following the 
electroporation event, the cells were left to grow for 24 hours before addition of 
geneticin, the selective agent, to a total concentration of 200[tg/ml. Tbree days 
after the transfection, some plates were confluent and so were sub-cultured and the 
concentration of geneticin was increased to 400gg/ml. Cells on other plates were 
patchier in growth and seemed to be responding better to the antibiotic. More 
geneticin was added to these plates to a total volume of 400[tg/mI but they were 
not sub-cultured. Half media changes were performed as necessary and after 3 
weeks the remaining cells were harvested, lysed and tested for His6-tagged EWI 
protein. No protein was detected in the lysed cell pellets or in the media. 
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6.3.9 EWI domain expression in the pET system 
Due to the unsuccessful attempts to express full length EWI proteins in GatewayTM 
vectors it was decided to attempt to clone into a different expression system. The 
pET32c vector was chosen (Figure 6.6) as this vector was available in the 
laboratory and is designed to be used in conjunction with Origami cells -a 
specially adapted E. coli strain, capable of forming disulphide bridges in the 
cytoplasm (see Discussion). It was also decided to clone and express double Ig- 
like domains rather than full length protein (Figure 6.7). 
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Figure 6.6. pET32c vector. The 
restriction sites used for cloning 
the insert are shown in blue (Notl 
and Sall). N- and C-tenninal 
tags are also highlighted. 
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Figure 6.7. EWI-2 and EWI-F. A schematic diagram showing EWI-2 and EWI-F surrounding 
their primary ligand, CD9 (or CD81). The blue hexagonal shapes represent Ig-like domains, of 
which there are 4 and 6 in EWI-2 and EWI-F, respectively. The black lettering adjacent to the 
hexagons represents the nomenclature of the single Ig-like domain cloning, and the construct 
numbers (1 -5) represent the nomenclature given when cloning double Ig-like domains. 
In order to clone individual EWI domains, firstly, the full length sequence was 
pasted into on-line search engines that predicted the boundaries of the 
immunoglobulin-like domains. EMIL-EMI, InterProScan and ScanProsite were 
used and they all predicted 4 and 6 Ig-like domains for EWI-2 and EWI-F as 
shown in the InterPro annotation (Figure 6.8A and 6.9A, respectively and Table 
6.4). 
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Ig domain EWI-F EWI-2 
1 28-141 34-149 
2 151-270 171-299 
3 284-390 311-435 
4 414-532 447-573 
5 556-676 N/A 
6 696-822 N/A 
Table 6.4. Ig-like domain predicted boundaries. EMBL-EMI, InterProScan and ScanProsite 
were used to predict the boundaries of immunoglobulin-like domains. The table shows the 
combined results for each domain. 
However, the boundaries for each domain differed slightly (Table 6.4). Figures 
6.8B and 6.9B show the final predicted domains for EWI-2 and EWI-F, 
respectively, as a result of the 3 searches pooled together. The forward 
oligonucleotide starting positions for each domain are shown. The pET-32c vector 
offers a number of restriction enzyme sites in its multiple cloning site. In order to 
determine which restriction enzymes would be compatible with my protein of 
interest, an on-line tool that searches for restriction sites within the chosen DNA 
was used (http: www4. carolina. com/cgi-bin/). The full length DNA sequences of 
EWI-2 and EWI-F were cut and pasted into this site and the results revealed that 
Sall and Notl did not cut within these sequences, and so these restriction sites 
were chosen for cloning the EWI proteins into pET32c. 
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EWI-2 
A. SEQUENCE: Seguence I CRO64: 
A7255D54D42EFB88 LENGTH: 613 aa It A 
InterPro Immunoglobulln subtype 
IPROO3599 
Domain SM00409 IG 
ýt- 
IntsiPro Immunoglobulln-like 
IPROO711 
Domain PF00047 Ig 
PS50835 IG_LIKE 
aaEI07; & Ig-like 
. ýLRPTLLPPSLPLLLLLMLGMGCWAREVLVPEGPLYRVAGTAVSISCNVTGYEGPAQQ 
NFEWFLYRPEAPDTALGTVSTKDTQFSYAVFKSP'ý'. ': - 
Domain 2 
M--'- SAAPPGPRGRQAPTSPPRMTVHEGQ 
ELALGCLARTSTQKHTHLAVSFGRSVPEAPVGRSTLQEVVGIRSDLAVEAGAPYAERLAA 
I 
GELRLGKEGTDRYRMVVGGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAH VQT 
Pollia in ý- 
LSSQLAVTVGPGERRI A 
Domain 4 
SARSRPLPVHVREEGVVLEAVAWLAGGTVYRGETASLLCNISVRGGPPGLRLAASWW 
VERPEDGELSSVPAL)LVGGVGQDGVAELGVRPGGGPVSVELVGPRSHRLRLHSLGPEDEG 
VYHCAPSAWVQHADYSWYQAGSARSGPVTVYPYMHALDTLFVPLL 
Figure 6.8. Immunoglobulin-like domain predictions and primer design for EWI-2. Figure A 
shows the results from one of the Ig-like domain searches using InterPro, and shows that there are 4 
ig-like domains (red). The other coloured domains predication are less probable matches. B. shows 
amino acid sequence with each domain highlighted. 
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EWI-F 
A. SEQUENCE: Seguence 1 CRC64: 9712C39BA74DF570 LENGTH: 879 aa InterPro Immunoglobulln subtype 
IPROO359 
Domain SM00409 IG 
ft 
. 
InterPro lmmunoglobulin-like 
IPROO711 
Domain PFOOD47 ig 
WIPM PS50835 IG_LIKE 
a 
SSF487Z§ Ig-like 
, RLASRPLLLALLSLAL, 1 PCNVL; DYDGPSEQNFDWýjý 
SLGSSFVELASTWE" ..... . 
j Domain 2 
ADSLHVGPSARPEIPSLlý1, REGEPFELRCTAASASPLHTH 
LALLWEVHRGPARRSVLALTHEGRFHPGLGYEQRYHSGDVRLDTVGSDAYRLSVSRALSA 
DQGSYRCIVSEWIAEQGNWQEIQEKAVEVATV 
Domain 4 
EAVSSPAGVGVTWLEPDYQVYLNASKVPGF 
ADDPTELACRVVDTKSGEANVRFTVSWYYRMNRRSDNVVTSELLAVMDGDWTLKYGERSK 
QRAQDGDFIFSKEHTDTFNFRIQRTTEEDRGNYYCVVSAWTKQRNNSWVKSI<DVFSKPVN 
ISLDQDSVVFIJ, ý: W 
Domain 6 
TEIDFQTSGPIFNASVHSDTPSVIRGDLIKLFCIITVEGAAL 
DPDDMAFDVSWFAVHSFCLDKAPVI, LSSLDRKGrVTTSPRDWKSDLSLERVSVLEFLLOV 
Figure 6.9. Immunoglobulin-like domain predictions and primer design for EWI-F. Figure A 
shows the results from one of the Ig-like domain searches, and shows that there are 6 Ig-like 
domains (red) The other colours in A show less probable Ig-like domain matches. B. shows amino 
acid sequence with each domain highlighted. 
Forward primers were designed with the SalI restriction site at the 5'end 
(GTCGACA). The pET32c vector has N-terminal tags and so there was no 
requirement for an initiation codon. The Yprimers were designed with the NotI 
restriction site at their 3' end (GCGGCCGC) followed by a stop codon for 
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termination and no addition of a C-term His6-tag (primer 3) or without the stop 
codons to allow transcription of the C-terminal His6-tag, (primer b3). The stop 
codons used were the same as the ones in the native proteins, EWI-2 uses TCA and 
EWI-F, CTA (Figure 6.10). 
FMIS ý, (, \ý \ATGGGCGCCCTCAGG 
FM 13 (iCGGCCGC I( \CACCTGGAGGACATCTG 
FMlh3 (i('G(iCCGCCACCTGGAGGACATCTG 
FNI25 61MAk \TCTGCTGCCCCCCCAG 
FM23 GCGGC'('(iC'l ( \GATCCGACGT-rCACCAG 
FM2b3 GCGGCC(iCGATCCGACGTTCACCAG 
FM35 OR (, V \GTGCAGACGCTGTCCAG 
FM33 GCGC, ('('(iC I( \CACCACACCTTCCTCCC 
FM3b3 GCGGCC6CCACCACACCT-rCCTCCC 
FM45 (i'F((, V \AGTGCCCGTTCCCGGC 
FM43 GCGGCCGCl ( \AGGCACAAATAGGGTGTCC 
FM4b3 GCG(i('('(i('AGGCACAAATAGGGTG'I'CC 
FM55 GFC(iA( \ATGGGGCGCCTGGCCT 
FM-" GCGGCC'(i('( I \GCCCACGTGCAGGGAG 
FM5h3 GCGGCC(jCGCCCACGTGCAGGGAG 
FM65 \GCCGACTCCCrCCACG 
FM63 (iCGGCC(-i('( I \CACGGTGGCAACTr 
FM6b3 (iCGGCCG('CACGGTGGCAACTT 
FM75 (i RG \(', \ACCGTGGTGATCCAGCC 
FM73 (iCG(; CCG('(I\TAGCCAGGTCACACCCA 
FM7b3 GCGGC('(, ('TAGCCAGGTCACACCCA 
FM85 \GTGTCT7CCCCAGCrGG 
FM83 GCGG('C(i('( I \TGCCCAAAATATG'FTAACAGG 
FM8b3 GCG(iC('GCTGCCCAAAATATGT-rAACA(iG 
FM95 6 1'('(iA( AGCATTAGAAGATTCCGTGC 
FM93 GCGGCCGC( ; \GGTTFGGAAGTCTATCTCAA 
FM9b3 (iCGGCCGC'GGMGGAAGTCTATCTCAA 
FM 105 61 (6A('\GAGATAGACTTCCAAACCTC 
FMI03 (i('(iGCC'(iCCTAGGGATACI'TGAAGGCG'I-F 
FMlOb3 (iC(i(iCC(i('GGGATACI-I'GAAGGCG'1-1' 
Figure 6.10. Oligonucleotide design for EWI domain expression. Forward primer names end in 
5 and reverse primers end in 3 (with a "stop" codon) or 3b (without a "stop" codon) depending on 
whether or not a C-terminal His6-tag is required. For shortened domain nomenclature, refer to Fig. 
6.1. Sall restriction sites are shown in red and Not I in blue. 
Double Ig-like domains were PCR amplified using the Highfidelity Reddy mix 
(Abgene), the specific primers and correctly sequenced full length EWI DNA in 
TOPO vectors as the template. The PCR products were run on I% high purity 
agarose gels, Figure 6.11 and Table 6.5. 
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A. 
B 
)ouble 
, -like 
WI-F 
)N A 
Figure 6.11. PCR amplification of EWI-2 and EWI-F double Ig-like domains. Full length 
EWI DNA from Gateway"' experiments was used as a template and the double Ig-like domains 
were amplified by PCR. Bands were observed at the correct height (800bp). N. B. DNA from EWI- 
2 (1) and EWI-F (5) with unidentified, smaller sized bands were not used again tor the remainder of 
the cloning experiments. 
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PCR mix components (pl) EWI-2 EWI-F 
Reddy mix 12.5 12.5 
Forward primer 2 2 
Reverse primer 2 2 
DNA template 6 2 
dH20 2.5 6.5 
Annealing temp (*C) 55 
Table 6.5. PCR conditions for initial cloning of Ig-like double domains. The table lists the 
conditions that gave single, discrete bands at - 800bp for each EWI double domain. 
Bands at 800bp were cut, the DNA was purified from the gel and the A-addition 
reactions were performed before TOPO-cloning. The plates contained X-gal and 
so blue/white screening could be carried out. White colonies were picked and PCR 
screened using specific oligonucleotides before being digested with EcoRl to 
confwn the presence of the insert in the TOPO vector (Figures 6.12 and 6.13). 
Positive colonies were sequenced using the T7 terminator primer. Correctly 
sequenced DNA and pET32c vector DNA were cut using Sall and Notl restriction 
enzymes. It was decided to continue with a couple of clones to begin with. EWI-F 
(5) and EWI-2 (2), the 2 membrane distal domains, were chosen because they are 
predicted to be the domains involved in the binding to CD9 and CD8 1. 
Sall is a less efficient cutter and so was incubated with the DNA for 4 hours before 
addition of Notl and incubation for a further hour. After the incubation period 
loading buffer was added and the samples were run on 1% high purity agarose 
gels under nonnal conditions (Figure 6.14). Positive bands at around 800bp were 
cut out as well as the - 6000bp band of vector DNA. The DNA was purified from 
the gel and ligations of the pET32c vector and EWI double Ig-like domain DNA 
were performed. 
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Figure 6.12. EcoRl digest of EWI-2 double domains. The double Ig-like DNA was cloned into 
the TOPO vector, transformed into TOPIO cells and the plasmid DNA from white colonies that 
grew was purified. The miniprepped DNA was cut with FcoRl (3 hours at 37'C) to confirm the 
presence of the insert. 
Figure 6.13. EcoRl digest of ENVI-Fdouble domains. I lie double Ig-like DNIA v'as cloned into 
the TOPO vector, transformed into TOPIO cells and the plasmid DNA from white colonies that 
grew was purified. The miniprepped DNA was cut with FcoRI (3 hours at 37"C) to confirm the 
presence of the insert. 
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Figure 6.14. Double digest of EWI inserts in TOPO vector and pET32c vector. DNA was first 
cut with Sall for 3 hours followed by addition of Notl for I hour. The reaction mixtures were run 
on high purity agarose gels and the EWI double domains (800bp) along with the pET32 c vector 
6000bp) were purified from the gel. 
The ligation reaction was transformed into OmnimaXTM cells (Invitrogen) and 
plated on carbenicillin selective plates in the presence of X-gal. White colonies 
were PCR screened using specific primers. Positive colonies were picked, the 
plasmid was purified and another double digest was performed to confirm the 
presence of the inserts (Figure 6.15) before being transformed into the Origami or 
BL21 for protein expression. 
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Figure 6.15. Restriction digest of ligated clones. Following ligation, 6 white colonies and one 
blue colony from each clone were picked and digested with Sall and Noll to confirm the presence 
of the insert. 
Expression of EWI-F (5) was attempted first. Origami cells were transformed with 
pET-32c-EWI-F (5), and colonies were picked, resuspended in 10ml of LB with 
selection and grown overnight. Overnight cultures were added to flasks containing 
400ml of fresh LB with selection. One flask was grown at 25'C and the other at 
37*C. The OD of the cultures was measured against a blank of LB alone and when 
cultures reached 0.2,0.4 and 0.8 OD, 5ml samples were taken out and induced 
with 0.1,0.5 or I. OmM IPTG. Cultures were grown for 2 hours, 4 hours or 
overnight giving a total of 54 different growth conditions as well as non-induced 
controls for each OD reading at each temperature. 
The cells were pelleted and lysed in 200ýtl of BugBuster and protease inhibitor 
cocktail. 100gl of whole cell lysate for each sample were loaded onto 
nitrocellulose membranes using a 96 well manifold. The membranes were probed 
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with anti-His6 antibodies but there was no recognition of any His6-tagged protein. 
Coomassie stained gels of whole cells lysates did not reveal any protein bands at 
the right size that were upregulated in comparison to the non-induced control 
(Figure 6.16). To ensure that the Origami cells were not ejecting the plasmid DNA 
after induction, induced and non-induced cells were grown in standard conditions 
(37*C, 0.5mM IPTG, 4 hour growth). The cells were pelleted and the plasmid 
DNA was extracted. Using specific primers to PCR amplify the DNA it was 
shown that the plasmid DNA was still present in the induced control. 
The inserts were transformed into BL21 cells to see if this strain could express the 
double Ig-like domains. A full expression screen, as described for expression in 
Origami cells, was carried out but no protein was detected. 
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A 
EWI-F (5) 
- 32 kDal 
kDal 
kDal 
kDal 
kDal 
OD600 OD600 OD600 
0.2 0.4 0.8 
123 10 11 12 19 20 21 0.1 mm 37'C 456 13 14 15 22 23 24 0. -" mm 789 16 17 18 25 26 27 
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Figure 6.16. SDS-PAGE analysis of pET-32c-EWI-F (5) expression in Origami cells. A large 
protein expression screen was performed, using the conditions are listed in B. Cells were pelleted 
by centrifugation at 400g for 3 minutes before being lysed by the addition of 200ld ol'BugBuster. 
100g] of the lysate was used in an immunoblot with anti-I lis6 antibody (1/1000 dilution in blocking 
buffer) followed by anti-mouse IgG-HRP (1/3000 in blocking buffer) (Figure not shown). 20ld of 
the remaining cell lysate from a selection of conditions were run on SDS-PAGE and Coomassie 
stained (A). 
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6.3.10 Protein expression using pET26b 
The pET26b vector has a pelB leader sequence for targeting of the newly 
synthesised peptide to the periplasm, the natural compartment in bacterial cells for 
protein folding to occur (Figure 6.17). This vector contains SaII and NotI 
restriction sites in the multiple cloning site and they are in the same reading frame 
as the ones in pET32c, thus permitting the use of the same oligonucleotides. The 
pET26b vector has only a carboxy-terminal His6-tag so the 3' oligonucleotides 
without the stop codon (FM b3 primers, Figure. 6.10) were used. Full length DNA 
in TOPO plasmids were used again and the same procedure for cloning into the 
pET32c vector was used for the pET26b. Construct 5 was the simplest to clone 
and was transformed into BL21 cells. A large protein expression analysis was 
carried out as described previously, and the periplasmic fraction was isolated by 
osmotic shock. 100gl of each sample was loaded onto nitrocellulose membrane 
with the aid of a manifold. When the blot was probed with the anti-His6 antibody, 
lysates from one of the conditions produced positive spots (Fig. 6.18). These 
corresponded to overnight growth at 25*C and induction at a culture OD600 of 0.8. 
The concentration of IPTG used for induction appeared not to be a factor in this 
assay. 
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Tt terminator - 26 
His tag - 140 
Noll - 166 - GC'GG('C_GC 
Sall - 1-9 - GrCGA_C 
pelB coding sequence - 224 
-- T- promoter - 361 
Figure 6.17. pET26b vector. The 
restriction sites used for cloning the 
insert are shown in blue (Notl and 
pET-26b 
Sall). N- and C-terminal tags are also 
5360 bp highlighted. 
control 2 hr growth 4 hr growth overnight growth 
Rabbit IgG 
[IPTGI 
OD 
600 
0.2 
0.4 
0.8 
0.2 
0.4 
0.8 
37'C 
25 'C 
Figure 6.18. Immunoblot of periplasmic fraction of BL21 cells transformed with pET-26b- 
EWI-F (5). A large protein expression optimisation experiment was performed, the variables being 
temperature, concentration of IPTG used to induce the plasmid expression, length of growth time 
and OD 600 of the culture before induction. The periplasmic fractions were isolated and 
immunoblotted with an anti-His6 antibody. Three spots appeared, corresponding to cultures grown 
at 25'C overnight after being induced at OD600 = 0.8 and induction with IIPTGJ ý 0.1,0.5 or 
LOMM. 
192 
1-ý 1-ýý 1-ý L-1-i 1--ý 1--r-j L_ý L--ri 1--rj 
01 05 1,0 0.1 05 10 01 05 10 
To confirm bands of the correct size, an SDS-PAGE gel was run and silver stained. 
The three samples were loaded along with a non-induced control and five other 
randomly selected samples from the same experiment. Surprisingly, not only the 
samples giving positive results in the immunoblot, but also all of the others tested, 
gave bands at the correct size that were absent in lane 4, the non-induced control. 
The protein produced in the culture grown overnight at 37*C (lane 4) appears to 
have degraded (Fig. 6.19). 
75KD 
50KD 
35KD 
30KD 
25KD 
0 
EWI-F 
Figure 6.19. Silver-stained gel of the 3 samples that were recognised by the anti-His6 
immunoblot. Lanes 7-8 are the samples recognised by the immunoblot and the dark band is at the 
right height to be EWI-F (5) double domain (- 35 kDal). 
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To further verify the results, a Western blot was perfonned the following day using 
an anti-His6 antibody. The anti-His6 antibody blot was only affimnative for the 
positive control and not for any of the samples. One can only presume that the 
protein tag is unstable and is degraded in time (the reminder of the periplasmic 
fractions had been through a freeze-thaw cycle in between the original immunoblot 
and the Western blot). 
6.3.6 Mass Spectrometry 
In the absence of a specific EWI antibody and the possible loss of the His6-tag, the 
decision was made to use mass spectrometry as a means to establish whether or not 
the band was the EWI-F protein domain. When the remainder of the isolated 
periplasmic fraction was run on a clean gel, the banding pattern was very different 
to the original. The protein bands that were believed to be the EWI double domain 
were absent, perhaps because the protein had degraded. Fresh colonies from the 
same transformation reaction were picked and following overnight inoculation, 
cultures were grown in what appeared to be optimum conditions; 25*C, induced 
with 0.5mM IPTG when OD600 -'ý 0.8 and then grown overnight. The periplasmic 
fraction was isolated as before and the concentration of protease inhibitors used 
was doubled. Mass spectrometry requires samples to be run on clean SDS-PAGE 
gels to cut down on contamination which could obscure the results. Instead of 
using the general Coomassie, Brilliant Blue G-Colloidal concentrate was used. 
The first attempt to make more protein was unsuccessful - there was no band in 
the induced that was absent from the non-induced at the correct weight. A second 
attempt gave better results, although still not as clear as the initial experiment. 
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There appeared to be far more background periplasmic protein in this fraction 
(Figure 6.20). 
The band highlighted (*) in Figure 6.20 was carefully excised and placed into a 
sterile, 1.5ml microcentrifuge tube. The gel was covered with dH20 and sent to 
the Mass Spectrometry Sequencing Department at the Aberdeen Proteome Facility, 
University of Aberdeen. The peptide searches were performed on human 
databases only. A probable identification was recorded but it was not EWI-F but a 
G protein-coupled receptor, GPR35. This protein was found on two independent 
searches, MS-Fit and Mascot and had 25 % sequence coverage to one particular 
peptide fragment. The molecular weight of GPR35 is 34kDal which is similar to 
that of EWI-F (6) but BLAST searches between GPR35 and EWI-F showed no 
significant homology. 
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35kDal) Im 
Figure 6.20. Protein identification by mass spectrometry. As no EWI-F antibodies were 
available, it was decided to use mass spectrometry to identify whether, or not, the protein at 35kDal 
was indeed 2 Ig-like domains from EWI-F. The SDS-PAGE gel was made an run taking care to 
keep all apparatus clean to prevent contamination of the protein sample. The 35kDal band present 
in the induced sample lane (lane 1) but absent in the non-induced control lane (lane 2) was carefully 
excised, placed into a 1.5ml tube and covered with dH20- It was then sent to the mass spectrometry 
sequencing facility in Aberdeen. 
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6.4 DISCUSSION 
6.4.1 Expression of full length proteins 
The GatewayTM cloning system was initially chosen due to the large number of 
cloning steps required for this project. The apparent simplicity of sub-cloning to 
quickly and easily obtain a variety of expression vectors for protein expression in 
different host systems was very appealing. It was initially decided to attempt 
expression in E coli as this is the simplest and most cost effective method of 
protein production. Once the gene of interest was cloned into the expression 
vectors, protein expression experiments were carried out using a range of 
conditions in an attempt to optimise any protein production. The first experiments 
were carried out at 37*C and did not produce His6-tagged protein at the correct 
weight to correspond to EWI protein and, in addition, there were no bands at the 
right size in a Coomassie gel of the cell lysates in the induced samples when 
compared to the non-induced controls. The next logical method when attempting 
protein production in E. coli is to lower the bacterial growth temperature which 
prevents protein aggregation and favours production of soluble protein (Van Heeke 
et al. 1989); (Lin et al. 1987). It is the general consensus that lowering the 
temperature of bacterial growth slows down the translational process allowing the 
expressed protein more time to fold properly. In the protein expression 
experiments using the GatewayTm system, the effect of lowering the temperature 
did not favour soluble protein expression. 
Although decreasing the temperature did not allow soluble protein expression, it 
was still possible that the proteins formed inclusion bodies. Inclusion bodies are 
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insoluble aggregates of mis-folded proteins that are frequently formed by over- 
expressing proteins in Ecoli (Cabrita ct al. 2004; Sorensen et al. 2004). If 
lowering the bacterial growth temperature does not prevent the aggregation of 
proteins into inclusion bodies, it is possible to extract the proteins under denaturing 
conditions (in guanadiniurn hydrochloride and urea) and then refold the proteins in 
vitro by dialysis against a re-folding buffer. However, conditions that allow re- 
folding to occur are often time consuming to optimise and yields for purification of 
protein from aggregates are low. If Yields are sufficient, it is possible to avoid 
inclusion body formation and increase soluble, active protein formation by co- 
ovcrexpression with molecular chaperones, such as heat shock proteins (hsp) 
(Thomas et al. 1996). For full length EWI expression in the GatewayTIA system, 
there was neither evidence of His6-tagged proteins in aggregates nor any refolded 
proteins following guanidinium/urea denaturation and re-folding. 
The decision to move on to EWI expression in mammalian cells was made because 
it seemed probable at this stage that the EWI IgSF protein was just too large and 
complex to be produced in a bacterial host. The original GatewayTm entry vector 
was used to but this time it was recombined with a mammalian expression vector 
containing C-terminal V5 and His6-tags. Initially, CHO and HEK cells were used 
because they were readily available in our laboratory. In addition, EWI production 
in COS-7 cells was tested as this cell line is frequently used for the production of 
human proteins (Helfrich ct al. 2000; Schneider et al. 2005; Zhang et al. 2005). It 
was decided to try transient transfection to optimise conditions. Lipofectamine 
reagent was chosen as this has been successful in previous transfections using 
these cells. The manufacturers' protocol was followed for initial transfection 
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experiments and then it was adapted by changing the amount of DNA transfected 
and varying the time period for this incubation with Lipofectamine, but EWI 
protein expression was not detected in the whole cell lysates or in the supernatant. 
Following on from this, stable transfection using Lipofectamine reagent, transient 
DNA transfection with Calcium phosphate and both stable and transient 
transfection by electroporation were all tried several times, but all attempts failed 
to produce the full length EWI proteins. There are a number of reasons why these 
attempts failed: The protein could be toxic to the cell and so was being rapidly 
degraded; the vector may have too weak a promoter driving expression; the protein 
folding is too complex for the host cells to synthesise. At this stage, all feasible 
methods had been tested and so it was decided to continue the project by 
expressing protein domains rather than the full length molecules. Additionally, 
hidden costs in the GatewayTM system, low colony yields and a large number of 
"false positive colonies" that did not contain the gene of interest, all contributed to 
the decision to change to a different cloning strategy after full length EWI protein 
expression was unsuccessftil in E. coli and mammalian cell lines. 
6.4.2 Domain expression 
It was concluded from the above mentioned experiments that the proteins would 
not express in prokaryotic nor eukaryotic hosts, simply due to their large size and 
complex folding patterns that involve multiple disulphide bridges. Therefore, it 
was decided to take the project forwards by attempting double Ig-like domain 
expression, rather than full length, using specially adapted E. coli cells and plasmid 
vectors, that are designed specifically for expression of mammalian proteins with 
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multiple disulphide bridges. There are numerous examples in the literature of Ig 
and Ig-like protein domains being produced in E. coli, as recently reviewed 
(McMahan et al. 2003; Anderson et al. 2004). 
6.4.2.1 Disulphide bridges 
Disulphide bridges are a common and necessary feature of many proteins; correct 
folding and stability is largely dependent on their formation. Newly synthesised 
proteins are initially subjected to the highly reduced environment of the cytoplasm 
and it is not until they are transported to oxidising compartments that the majority 
of disulphide bridges are formed (reviewed in (Bardwell 1994). Such 
compartments are the mammalian endoplasmic reticulum and the bacterial 
periplasm. Not only is the periplasm an oxidising environment, it is also contains 
a number of proteins that facilitate disulphide bridge formation. The f irst 
periplasmic protein with disulphide isomerase activity to be discovered was DsbA 
in 1985 (Edman et A 1985). A further two proteins of this type, DsbC and DsbD 
(Missiakas et al. 1993), were later discovered. These proteins catalyse the 
fonnation of disulphide bridges and are characterised, by the presence of a Cys-X- 
X-Cys motif involved in the thiol-disulphide bridge exchange (Holmgren 1985). 
Mutations in these proteins impair formation disulphide bridges (Bardwell et al. 
1991; Kamitani et al. 1992). 
In order to overcome the problem of disulphide bridge formation and folding of 
recombinant proteins in E. coll, two main strategies have been developed. The 
first is to mimic the periplasmic environment in the cytoplasm. This is done by 
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mutating proteins that control the redox potential of the cytoplasm and is discussed 
in 6.4.3. The second method is to direct the newly synthesised, recombinant 
protein to the periplasm by the using a specific leader sequence (see 6.4.4) 
6.4.3 Protein expression of pET 32c EWI double domains in Origami cells 
The reducing environment of the cytoplasm, which is unfavourable for disulphide 
bridge formation, is maintained by two enzymes; thioredoxin reductase and 
glutathione/glutaredoxin reductase. In an attempt to create a more oxidising 
environment in this compartment, Mossner and colleagues made a thioredoxin null 
mutant (Mossner et al. 1999). This knockout of the trxB gene product allowed the 
formation of disulphide bridges within proteins in the cytoplasm but with poor 
yields (Mossner et al. 1999). Double knockout mutations of the trxB and gor (the 
gene encoding glutathione reductase) increased the yields of soluble protein 
production in the cytoplasm (Bessette et al. 1999). There are now a number of 
commercially available host strains that carry these mutations on plasmids that 
require selection. These strains are becoming increasingly popular for expression 
of mammalian proteins in E. coli (Levy et al. 2001; Santala et al. 2004; Sorensen et 
al. 2005). The host strain chosen here was Origami (Novagen), a trxBlgor mutant. 
The recommended vector to be used in conjunction with these cells is the pET32 
vector. 
Correctly sequenced EWI-2 and EWI-F double 19-like domains were cloned 
successfully into the pET32c vector with the aid of on-line database searches to 
predict Ig-like domain boundaries. Oligonucleotides were designed for each Ig 
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domain but it was decided to initially attempt double, rather than single domain 
expression, as antibody fragments consisting of 2 Ig domains have been commonly 
expressed in bacteria (Levy et al. 2001); (Kipriyanov et al. 1997; Mukherjee et al. 
2004). The pET32c vector allows an optional C-terminal His6-tag in addition to 
the N-terminal tag and so primers were designed with and without stop codons 
leaving open the option of expressing either construct. EWI-F (5) was the first 
construct to be successfully cloned and so its expression was tested first. Once 
again, a large optimisation of protein expression experiment was performed with 
transformed, but non-induced cultures acting as the negative controls; no EWI 
protein expression was observed. Since the construct in the pET32c expression 
vector was made, expression in BL21 codon plus cells (Stratagene) was attempted 
but to no avail. 
Although in many cases the mutations in Origami and similar cell types are 
beneficial, there are some drawbacks. In the oxidised environment of double 
trxBlgor mutants, proteins with larger numbers of cysteines are more likely to form 
random, non-native disulphide bridges. To prevent this, a periplasmic enzyme 
DsbC has been engineered without its leader sequence and so is able to reside in 
the cytoplasm of the double mutant E. coli where is was able to facilitate correct 
protein folding (Bessette et al. 1999). Certain Origami cells have the modified 
DsbC in the cytoplasm to aid disulphide bridge formation further. In addition, 
cloning vectors are available from Novagen with DsbC tags to aid the folding of 
the native protein in the cytoplasm. The DsbC tag can be cleaved afterwards and 
the advantage is that the enzyme is there, actually attached to the recombinant 
protein to assist the folding. Time constraints in this project did not permit these 
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methods to be tested but either of these methods would be worth attempting if the 
work were to be continued and protein expression in the cytoplasm was desired. 
6.4.4 Periplasmic expression of EWI proteins 
As a final attempt to express these proteins the decision was made to try 
periplasmic expression by means of a vector containing a signal sequence that 
would direct the native protein to the periplasm, the natural environment for 
disulphide bridge formation in the bacterial cell (reviewed in (Missiakas et al. 
1997). Directing nascent proteins to the bacterial periplasm is a relatively 
common method used for the production of mammalian proteins in bacteria 
(Battistoni et al. 1995), especially antibody fragments (Kipriyanov et al. 1997; 
Simmons et al. 2002; Mukherjee et al. 2004). The pET26b vector that carried the 
peIB leader sequence was used here because it has a C-terminal His6-tag and the 
same restriction enzymes (Noff, Saff) in its multiple cloning site so that the gene in 
the pET32c vector could be shuffled across easily without the need for new 
oligonucleotides. These cloning steps were carried out successfully. After 
translocation across the cytoplasmic membrane, the pelB leader sequence is 
removed due to the presence of a signal peptidase cleavage site immediately 
downstream from the leader sequence. Expression of the EWI-F (5) was tested 
first and the results indicated that the protein was present in the periplasmic 
fraction in the majority of the conditions tested and not in the non-induced 
controls. However, it appeared that most of the EWI-F (5) produced had lost their 
His6-tags because they were not picked out in Western blots using anti-His6 
antibodies. The samples that were initially recognised in an immunoblot by an 
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anti-His6 antibody (Figure 6.18) also appeared to lose their Hig6 tag over time 
suggesting that the tag was extremely labile. 
In the absence of an EWI-F antibody, or to be more precise, an antibody directed 
against the two membrane proximal Ig-like domains, it was decided to identify the 
protein by mass spectrometry. 
The mass spectrometry results (6.3.4) were somewhat confusing given that the 
probable match to a human GPR35 was highly unlikely to be due to sample 
contamination and the protein domain that was cloned, EWI-F (6), had no 
similarity to this probable match. Further more, no colleagues in the laboratory 
were working with GPR35 so cross contamination was also ruled out. When the 
results were queried with the Proteorne Facilities Co-ordinator, we were assured 
that no mix-up of samples could possibly have taken place. The protein 
production was scaled up in an attempt to get more EWI-F (5) protein to send to be 
analysed by mass spectrometry elsewhere. However, the results were not repeated 
in the first two attempts and eventually time limitations of the project prevented a 
second protein domain sample being sent for mass spectrometry analysis. 
Furthermore, problems were encountered in cloning the remaining EWI double Ig- 
like domains into the pET26b vector, which meant that this work could not be 
completed. However, given the encouraging results from the initial protein 
screening experiment, (Figure 6.19), double Ig-like domain expression in the 
periplasm would be a good starting place to continue this project in the future. 
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CHAPTER 7 
FUNCTIONAL ANALYSIS OF TETRASPANIN EC2 
DOMAINS: EC2 DOMAINS ARE POTENT INHIBITORS OF 
THE INFECTION OF MACROPHAGES BY HIV-1 
7.1 INTRODUCTION 
There are an estimated 39.4 million people worldwide living with HIV/AIDS and 
since 1981 the virus has accounted for more than 20 million lives. In 2004,4.9 
million people acquired the virus and so the epidemic lives on. Since 2001 there 
has been an increase in the global AIDS funding from US$ 2.1 billion to an 
estimated US$ 6.1 billion in 2004 (www. unaids. org). 
Entry of the retrovirus HIV (genus Lentivirus) into cells occurs in three distinct 
steps: the attachment of virions to cell surface CD4 by envelope gp 120 protein, the 
subsequent interplay of the conformationally altered gp120 with cellular CCR5 
and CXR4 co-receptors, and, finally, envelope gp4l. protein-mediated fusion to 
target cells (Moore et al. 2003). The HIV genome consists of two copies of RNA 
which are reverse transcribed to DNA to form the pre-integration complex (PIC) 
containing the viral matrix (MA), integrase and Vpr proteins as well as several 
host proteins. The PIC is imported into the nucleus and incorporated into the host 
chromosomes, where it can become latent for 3-10 years (Greene 2004). The 
subtypes of HIV, HIV-1 and HIV-2, have the same modes of transmission and are 
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associated with similar opportunistic infections, but immunodeficiency seems to 
develop more slowly in HIV-2 (Marlink et al. 1994). There are different strains of 
HIV-1, the most common being the R5 and X4 strains that have evolved to utilise 
the chemokine receptors CCR5 and CXCR4, respectively. 
In 2003 it was reported that anti-CD63 mAbs were able to inhibit HIV infection in 
macrophages (von Lindern et al. 2003), and so it was decided to investigate the 
inhibitory properties of our tetraspanin GST-EC2 fusion proteins in HIV-1 
infection of MDM. This work was done in collaboration with Cecilia Cheng- 
Mayer's laboratory (Aaron Diamond Aids Research Centre, New York). My part 
in the work was to provide all of the tetraspanin EC2 constructs for the study. 
CD63 EC2 without the GST tag was also made to use in this study in addition to 
the structural studies (Chapter 5), because we wanted to confirni that the effects we 
were observing were not simply due to the presence of GST. Parthasarathy 
Varadjaran (Department of Molecular Biology and Biotechnology, University of 
Sheffield) performed the EC2 FITC labelling experiments. 
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7.2 MATERIALS AND METHODS 
7.2.1 Preparation of PBMC and monocyte-derived macrophage cultures 
PBMCs were prepared by Ficoll gradient centrifugation, stimulated with 
phytohernagglutinin (PHA) (3gg/ml) in RPMI 1640 medium containing 10 % FCS 
and 20U IL-2 (kindly provided by Chiron Corp., Emeryville, CA). Monocytes 
were enriched by centrifugation of PBMCs through a 46 % Percoll cushion. Cells 
were then resuspended in RPMI 1640 medium supplemented with 10 % FCS and 
5% human AB serum. Monocytes were allowed to adhere overnight, harvested 
and replated in 96well at 7X 104 cells/well for infection. For microscopic studies, 
cells were replated in 35mm glass bottom No 1.5 poly-d-lysine dishes (Mat-Tek 
Corp., Ashland, MA) at 7.5 x 105 cells/plate. Monocytes were allowed to 
differentiate for 5-7 days before use. 
7.2.2 Generation of Viruses 
Luciferase reporter viruses pseudotyped with different envelope glycoproteins 
werc generatcd by transcomplcmcntation, as dcscribed prcviously (Connor et al. 
1996). The reporter viruses were derived from the HIV-1 pNL4-3 proviral DNA, 
in which the env gene was deleted and a firefly luciferase cassette was inserted in 
place of the nef gene. The env constructs used were: pEnvl62P3 expressing an 
CCR5-using HIV-1 envelope (Hsu et al. 2003), pEnvA2 expressing an CXCR4- 
using HIV-1 envelope (Chakrabarti et al. 2002), and a plasmid expressing VSV-G 
(pVSV-G, kindly provided by J. McKeating, University of Binningham, UK) 
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(Pohlmann et al. 2003). Because of the lack of a proviral env gene, pseudotyped 
viruses were capable of only a single round of replication. The viruses were 
generated by lipofection of 1.5ug each of pNL-LucE-R+ plasmid and of a pEnv 
vector in 293T cells plated at 7x 105 cells per well in six-well plates. The 
lipofection was performed with the DMRIE-C reagent according to the 
manufacturers' recommendations (Gibco-BRL, Gaithersburg, Md. ). Cell culture 
supernatants were harvested 72 hours post-transfection, centrifuged at 800 g, 
filtered through 0.451im-pore-size filters, and stored at -70 C until use. The viral 
content was quantified by a p24 Gag ELISA, (Abbott Laboratories, Chicago, 111. ). 
To generate Vpr-eGFP viruses, 293T cells were co-transfected with a full length 
NL4-3 proviral genome in which the envelope gene has been replaced with that of 
R5-SHIVSF162P3 (Hsu et al. 2003) and an expression plasmid for Vpr-EGFP (kindly 
provided by N. Landau, Salk Institute, La Jolla, CA. ). Culture supernatants were 
harvested 48 h later, centrifuged at 800 x g, filtered through 0.45 pm-pore-size 
filters and concentrated by centrifugation through a 20 % sucrose cushion. The 
pelleted virions were resuspended in Hanks balanced salt solution, aliquoted and 
stored at -700C until use. The viral content was quantified by a p24 Gag ELISA. 
7.23 Virus infection inhibition assays 
Inhibition assays were performed as follows: macrophages (7 x 104 cells per well ) 
or PBMC (106 cells per well) in 96-well plates were pretreated with 50 gl of serial 
dilutions of GST or GST-tetraspanin fusions for 30-60 minutes at 37*C. Control 
cells received Hanks BSS alone. An equal volume containing 5ng p24 Gag 
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equivalent of each of the pseudotype viruses was then added and incubated for 3 
hours at 37 C. At the end of the incubation period, 1001il of macrophage or PBMC 
culture medium was added and the culture maintained for 72 hours before being 
tested for luciferase activity. Cells were lysed and incubated with the luciferase 
assay reagents according to the manufacturers' instructions (Promega, Madison, 
Wis. ). The luciferase activity was measured in a Dynex MLX microtitcr plate 
luminometer (Dynex Technologies, Inc., Chantily, Va. ). All infections were 
performed in duplicate. 
7.2.4 Labelling of cells with virus expressing Vpr-eGFP 
Macrophages in Mat-Tek plates were treated with 50gl of Hanks, GST or GST- 
CD63 at 4pg per ml for 60 minutes at 37*C. 50pl of Vpr-EGFP virus (containing 
200ng p24 Gag equivalent) was then added and incubated for 2 hours at 370C. At 
the end of the incubation period, infected macrophages were washed extensively 
and fixed with 3% formaldehyde in PBS ON at 4*C. Next day, cells were stained 
with ConA-Rhodamine (Ing/ml) at RT for 15 minutes and washed 5x with PBS. 
DAPI was then added and images were obtained with Delta Vision. Viral uptake 
was measured by counting fluorescent particles inside cells. 
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7.3 RESULTS 
Following the recent publication by the Von Lindern. laboratory (von Lindern et al. 
2003), we were intrigued to see if our EC2 constructs had any inhibitory potential. 
It is reasonably well documented that tetraspanin EC2 proteins can inhibit 
tetraspanin-dependent functions such as fertilisation (Higginbottom et al. 2003), 
leukocyte adhesion (Barreiro et al. 2005) and monocyte fusion (Takeda et al. 
2003), which were initially identified by the use of anti-tetraspanin antibodies. We 
therefore tested a range of tetraspanin EC2-GST proteins for their inhibitory 
activity of R5 and X4 HIV-1 strains. Soluble CD4 was used as a positive control 
and GST alone as a negative. Monocyte derived macrophages (MDM) or 
peripheral blood mononuclear cells (PBMC) were pre-incubated with EC2 proteins 
and washed before addition of virus. All of the tetraspanin EC2 proteins inhibited 
both R-5 and X4 and R5/X4 chimeric virus infection in MDM (Fig 7.1). Indeed, in 
MDM, all the tetraspanin EC2 proteins were better inhibitors than CD4. There 
appeared to be a hierarchy of potency with CD63 EC2 being the most potent 
inhibitor of R5 and X4 virus, followed closely by CD9 EC2. CD81 EC2 and 
CD151 EC2 were 5- 10 fold less potent, and mCD9 EC2 10 - 50 fold less potent, 
than CD63 EC2. GST alone did show some inhibitory activity but in each case 
this was at notably higher concentrations than the tetraspanin EC2. 
Von Lindern and colleagues described inhibition using anti-CD63 antibodies in 
MDM but not in PBMC. Using the EC2 proteins we were able to detect inhibition 
of R5 virus in PBMC, albeit to a lesser extent that in the MDM. There was no 
specific inhibition of X4 virus in PBMC by any of the tetraspanins tested, even at 
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high concentrations of lOpM. Soluble CD4 could completely inhibit infection, 
confirming that the assay was still viable (Figure 7.2). Mouse CD9 is seen to have 
an inhibitory effect in MDM but interestingly the effect is not significant in 
PBMC. 
To examine the role of the GST fusion partner protein, GST was cleaved from 
CD63-GST EC2. The pGEX-2KG contains an extended linker region between the 
GST tag and the protein of interest. The linker region contains a thrombin protease 
site. Re-adherence of purified CD63-GST to glutathione Sepharose beads, 
followed by on-bead cleavage with thrombin enables elution of purified CD63 
EC2 whilst the GST remains adhered to the beads. GST was undetectable on 
silver stained SDS-PAGE gels (see chapter 5). 
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Figure 7.1 the effects of recombinant human tetraspanin large extracellular domain-GST 
proteins on infection of MDM by CCR5 and CXCR4-tropic HIV-1. MDM were isolated as 
described in Materials and Methods and treated with different concentrations of recombinant 
tetraspanin large extracellular domain-GST fusion proteins, GST alone or with lg-CD4 for 30 - 60 
minutes prior to the addition of HIV-1 virions expressing CCR5 or CXCR4 specific env protein. 
Infection was measured after 3 days as chemi luminescence from luciferase expressed under the 
control of the HIV-1 LTR promoter. Infection of MDM (A and B) pre-treated with human CD9, 
CD63, CD8 1, CID 151 or mouse CD9 large extracellular domain-GST fusion proteins, GST alone or 
1g-CD4. Results are shown as percentage inhibition of infection relative to untreated control cells 
and are the means of at least 3 separate experiments (A) or log IC. s, ) values in (B), Significance of 
difference from GST control was assessed by two tailed Mest, *** p <0.001. 
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Figure 7.2 The effects of recombinant human tetraspanin large extracellular domain-GST 
proteins on infection of PBMC by CCR5 and CXCR4-tropic HIV-1. PBMC were isolated as 
described in Materials and Methods and treated with different concentrations of recombinant 
tetraspanin large extracellular domain-GST fusion proteins, GST alone or with lg-CD4 for 30 -- 60 
minutes prior to the addition of HIV-1 virions expressing CCR5 or CXCR4 specific env protein. 
Infection was measured after 3 days as chemilurninescence from luciferase expressed under the 
control of the HIV-1 LTR promoter. Infection of PBMC pre-treated with human CD9, CD63, 
CD81, CD151 or mouse CD9 large extracellular domain-GST fusion proteins, GST alone or lg- 
CD4. Results are shown as percentage inhibition of infection relative to untreated control cells and 
are the means of at least 3 separate experiments (A) or log IC50 values in (B). Significance of 
difference from GST control was assessed by two tailed t-test; *** p <0.001. 
Inhibition of R5 and X4 infection was not prevented by the removal of GST in 
MDM. In R5 virus assays the cleaved CD63 EC2 was 10 fold more active than 
GST alone however, is was around 6 fold less active than GST-CD63 EC2 (Figure 
7.3). X4 infection was inhibited to the same extend with cleaved CD63 EC2 and 
GST-CD63 EC2 (Figure 7.3). 
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Figure 7.3 The effects of removal of GST from recombinant CD63 EC2 domain on the 
inhibition of infection by MDNI by CCR5-tropic HIV-1. MDM were isolated as described in 
Materials and Methods and treated with different concentrations of recombinant human CD63-EC2 
GST fusion protein (CD63-EC2), CD63-EC2 with GST removed (CD63) by thrombin cleavage or 
GST alone for 30-60 minutes prior to the addition of virions expressing CCR5-specific IIIV-I env 
protein. Infection was measured after 3 days as chemiluminescence from luciferase expressed under 
the control of the HIV-1 LTR promoter. Results are shown as percentage inhibition of infection 
relative to untreated control cells are the means of at least 3 separate experiments ± SEM. 
Critical amino acid residues in the EC2 domains have been highlighted in the past 
as being essential for a particular function. For example, in spen-n-egg fusion 
assays the residue Phe176 in CD9 EC2 was identified as being critical for C139- 
EC2 inhibition of mouse fertilisation, since mutation of this residue to alanine 
completely removed the inhibitory action of the CD9 EC2 (Zhu, G. Z. et al. 2002; 
Higginbottom et al. 2003). Mutations of cysteine residues that are predicted to 
form disulphide bridges in this EC2 domain also bring about an abolishment of 
inhibition, presumably because the disulphides are not fon-ned and the EC2 
proteins loses any structure it may have had. In an attempt to understand the mode 
of action of the EC2 proteins in the HIV inhibition assays, we used the CD9 
mutants to determine whether a similar mechanism was responsible here. The 
cysteine mutants that had the greatest effect in the mouse fertilisation assays, 
Cysl52Ala and Cysl53A]a, and the mutation Phe176Ala were tested. Although 
214 
significant, there was only a small decrease in inhibition by either Cys mutant 
compared to WT (Figure 7.4). Mutation of either Cys residue to Ala in R5 
infection assays had a three fold decrease in IC5o value. In X4 infection the results 
were a little more varied. Cys 152 could significantly affect infection by X4 virus, 
giving a9 fold decrease in IC50 and mutation of CysI53 had a smaller affect 
lowering the IC50 by 4 fold (Figure 7.4). Mutation Phel76Ala, had no effect on 
inhibition for either virus (Figure 7.4). 
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Figure 7.4 The effects of mutation of residues in the CD9 EC2 domains on the potency of 
inhibition of HIV-1 infection in MDM. MDM isolated as described in Materials and Methods 
were treated with different concentrations of wild-type or mutant recombinant human CD9 EC2 - 
GST or GST alone for 30-60 minutes prior to the addition of virions expressing specific IIIV-1 env 
protein. Infection was measured after 3 days as chemiluminescence from luciferase expressed 
under the control of the nef promoter. Results are shown as IC5o values and significance of 
difference from GST control was assessed by two-tailed t-test; ***p>0.001; **p>0.01; *p>0.05 
It is possible that treatment with GST-CD63 EC2 imposes inhibitory effects on 
virus infection by altering the expression levels of receptor/co-receptor at the 
plasma membrane. It is also a possibility that the difference in inhibitory effects in 
MDM and PBMC is due to differential expression levels of CD63, CD4 and IIIV- I 
coreceptors on these cell types. To address these possibilities, cells were incubated 
with and without O. IlpM GST or GST-CD63 EC2 (Figure 7.5. B) and the 
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expression levels of CD4 and HIV-1 coreceptors were determined by FACS 
analysis. Our results were in agreement with previous reports (Wu et al. 1997; 
Naif, H. M. et al. 1998), MDM express lower levels of CD4 and HIV-1 
coreceptors than PBMC and the percentage of cells expressing HIV-1 coreceptors 
is lower in MDM (Figure 7.5. A). In contrast to these findings, the level of CD63 
expression as well as the percentage of cells expressing CD63 is higher in MDM 
than PBMC (Figure 7.5. A). Treatment with CD63 did not decrease expression 
levels of any of the proteins (Figure 7.5.13). Levels of the cell surface marker 
CD14 and co-receptor CXCR4 were unaltered whereas CD63, CCR5 and CD4 
were actually slightly increased (Figure 7.53). There was no detection of GST 
suggesting that the elevated level of CD63 in treated compared with untreated cells 
is due to the redistribution of endogenous CD63 and not GST-CD63 (Figure 
7.5.13). 
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Figure 7.5 The effects of treatment of MDM with recombinant CD63 EC2 domain on 
membrane protein expression. Adherent MDM were incubated with 0.11ýLM CD63 EC2 for I 
hour and the cells were extensively washed and harvested by scraping. After incubation with 
appropriate primary antibodies and secondary antibody labelled with FITC, fluorescence was 
quantified by flow cytometry. (A) Percent and mean fluorescence intensity (MFI) of CD4, CD63, 
CCR5 and CXCR4 on untreated MDM and PBMC. (B) Difference in expression of CD4, CD14, 
CD63, GST, CCR5 and CXCR4 in cells treated with GST-CD63 EC2 compared to treatment with 
GST alone. Results are shown as mean SEM of three separate experiments performed in duplicate. 
Significance was assessed by one sample t-test; * p>0.5. N. D, Not detected. 
It is generally accepted that the predominant route of entry of HIV-1 in T cells is 
by receptor/co-receptor dependent fusion at the plasma membrane but it is now 
thought that the preferred route of entry in macrophages is receptor/co-receptor 
independent endocytosis. To determine the mechanism of entry of the virus in our 
assay we decided to use a VSV pseudotype virus. This is the HIV-1 core virus 
ci 
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expressing VSV coat proteins. VSV is known to enter cells by endocytosis in a 
receptor independent mechanism. Surprisingly, all of the tetraspanin EC2 proteins 
inhibited the pseudotype infection in a similar manner to R5 inhibition (Figure 
7.6). Like R5 infection, VSV was also partly inhibited in PBMCs. In contrast to 
R5 inhibition, mCD9 EC2 was ineffective in VSV infection (Figure 7.6). 
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Figure 7.6 The effects of recombinant human tetraspanin large extracellular domain-GST 
proteins on infection of MDM by VSV-pseudotype HIV-1. MDM were isolated as described in 
Materials and Methods and treated with different concentrations of recombinant tetraspanin large 
extracellular domain-GST fusion proteins, GST alone or with Ig-CD4 for 30 - 60 minutes prior to 
the addition of HIV- I virions expressing VSV-G glycoprotein. Infection was measured after 3 days 
as chemiluminescence from luciferase expressed under the control of the IIIV-I LTR promoter. 
Infection of MDM pre-treated with human CD9, CD63, CD81, CD151 or mouse CD9 large 
extracellular domain-GST fusion proteins or GST alone. Results are shown as log IC50 values in 
and significance of difference from GST control was assessed by two tailed t-test; *** p <0.001; 
**p>0.01; *p>0.05. 
To determine whether the tetraspanin EC2-dependent inhibition is occurring at the 
stage of binding/uptake of virus or at a later stage of the virus life cycle, we used 
fluorescently labelled virus. MDM were pre-incubated with 0.4pM GST or 
different concentrations of GST-EC2 (0.11 [tM and 0.33gM) for 30 minutes prior 
to the addition of R5 virus tagged to a vpr-eGFP fusion protein. Infection was left 
to proceed for 10,30,60 or 120 minutes before being terminated by washing and 
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fixation. CD63 does significantly inhibit viral uptake at both concentrations tested 
(Figure 7.7. A and B). To asses the time of inhibition, MDM were incubated with 
CD63-EC2 or GST control upon inoculation or immediately after. The inhibitory 
effect by CD63-EC2 was most potent when GST-CD63 EC2 is added to MDM at 
the same time as the virus, and is significantly reduced at all other time points 
suggesting that the EC2s are inhibiting at the viral entry stage (Figure 7.7. Q. The 
inhibition seen by GST alone is independent of the time of addition which suggests 
that the mechanism of this less potent inhibition is unrelated to that seen by the 
tetraspanin EC2 domains. 
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Figure 7.7 The effects of treatment with high concentrations of recombinant CD63 EC2 
domains on the uptake of CCR5-tropic HIV-1 by MDM. MDM were pre-incubated with 0.4l. IM 
GST orO. 1 IpM orO. 33ýtkf GST-CD63 EC2 for30min priorto addition of Vpr-eGFI' R5 virus, and 
infection terminated after 10,30 or 60min after virus addition. Virus uptake was quantified by flow 
cytometry of cells in suspension (A) or by counting ot'green particles in micrographs (examples 
shown in B) of adherent cells. As CD63-EC2 had an inhibitory effect on the numbers of green 
particles associated with cells at all of these time points, data were pooled. Results are the means 
SEM of at least three experiments. The differences between each dose of CD63 EC2 and the GST 
only control (=100) were significant (*** p<0.01) by one sample t-test. C) MDM were incubated 
with R5 virus for I hour at 37'C. Serial dilutions of GST alone or GST-C'D63 FIC2 were present 
either during virus inoculation or added immediately after the virus was removed by washing. 
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To test whether the tetraspanin proteins are being endocytosed by the cells we used 
fluorescently labelled GST and GST-EC2 proteins. MDM were pre-incubated 
with 0.11[tM of FITC labelled GST or GST-CD63 for one hour at 37*C. Flow 
cytometry and fluorescence microscopy was used to measure cell-associated 
fluorescence. CD63 and GST were indeed internalised and shown by fluorescence 
microscopy to localise in intracellular vesicles along with endocytosed dextran. and 
transferrin (Figure 7.8A, B). CD63 appeared to be internalised at a faster rate than 
GST alone (Figure 7.8A, B). Co-incubation of MDM with Vpr-eGFP virus and 
CD63-EC2 labelled with AlexaFluor647, rare instances of virus and tetraspanin 
co-localisation. could be detected after 20 minutes (Fig 7.8. Q. 
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Figure 7.8 Uptake of fluorescently-labelled CD63 EC2 in MDM. (A) MDM were incubated with 
0.11 M of fluorescently-labelled GST or GSTCD63 EC2 protein for I hour at 37'C and cell- 
associated fluorescence measured by flow cytometry (MFI) or by analysis of images using lmagcj 
software (green pixels). The data are the means of 4 separate experiments ± SEM and significance 
of differences from GSTcontrols assessed by two-tailed t-test, * p<0.05. (B) 0.11 M 6ST-C'D63 
EC2-FITC proteins were added to MDM together with dextran-rhodamine (Dex) or transferrin- 
AlexaFluor647 (TF) for 30 minutes at 37T. Representative images are shown. (C) MDM were 
incubated with 0.11 M of GST-CD63 EC2 labelled with AlexaFluor647 and P3-Gag-eGFP virus for 
20 minutes at RT. Microphotographs illustrating the patterns of expression were taken after fixation 
and representatives are shown. 
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7.4 DISCUSSION 
The most obvious, conclusions that can be made are as follows; 1) The inhibition 
that we are observing with our EC2 proteins is more potent in MDM. 2) Inhibition 
is not HIV-1 strain specific in these cells. Although inhibition of R5 but not X4 
infection is seen in PBMC it is of much less potency suggesting a macrophage 
specific effect. 3) The target of inhibition is the cell rather than the virus as 
following pre-treatment of MDM with EC2 proteins, we can wash the cells before 
addition of the virus and the same level of inhibition occurs. 4) As all the 
tetraspanin EC2 proteins that we tested could significantly inhibit infection, we are 
likely to be inhibiting the functioning of a tetraspanin enriched microdomain 
(TEM), rather than a specific tetraspanin-ligand interaction. 5) Because the VSV- 
pseudotyped virus could be inhibited with equal potency, the inhibition is likely to 
be independent of receptor/co-receptor. The mechanism of inhibition remains to 
be elucidated but in this discussion, I will highlight some possibilities. 
A number of lentiviruses including human, simian and feline immunodeficiency 
viruses (HIV, SIV and FIV respectively) have acquired a wide tropism and an 
expanded range of target cells including cells of the monocyte/macrophage lineage 
and CD4+ T lymphocytes. Lentiviruses may cause depletion and 
immunodeficiency of CD4+ T cells but it is the ability of the virus to infect 
macrophages and other antigen presenting cells (APQ that determines the 
persistence and pathogenesis of infection. Macrophages play a central role in the 
immune response by either directly destroying invading pathogens or secreting 
cytokines that can activate the adaptive immune response thereby providing an 
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important cross-talk between the innate and adaptive immune systems. In the case 
of lentiviruses, macrophages appear to do neither of these roles and instead they 
provide a safe reservoir, harbouring the virus. Aside from the resistance of 
macrophages to the cytopathic effects of HIV, there are a number of differences 
between the HIV life cycle in macrophages and T cells. Firstly, different strains of 
HIV-1 have different tropisms for T cells and macrophages. HIV-1 strains that 
predominantly infect T cells are CXCR4 dependent (X4 strains) and those 
infecting macrophages utilise the CCR5 coreceptor (R5 strains). CXCR4 is 
expressed in macrophages yet there is much debate in the literature as to whether 
or not X4 utilising strains can infect these cells (Naif, H. M. et al. 1998; Verani et 
al. 1998; Valentin et al. 2000). Some have found that X4 strains can efficiently 
enter macrophages but are restricted at the post-entry level and can not replicate 
(Schmidtmayerova et al. 1998). O'Brien's group found that the inhibition they 
observed with anti-CD63 antibodies in primary isolates was specific to R5 utilising 
virus (von Lindern et al. 2003), whereas using EC2 proteins, the inhibition was 
independent of co-receptor. This could be an effect of EC2 proteins vs. mAb or 
primary isolates vs. laboratory adapted strains. The EC2 proteins have been 
preliminarily tested by O'Brien's laboratory and appear to be having a similar but 
less potent effect as with the laboratory adapted HIV-1 strains (William O'Brien 
personal communication). 
Another possible mechanism is that endogenous tetraspanins act to regulate the 
expression levels of virus receptors at the cell surface, rather like the Drosphila 
tetraspanins SUN. This tetraspanin down-regulates rhodopsin in the presence of 
intense or prolonged exposure to light (Xu et al. 2004). In untreated cells the 
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expression of CD4 and coreceptors may be regulated by endogenous tetraspanins. 
Exogenous EC2 domains, by disrupting the formation of TEM, could prevent 
upregulation signals thereby decreasing levels of receptor/coreceptor expression 
which would in turn inhibit infection. We tested expression levels of receptor and 
coreceptors in cells that had been pre-treated with GST-CD63 EC2 or GST alone 
and did not find any decrease in expression of CD4, CCR5 nor CXCR4 in the 
CD63-treated cells. 
7.4.1 VSV pseudotype and endocytosis 
The differences between HIV-1 infection in macrophages and T cells are not 
limited to cell binding properties. It is becoming the general consensus that 
although HIV-1 assembly and budding takes place at the plasma membrane in T 
cells, it is thought that intraccllular vesicles are the main sites for assembly and 
budding of virus particles in macrophages (Raposo et al. 2002; Pelchen-Matthcws 
et al. 2003; Ono et al. 2004). Evidence for this has come from studies of newly 
synthesised virus membranes that found high levels of lysosomal marker proteins 
including the lysosomal associated proteins LAMP-I and LAMP-2 as well as 
CD63 (Meerloo et al. 1992; Meerloo et al. 1993). CD63 was found in these 
studies to be selectively upregulated into the budding virion membrane and a later 
study confirmed CD63 selective incorporation into virions as well as the 
tetraspanins CD81 and CD82 (Pelchen-Matthews et al. 2003). Indeed, in this 
study anti-CD63 antibodies were shown to precipitate over 95% of infections 
particles from the medium (Pelchen-Matthews et al. 2003). These reports of virus 
and tetraspanins in endosomal compartments prompted us to consider endocytosis 
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as a mtchaxAsm of ell" in our virus assays as oppose. to Teceptor-med7lated fuýjon 
at the plasma membrane. 
Vesicular stornatitis virus (VSV) is -a mem)om of the 
Rhabdovirus family. It was first reported in 1971 that vsv ellter, ,, Is 6Y 
endocytosis and the basic pH-dependent mechanism has been well documented 
(Heine ct al. 1971; Fan et al. 1978; Matlin et al. 1982); (Schlegel et al. 1981). Its 
single-stranded, negative sense RNA encodes 5 major proteins, glycoprotein (G), 
matrix protein (M), nucleoprotein (N), large protein (L, ) and phosphoprotein (P). 
The glycoprotein (G) is of most interest here because it is responsible for the virus 
attachment to the host cell as well as the fusion of the virus envelope with the 
endosomal membrane (Fan et al. 1978; Matlin et al. 1982). Protein G contains an 
internal fusion peptide responsible for mediating the fusion event at acidic pH (Fan 
et al. 1978; Fredericksen et al. 2002). Various conformational changes take place 
when the virus encounters the low pH environment of endocytic vesicles, allowing 
exposure of the protein G and therefore membrane fusion to take place. VSV 
attachment and entry, therefore, does not require CD4 or the two chemokine 
receptors that HIV strains have adapted to exploit. To determine the dependency 
of inhibition that we observed with our EC2 proteins on CD4 and the coreceptors, 
we used a VSV-HlV pseudotype virus; that is a functional HIV virus that 
expresses VSV Glycoprotein G and not HIV glycoproteins. When used in the 
same assay as the R5 and X4 pseudotypes, it was observed that this virus was also 
inhibited in the same manner as the R5 pseudotype. Due to these findings we 
hypothesise that HIV-1 uses an endocytic pathway to enter MDM. This 
hypothesis also accounts for the partial inhibition of R5 strain and the complete 
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lack of inhibition of X4 strain in PBMC because the X4 strain is "fusogenic" and 
predominantly fuses with the plasma membrane and is not taken up by endocytosis 
(Marechal et al. 2001). 
Virtually all cells use endocytosis to take up exogenous materials for nutritional 
value, to take up pathogens in immune mechanisms or simply to monitor the 
extracellular environment. There are four main strategies for the uptake of 
exogenous material by mammalian cells: 1) Clathrin-mediated endocytosis was 
the first pathway to be discovered and remains the best characterised pathway as 
reviewed by Schmid (Schmid 1997). This mechanism of endocytosis allows 
internalisation of transmembrane proteins and their bound ligands. Firstly the 
clathrin molecules and transmembrane proteins cluster into clathrin coated pits that 
eventually pinch off resulting in the formation of vesicles, 85-110 mn in diameter. 
Vesicles then release their cargo into endosomes, where receptors are either 
recycled or sent to lysosomes for degradation (Schmid 1997). The clathrin 
molecules, along with the different adaptor proteins, shape the vesicle and 
determine the selected cargo to be taken up (Schmid 1997). 2) Non-clathrin 
mediated endocytosis is another form of receptor-mediated endocytosis and 
includes calveolae. These vesicles are the smallest of the 4 types (50 to 80 nm). 
They are enriched with calveolin, cholesterol and spingolipids and participate in 
the entry of some viruses (i. e. simian virus), bacteria and macromolecules. 
3) Phagocytosis involves the internalisation of large particles (>500 run), it is an 
actin-dependent and usually clathrin-independent mechanism that takes place 
primarily in specialised phagocytic cells such as macrophages and neutrophils. 
Phagocytosis is critical in Metazoa for the uptake and degradation of infectious 
particles and apoptotic cells. There are 3 types of phagocytosis; Fc receptor 
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mediated, complement receptor mediated and mannose receptor mediated as 
reviewed by Aderern and Underhill, 1999 (Aderem, et al. 1999). 
4) Macropinocytosis was first discovered by Warren Lewis in 1931 (Lewis 193 1). 
He used time-lapse microcinematography and revealed, by speeding up the 
movements of macrophages, membrane ruffling events that led to the formation of 
intracellular vesicles. Unlike clathrin-coated micropinocytosis that takes place 
uniformly across the cell surface, macropinocytosis usually occurs at the 
boundaries of membrane projections of a spread cell. Macropinosomes are 
heterogeneous in size and are considered to be more similar to non-clathrin 
mediated vesicles (Swanson et al. 1995). There are numerous examples in the 
literature of viruses exploiting endocytic pathways to gain entry to cells (i. e. 
human adenovirus is internalised by both clathrin mediated endocytosis and 
macropinocytosis (Meier et al. 2004). There have been two reports that describe 
the uptake of HIV-1 by macropinocytosis (Marechal et al. 2001; Liu et al. 2002). 
One report implicated macropinocytosis as the method of choice for HIV-1 to 
cross the blood-brain barrier. It describes the uptake of HIV-1 by brain 
microvascular endothelial cells (BMVEQ by macropinocytosis in a mechanism 
dependent on lipid rafts. The internalisation is also dependent on mitogen 
activated protein kinase (MAPK) signalling since inhibition of the MAPK/Erk 
pathway inhibited virus entry (Liu et al. 2002). The second report is specific to 
macrophages and so is of more interest here. Electron microscopy was used to 
identify the presence of HIV-1 virus particles at the plasma membrane of 
macrophages as well as inside clathrin coated pits and in macropinosomes 
(Marechal et al. 2001). It was demonstrated the macrophages were not selective in 
their internalisation. Non-infectious HIV-1 virions lacking env proteins 
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(HIVAenv), HIV-1 virions coated with env and VSV-G glycoproteins were all 
internalised. However, the HIVAenv remained in the lumen of intracellular 
vesicles and were not delivered to the cytosol for infection to take place. This 
implies that without the env proteins, although the HIV can enter macrophages via 
macropinocytosis, subsequent steps of the viral life cycle can not occur (Marechal 
et al. 2001). 
There are numerous membrane fusion events within the endocytic pathway that 
could be inhibited with by the EC2 proteins. Interestingly, the results presented in 
Figure 7.7 suggest that partial inhibition takes place at the plasma membrane 
during binding and entry of the virus. Fluorescent microscopy studies of MDM 
incubated with GST or CD63 prior to infection with fluorescently labelled virus, 
showed a significant reduction of virus particles in the cytoplasm of CD63 treated 
MDM compared to GST treated cells. In addition, the inhibitory effect of CD63 
was only observed when CD63-EC2 was added to the MDM prior to, or 
immediately after infection. Taken together, these data strongly suggest that the 
EC2 domains are inhibiting a receptor independent endocytic event that takes place 
at the plasma membrane. 
7.4.2 Concluding remarks 
Although this work does yield potentially interesting data on the role of 
tetraspanins in HIV infection of macrophages, there is still much work to be done 
and many questions that are currently unanswered. GST appears to have a 
substantial amount of anti-HIV activity which is, in some cases, comparable to that 
of CD4 (Figure 7.1). Glutathione S -transferases are a family of enzymes that play 
a key role in the detoxification if substances such as products of oxidative stress. 
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They act by catalysing the reaction between glutathione and a substrate to form a 
sulphur-substituted glutathione. The GST tags used in the Amersham pGEX 
system are from Schistomajaponicum. Interestingly, a high activity of the GST 
control in the inhibition of sperm-egg fusion was also observed (Higginbottom et 
al. 2003). It was clear from these experiments that, whatever the mechanism of 
inhibition is, it is certainly different from the mechanism used by the recombinant 
CD63 EC2 - the latter mechanism was lost when CD63 EC2 was added post- 
infection whereas the inhibition seen by GST was the same when added to MDM 
before and after viral infection. 
Clearly, further characterisation of the effects seen with the EC2 proteins using 
primary HIV-1 isolates is needed here. It would also be of immense interest to 
determine the critical amino acids in CD63 EC2 that are required for the inhibition, 
and to design small peptides inhibitors based on the critical region of CD63 EC2. 
Also, it must be determined whether the inhibition seen by CD63 and the other 
tetraspanins is a general inhibition of the endocytic pathway in macrophages. 
Given the fact that a much less potent inhibition of HIV-1 infection is observed in 
PBMC, and that there appears to be some cellular localisation of CD63 EC2 with 
CD4 and co-receptors (Figure 7.8), it is possible that IHV-l associates with CD4 
and co-receptors at the plasma membrane of macrophages, but membrane fusion at 
the plasma membrane does not occur and the virus is intemalised by endocytosis. 
Clearly, electron microscopy would be the best way to get a clearer picture of the 
events during inhibition of IHV by CD63 EC2. 
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CHAPTER 8 
GENERAL DISCUSSION 
8.1 Summary and perspectives 
A major part of this work was to continue and optimise the production of 
recombinant tetraspanin EC2 domains in Exo1i. The total yield of recombinant 
protein was increased without effecting the quality or timescale. This was 
successfully achieved by developing a method for producing large quantities of 
recombinant protein using a 20L biofermenter. The same media and antibiotic 
selection was used making the cost per litre of culture unaltered, yet the yield per 
litre was more than tripled. 
It was also planned to clone and express the EC2 domains of CD231 and CD82. 
The cloning of both constructs was carried out successfully, but problems were 
encountered when it came to the expression of these larger EC2 domains. Neither 
protein would express in the bacterial host that was used to make the other 
recombinant EC2 proteins despite altering the general protocol for EC2 production 
by changing the concentrations of induction agent, the growth temperature and the 
density that the cultures reached before induction. Amongst the possible 
explanations for this was that the disulphide bridges in the protein were not 
forming properly leading to degradation, and so it was decided to use an alternative 
EcoU stain that promotes the formation of disulphide bridges in the bacterial 
cytoplasm. GST-CD82 was expressed and purified in this strain of E. cou, 
Origarni (Novagen) and was detected by a widely used anti-CD82 mAb, Tspan2. 
This was an exciting achievement due to the greatly studied role of CD82 as a 
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suppressor of metastasis (reviewed in (Jackson et al. 2005), and the recombinant 
GST-CD82 EC2 protein will hopefully be used in functional studies in the future. 
Although CD231 was cloned into pGEX-KG successfully and the sequence was 
correct, expression was not detected in BL21 or Origami cells. Using an 
expression vector with a periplasmic leader sequence to direct protein folding to 
the periplasm would be the next obvious method to use here. Failing that, protein 
expression in a mammalian cell would be advisable, though yields would 
undoubtedly be lower. Although there were some problems encountered when 
producing recombinant EC2 proteins, on the whole, the method established in our 
laboratory, allows rapid expression and purification of high yields of recombinant 
EC2 proteins that have already proved to be an extremely useful tool in the study 
of tetraspanin proteins (Higginbottom et al. 2000; Higginbottom et al. 2003). 
Here, recombinant murine CD9 EC2 was shown to bind specifically to PSG17 
using ELISA as previously reported by Dveksler and co-workers (Waterhouse et 
al. 2002). However, as our human CD9 did not bind to PSG17, we were unable to 
use our range of mutant human CD9 EC2 constructs to identify critical amino 
acids utilised in this binding. Of relevance to this work, and in support of murine 
CD9 binding directly to plasma proteins, a second report describing an external 
ligand for CD9 has recently been published. Here, it was shown that murine CD9 
can function as an alternate interleukin 16 OL-16) receptor (Qi et al. 2005). CD4 
is a putative IL-16 receptor but haernatopoietic cells isolated from CD4 null mice 
were shown to be as responsive to IL-16 as wild-type mice, and so the concept of a 
second IL-16 receptor was initiated (Qi et al. 2002). CD9 and other tetraspanins 
were postulated to be involved in the IL-16 receptor complex given their 
expression on haematopoietic cells and their association with CD4 and it was 
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demonstrated that CD9 is likely to be the major IL-16 receptor on murine mast 
cells (Qi et al. 2005). Although murine and human CD9 are close homologues 
sharing 77% homology in the EC2 domain, and can be interchanged in the sperm- 
egg fusion assays (Kaji et al. 2002), there is a growing amount of evidence here to 
suggest that this may not always be the case. In addition to human CD9 not being 
able to bind PSG17, murine CD9 could not inhibit monocyte fusion (Appendix and 
(Takeda et al. 2003). It would be interesting to investigate the interaction between 
IL-16 and CD9 in human cell lines and using human and mouse GST-CD9 EC2. 
In addition, we showed that our recombinant CD9 EC2 did not bind to fibronectin 
in ELISA and FACS assays as previously reported (Longhurst et al. 2002). Our 
data highlights the requirement for additional proteins in the interaction between 
the cell and ECK in the case of interaction with fibronectin, integrin molecules 
are likely to directly bind to fibronectin and CD9 is likely to be required for the 
accurate and intricate organisation of an involved TEM. This assumption is based 
on the fact that fibronectin contains II integrin binding sites and it is well 
documented that certain integrins associate with CD9 (Baudoux et at. 2000; 
Kawakami et al. 2002; Gutierrez-Lopez et al. 2003). To date only one group has 
described a direct association between CD9 and a component of the ECM. 
Structural information about a protein or protein domain is an invaluable tool when 
attempting to determine the functional significance of a protein and the molecular 
mechanisms employed by a protein. Until now, the only structural information 
available for members of the tetraspanin family is the Crystal structure of CD81 
EC2 (Kitadokoro et al. 2001; Kitadokoro et al. 2001). Although tetraspanins are a 
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family of closely related proteins, further structural information for other members 
of the family would no doubt aid future studies. We attempted to solve the 
structure of CD63 EC2 by X-ray crystallography but were halted at the first hurdle; 
no protein crystals grew. ID-NMR studies did reveal that the EC2 domain had 
alpha helical content and plans are in place to continue this structural study using 
NMR spectroscopy. The recent advances in crystallography screening methods 
which allow smaller and smaller proteins volumes to be screened against 
thousands of different crystallising conditions in a matter of hours, should speed up 
the process of gaining crystals to use in X-ray crystallography studies. Coupled 
with the advances in molecular replacement and structural modelling software, the 
crystal structures of more tetraspanin EC2 domains (and some of the larger ECI 
domains) should be a realistic possibility within the next few years. 
Probably the most exciting usages of the EC2 domains in terms of beneficial 
potential, is the ability to inhibit MV-1 infection in macrophages (Chapter 7) and 
the inhibition of monocyte fusion (Appendix). If it is to be believed that the EC2 
recombinant proteins inhibit cellular events such as fusion and viral entry, by 
disrupting the formation and organisation of TEMs, then the full length EC2 
protein would be a poor drug to prevent HIV-1 infection in macrophages since 
every cell line expresses tetraspanins and is therefore likely to contain these 
organised clusters of molecules on their cell surface and so, disrupting the 
functioning of them all could have dire consequences. However, a small peptide 
modelled on the EC2 domain that specifically inhibits the infection of HIV-1 in 
human MDM would have quite the opposite effect. Macrophages harbour HIV-1 
virus leaving them hidden from the host's immune attack. In this sheltered 
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environment they can propagate freely and be released en-masse to cause 
heightened destruction. A small peptide drug based on the CD63 EC2 domain 
which specifically inhibits the admission of HIV-1 into macrophages, could be 
used in conjunction with other therapies in anti-HIV vaccinations. 
The inhibition of monocyte fusion seen by the EC2 domains of tetraspanins CD9 
and CD63 (see Appendix) could also make these proteins potential therapeutic 
agents for quite different disorders. Osteoclasts are multinucleated giant cells that 
are derived from the monocyte/macrophage lineage, and in certain types of 
inflammatory arthritis (e. g. rheumatoid arthritis), these cells are thought to 
contribute to bone destruction (Suzuki et al. 2001). Anti-CD9 antibodies have 
already been shown to inhibit osteoclast fonnation (Tanio et al. 1999) and so it is 
feasible that small peptides based on the EC2 domains could have the potential to 
be developed as drugs to treat the symptoms of inflammatory diseases such as 
rheumatoid arthritis. 
Since tetraspanins have been described in cell fusion events both here and in the 
literature (Kaji et al. 2000; Takeda et al. 2003), it is possible that they are involved 
in the control of numerous cellular fusion events. Using the recombinant 
tetraspanin EC2 proteins as tools, fusion events such as tumour formation, fusion 
of other virus membranes with host cell membranes, endocytic processes and 
multinucleated cell formation could be studied for any involvement of tetraspanin 
proteins. Any involvement of tetraspanins in such processes could be investigated 
quickly by pre-incubating cells with recombinant EC2 domains before addition of 
virus or fasogenic stimuli and viewing any differences in fusion patterns under a 
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microscope. The most probable role of tetraspanins in such events, should they be 
discovered, is the in cis organisation of a TEM to regulate a fusion event. 
In summary, this thesis has highlighted the importance and the diverse usage of 
tetraspanin EC2 domains and has demonstrated for the first time that functional, 
recombinant EC2 proteins can be made in large quantities in biofermenters, and 
used as tools to study the role of tetraspanins in a variety of biological assays. 
The production of the EC2 proteins in this study has led to the identification of 
tetraspanin EC2 domains that are able to inhibit HIV infection and monocyte 
fusion, giving these recombinant Proteins enormous and exciting potential as 
future therapeutic agents. 
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Introduction 
Certain tetraspanins have been implicated in cell fusion processes. Most notably, CD9 
has been shown to play a critical role in sperm-egg fusion, since oocytes from CD9 
knockout mice are unable to fuse with sperm, resulting in infertility (Kaji et at. 2000; Le 
Naour et al. 2000; Miyado et al. 2000). Fusion is restored by the expression of ectopic 
CD9 (Kaji et al. 2002; Zhu et al. 2002) and it appears that the tetraspanin CD81 can 
compensate for loss of CD9 (Kaji et al. 2002; Zhu et al. 2002). Monoclonal antibodies 
(mAbs) to the EC2 region of CD9, as well as recombinant proteins corresponding to CD9 
EC2, inhibit fusion (Chen et al. 1999; Zhu et al. 2002; Higginbottom et al. 2003). CD9 
and CD81 are also implicated in muscle cell fusion (Tachibana et al. 1999) and CD9, 
CD81 and CD82 have been linked with virus-induced syncitium, formation (reviewed in 
(Martin et al. 2005)). 
Most recently a role for CD9 and CD81 in the formation of multinucleated giant cells has 
been proposed (Takeda et al. 2003). Antibodies to CD9 and CD81, but not CD63, were 
found to enhance Con A induced fusion of human monocytes and mouse alveolar 
macrophages in vitro. In addition, macrophages from CD9 and CD81 null mice showed 
enhanced formation of multinucleated cells in vitro and CD9/CD81 double knockout 
mice showed spontaneous formation of multi-nucleated giant cells. This led the authors 
to speculate that CD9 and CD81 normally act to negatively regulate 
monocytes/macrophage fusion (Takeda et al. 2003). Here we report the use of 
recombinant tetraspanin EC2 domains to more fully investigate the role of tetraspanins in 
2 
monocyte fusion. We show for the first time that the EC2 domains of tetraspanin CD63 
but not CD81, CD82 or CD151 can inhibit monocyte fusion leading to multi-nucleated 
giant cell formation. Thus it is likely that both CD63 and CD9 but not CD81 have roles 
in the fusion process, suggesting that the role of tetraspanins is more complex than 
previously thought. 
3 
Materials and Methods 
Monocyte fusion assay 
Peripheral blood monocytes were derived from peripheral whole blood of healthy, 
anonymized human volunteers by Ficoll-Hypaque density centrifugation as described 
elsewhere (Stevanin et al., 2005). 
The study was approved by the South Sheffield Research Ethics Committee (protocol 
number SSREC/02/299). Mononuclear cells were seeded at 5xlO5cells. chambef, in 
0.5ml RPMI-1640-10% FCS in an 8 chambered slide (Lab-Teký). After overnight 
culture, non-adherent cells were removed by washing three times and adherent cells 
cultured in RPMI-1640 + 10% FCS in the presence/absence of 10pg. ml-l Con A (Sigma) 
for 72 hrs at 37"C. Recombinant tetraspanin EC2s or GST protein were added to some 
assays. The cells were washed with PBS, fixed and permeabilised with acetone (5 mins, 
room temperature), rehydrated with PBS then labelled with FITC-anti-CD52 and the 
nuclei counter-stained with propidium iodide. Fusion rates were determined essentially 
as described previously (Most et al. 1990) by counting the number of nuclei in fused 
cells (>3 nuclei per cell) and unfused cells in 6 randomly chosen fields using a Nikon 
Eclipse E400 immunofluorescence microscope (fusion rate = no. of nuclei in fused cells/ 
number of nuclei in total (%)). In some cases, the numbers of nuclei in MGCs in 6 
random fields was recorded. 
4 
Results 
Effects of GST-EC2 tetraspanins on MGC formation 
Soluble forms of tetraspanin EC2 regions have been shown to have biological activity in 
a number of systems including sperm-egg fusion (Zhu et al. 2002; Mgginbottom et al. 
2003), hepatitis C virus binding (Flint et al. 1999; Higginbottom et al. 2000; Petracca et 
al. 2000), and leukocyte transmigration (Barreiro et al. 2005). We therefore investigated 
a range of recombinant human tetraspanin EC2 domains produced as GST fusion 
proteins (GST only, GST-CD9 EC2, CD63 EC2, CD81 EC2, CD82 EC2, CD IS I EC2) 
for their effects on MGC formation. The effects of GST mouse CD9 EC2 (GST-mCD9), 
and a human CD9 EC2 with a mutation in one of the conserved cysteines involved in 
disulfide bond formation (GST-CD9CI53A) were also investigated (Fig. 1). GST alone 
had no effect on cell fusion, and neither did the soluble tetraspanin EC2 proteins GST_ 
C1381, GST-CD82 or GST-CD151. The lack of an effect with GST-CD81 EC2 is 
unexpected in view of previous observations that anti-CD81 antibodies enhance MGC 
formation (Takeda et al., 2003) Recombinant GST-CD63 and GST-CD9, however, 
showed significant inhibition of MGC formation. Our results are consistent, however, 
with those of Takeda and co-workers on MGC formation. The effect of the GST-CD9 
appears to be sequence-specific, since mouse CD9-EC2, which has 77% identity with 
human CD9 EC2, had no effect. Interestingly, however, a CD9-EC2 containing a C153A 
mutation had a slight but significant negative effect on MGC fonnation. This mutant is 
not recognised by conformation-specific antibodies and would not be expected to contain 
a correctly folded subloop in its EC2 region. 
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Figure 1. Effects of different GST-EC2 tetraspanins on Con A induced monocyte fusion. Monocytes 
in Lab-TeV chamber slides were stimulated with Con A (10pg. ml") for 72hrs in the presence or absence 
of 20;. Lg/ml GST-EC2 tetraspanins or GST control. A) shows ConA-stimulated monocytes lablied with 
propidium iodide and anti-CD52 antibody in the absence (left panel) and presence (right panel) of GST- 
CD63 EC2. B) shows data obtained using a range of EC2 domains. The results with Con A. GST. GST- 
CD63 EC2 and GST-C I 53A EC2 are the means +/- SEM of 17 experiments in duplicates carried out with 
monocytes from 12 blood donors; the results of GST-CD9 EC2 are the means +/- SEM of 12 experiments 
in duplicate using monocytes from 12 blood donors and the results of other GST-EC2 tetraspanins are the 
means +/- SEM of 3 experiments in duplicate with monocytes from 3 different blood donors. ]'he level of' 
significance between the Con A control and different treatment was tested by unpaired t test, 
P<0.000 1, * P<0.0 1, NS P>0.05. 
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Inhibition of MGC formation is not dependent on the presence of GST 
Although GST alone had no effect on MGC formation, we considered that the fusion 
protein might affect tetraspanin EC2 activity. To investigate this, we cleaved GST- 
CD63EC2 and removed the free GST by affinity chromatography (Fig 2). Cleaved 
CD63EC2 was even more potent than GST-CD63EC2 OC50 1.6nM and 59nM, 
respectively). 
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Figure 2. Effects of different CST-CD63 EC2 and cleaved CD63 EC2 on Con A induced inonocyle 
fusion. Monoc,, tes in Lab-Tek' chamber slides were stimulated %%Ith ('on A( lopg. ml 
') for 72hrs in he 
'C2 and the monocyte fusion index "as calculated. presence ot'GST-CD63 EC2 or cleaved (D63) E 
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Conclusions 
Overall, our results indicate roles for tetraspanins CD9 and CD63 in MGC formation. 
Since inhibitory effects were observed with recombinant EC2 regions, we can conclude 
that these regions of the CD9 and CD63 molecules are involved. The effects are 
tetraspanin-specific, since no inhibition was observed with recombinant EC2s of CD81, 
CD82 or CD151. In addition, no inhibition was observed with murine CD9 EC2, which 
shows 77% sequence identity in this region. 
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